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ABSTRACT OF THE DISSERTATION 
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Professor David L. Brody, Chairperson 
 
The amyloid-β peptide (Aβ) plays a central pathophysiological role in 
Alzheimer’s disease, but little is known about its dynamics in the brain’s extracellular 
space. A recent microdialysis-based study in human patients with severe brain injuries 
found that extracellular Aβ dynamics correlate with changes in neurological status.  
Because neurological status is generally diminished following injury, this correlation 
suggests that extracellular Aβ is reduced relative to baseline. However, human studies 
cannot assess pre-injury Aβ levels, very early post-injury Aβ levels, nor the relationship 
between extracellular Aβ and total tissue levels.  Therefore, we developed a mouse model 
that combines experimental TBI with microdialysis to address these gaps.  In this model, 
Aβ levels were stable at baseline and after sham-injury.  Following controlled cortical 
impact TBI, we found that Aβ levels were immediately and persistently decreased in the 
ipsilateral hippocampus. These results were found in both wild-type mice and young pre-
plaque PDAPP mice that produce human-sequence Aβ.  Similar decreases were observed 
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in PBS-soluble hippocampal extracts, but no changes were found in carbonate or 
guanidine extracts.  Reductions in Aβ were not due to changes in microdialysis probe 
function, APP levels nor Aβ deposition.  Hippocampal depth electrode recordings 
demonstrated that electroencephalographic activity was decreased over 24 hours 
following TBI.  Thus, we propose that in mice and likely injured human patients, post-
injury extracellular Aβ levels are acutely decreased relative to baseline. Reduced 
neuronal activity may contribute, though the underlying mechanisms have not been 
definitively determined.  
 One hypothesized mechanism for reduced extracellular levels is that Aβ is 
retained at the synapse following injury.  To test this, we prepared synaptosomes in sham 
and injured PDAPP mice and measured levels of Aβ and APP by ELISA.  No significant 
differences between sham and 2.0 mm-injured mice were detected.  Future experiments 
will determine whether enhanced clearance accounts for decreased extracellular Aβ.   
 In summary, we have designed a mouse model to address questions that cannot be 
answered in patients.  Using this model, we measured Aβ dynamics and their relationship 
to tissue levels and a possible relationship with neuronal activity.  Studies of other 
peptides and treatment strategies might benefit from use of this model.  
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Traumatic brain injury is thought to be an important acquired risk factor for 
dementia and Alzheimer’s disease (Jellinger, 2004, Lye and Shores, 2000, Van Den 
Heuvel, et al., 2007).  However, the mechanisms responsible for the development of TBI-
associated dementia are poorly understood.  The amyloid-β peptide (Aβ) is believed to 
play a central role in both familial and late-onset Alzheimer’s disease (AD), and may also 
be involved in TBI-related dementia.  Before we consider its specific role, let us review 
the literature for the evidence of a link between TBI and dementia.  
 
Evidence for increased risk of dementia after TBI: scope and definition 
There is much evidence to support a link between TBI occuring in early or middle 
adulthood with the development of dementia later in life.  However, not all studies 
conclude that TBI is a risk factor.  Still others find that increased risk may depend on 
injury severity, gender, or genetic predisposition.  These seemingly variable results are 
likely due to differences in study populations, inclusion criteria for brain injury, and the 
definition and diagnosis of dementia.  To review the more recent literature, we will use 
the following 3 questions to summarize the main findings of individual studies:  
 
1. Does TBI increase risk for development of AD or other dementias? 
2. Does TBI hasten the onset of AD or other dementias? 
3. What genetic factors may interact with TBI to increase risk of dementia?   
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First, let us narrow the scope of the review to studies that consider only single or 
several instances of TBI, in contrast to the repeated injuries suffered by professional 
boxers or football players on a regular basis.  Second, we will include only studies that 
consider long-term outcome, years after the initial injury, as opposed to the short-term 
cognitive sequelae that are common in the weeks to months following TBI.  Third, 
“dementia” will be broadly defined, since many studies differ in their diagnostic criteria. 
How should dementia be defined?  Many studies used common rating scales for 
diagnosis of AD patients such as the DSM-III or NINCDS-ADRDA criteria.  Some of 
these scales are “snapshots” of cognitive functioning, while others (CAMDEX, for 
example) account for decline in function.  However, Leon-Carrion is careful to note that 
an acquired dementia syndrome in TBI patients is often distinct from other progressive 
dementias in elderly patients (Leon-Carrion, 2002). 
The DSM-IV syndrome of Dementia Due to Head Trauma offers an alternative to 
the scales developed for diagnosis of Alzheimer’s disease.  According to these criteria, 
there must some degree of memory impairment, either the ability to form new memories 
or to recall formerly learned information; at least one of the following: aphasia, apraxia, 
agnosia, or impaired executive function; and a significant decrease from previous 
functioning and impaired social functioning.  In contrast to other types of dementia, 
progression is not required to fulfill these criteria. 
Not all patients who suffer TBI go on to develop a clinical dementia, however.  
The concept of cognitive reserve might explain how TBI increases this risk.  Cognitive 
reserve is the cumulative effect of genetic endowment, education, health status, and other 
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aspects of social and intellectual functioning early in life that protects or delays 
neurodegenerative processes (Stern, 2009).  Likewise, insults acquired early in life, such 
as TBI, chronic stress, and lower educational attainment, challenge cognitive reserve, 
possibly lowering the threshold for development of a clinical dementia later in life.  In 
this scheme, a testable model would have to account for such early-life contributors in the 
evaluation of risk of dementia following TBI (Kesler, et al., 2003).  Few studies to date 
have done this on a broad scale.  For now, the protective role of cognitive reserve against 
TBI-related dementia remains a hypothesis to be tested, ideally in a large prospective 
study.  Further research in the epidemiology of TBI-related dementia is necessary as our 
“baby boomer” population continues to age, and the obligation of society to care for 
those patients grows ever larger. 
 
Epidemiology of TBI-related dementias: early investigations 
 Over the past decades, many studies have considered the role of traumatic brain 
injury in the development of an Alzheimer’s-type dementia.  A well-documented 
example of dementia after TBI is that of professional as well as amateur boxers (Clausen, 
et al., 2005, Loosemore, et al., 2007).  Those studies will not be addressed here due to the 
uniquely repetitive, chronic nature of the trauma.  Here, we will consider only the effects 
of one or several, remote TBI on the later development of dementia. 
As early as the 1940s, case reports described insidious intellectual deterioration 
following a single TBI.  For example, one paper details the course of a 50-year-old male 
patient who suffered a brain injury in a car accident (Corsellis and Brierley, 1959).  There 
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was a documented loss of consciousness immediately following the accident, with post-
traumatic amnesia.  Over the next four years, this patient visited his physician frequently, 
complained of concentration and memory problems, and became unable to run his 
business.  Over the next few years, this patient experienced emotional disturbances and a 
progressive deterioration in intellectual function until he became severely demented.  
Approximately five years after the injury, the patient died and the brain was autopsied for 
the presence of Alzheimer’s-like pathology.  It was found that this 55-year-old man 
possessed plaques and tangles as revealed by silver staining techniques.  These features 
were especially prominent in more superficial layers of cortex, as was later demonstrated 
in a large case series of TBI patients (Jellinger, et al., 2001).  Other case reports have 
described similar findings in young patients not otherwise expected to have such 
pathology (Clinton, et al., 1991, Ikonomovic, et al., 2004, Roberts, et al., 1994).   
Beginning in 1960s and 1970s, researchers began to consider the issue of TBI-
related dementia more systematically.  For example, a study published in 1979 looked at 
the outcomes in a consecutive series of 291 head-injured patients from among 7000 
admittances to a single hospital (Lewin, et al., 1979).  The criterion for inclusion was 
amnesia greater than 1 week.  All injuries had occurred between 10 and 24 years before 
the outcome assessment.  Of the 291 patients contacted for follow-up, 31 or 11% had 
progressive intellectual deterioration, which was twice the prevalence in the local 
population over 65 years old.   
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Many studies involving tens to thousands of patients have since been published.  
The following discussion will be organized by 3 questions to summarize the main 
findings of individual studies. 
1. Does TBI increase risk for development of AD or other dementias? 
2. Does TBI hasten the onset of AD or other dementias? 
3. What genetic factors may interact with TBI to increase risk of dementia?   
 
Does TBI increase risk for development of AD or other dementias?   
 The types of studies that have attempted to answer this question include 
retrospective (historical) and prospective cohort, matched and unmatched case controls, 
and meta-analyses of case-controls.  Most of these considered a population of patients 
with probable or definite dementia, including Alzheimer’s disease, and asked whether 
they had suffered a TBI at any point prior to the onset of their dementia. 
 Graves et al. conducted a case-control study of 130 matched pairs in geriatric 
psychiatry clinics to ask whether a head injury severe enough to have warranted a visit to 
a physician or a hospital, or to have experienced any loss of consciousness, increased the 
risk for development of dementia or Alzheimer’s disease (Graves, et al., 1990).  Two 
cohorts of cases and controls were enrolled.  Between 1980 and 1982, dementia was 
diagnosed by the DSM-III criteria for primary degenerative dementia.  Between 1983 and 
1985, both the DSM-III and NINCDS-ADRDA criteria were used.  Patients were 
considered not to be demented if the MMSE > 26.  Overall, irrespective of loss of 
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consciousness, incidence of TBI increased the odds ratio for dementia to 3.5 (95% C.I., 
1.6-7.7).  One weakness of this study was the low statistical power. 
In a retrospective cohort study drawn from the resources of the Rochester 
Epidemiology Project, Williams et al. reviewed the medical records of Olmsted County 
residents kept between 1935 and 1974 for a diagnosis of dementia (Williams, et al., 
1991).  Records were limited to residents at least 40 years old at last visit.  Dementia was 
qualitatively described as a decline in intellect, memory, or social function of duration 
longer than 6 months.  This diagnosis was made by the patient’s own physician.  There 
were 821 records that met these criteria that were then screened for documented head 
injury.  Among these, 23 men and 13 women were identified as having had both a head 
injury and dementia.  When compared to the expected incidence rates of dementia in 
Olmsted County by a standardized morbidity ratio (SMR), the authors concluded there 
was no increased risk for dementia conferred by TBI.  For males, the SMR = 1.22 (95% 
C.I. 0.77-1.83), and for females, the SMR = 0.87 (0.46-1.49).  One weakness of this study 
was the lack of standardized, published criteria to evaluate dementia or AD.   
 In an earlier case-control study,  French and Mortimer described a population of 
78 male patients in the V.A. system with a diagnosis of dementia of the Alzheimer’s type 
(French, et al., 1985, Mortimer, et al., 1985).  The 40 control subjects were drawn from 
both hospital and neighborhood populations.  Diagnosis of head injury was made from a 
structured interview with an informant along with evaluation for other putative risk 
factors (toxic, metabolic, infectious, etc.).  The criteria for dementia were insidious onset, 
gradual progression, intact consciousness and no focal neurological signs.  In 30 cases 
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that subsequently died during the course of the study, 16 brains came to autopsy.  
Histopathological confirmation of Alzheimer’s disease was found in 14 of these 16 
brains.  The odds ratio for having dementia after a TBI was 4.50 (95% C.I., 1.44-15.69).  
However, this series was limited by a low statistical power, and was later reconsidered in 
the context of a meta-analysis (Mortimer, et al., 1991). 
 In another case-control study of patients with dementia, Rasmusson et al. queried 
patients enrolled at an Alzheimer’s Disease Research Center (ADRC) for prior history of 
traumatic brain injury (Rasmusson, et al., 1995).  They compared the incidence of TBI in 
familial AD to TBI in sporadic AD, and to TBI in cognitively normal age-matched 
controls.  The TBI was ascertained by a structured telephone interview with a spousal 
informant, and AD was evaluated by NINCDS-ADRDA criteria.  It was found that TBI 
was significantly more common in AD cases (n=68) than in controls (n=34) (OR = 13.75, 
95% C.I. 1.76-107.52).  Although TBI was more common in true sporadic AD (10 of 23) 
than in familial AD (6 of 30), the odds ratio was not statistically significant.  One 
potential criticism of this study is that severe head injury warranted exclusion from initial 
enrollment in the ADRC.  The enrolled patients in the AD group, then, were thus likely to 
have suffered milder injuries.  These researchers concluded that even mild injuries confer 
risk for AD. 
 In an unmatched case-control study of patients referred to a psychogeriatric 
hospital, Salib and Hillier asked whether TBI increased the risk of Alzheimer’s disease or 
of dementias in general (Salib and Hillier, 1997).  The AD population consisted of 198 
patients with AD by NINCDS-ADRDA criteria, compatible with DSM-III and ICD-9 
9 
 
standards.  The “other dementias” population was comprised of 164 patients who scored 
less than 17 on the MMSE and either a Hachiniski score > 7, or another known etiology 
(alcohol abuse, metabolic disorder).  History of TBI was ascertained by interview with an 
informant, where open-ended questions were asked to determine age at the time of TBI, 
severity, circumstances surrounding the injury, and aspects of the medical treatment.  The 
control (non-demented) group consisted of 176 patients with an MMSE score > 23.  This 
study found that TBI increased the risk of “dementia” when defined as all dementias (OR 
= 2.4, 95% C.I. 1.4-4.1), any dementias other than AD (OR = 2.36, 95% C.I. 1.4-4.0), 
and AD alone (OR = 2.4, 95% C.I. 1.3-4.1).  A clear weakness of this study is the 
potential disparities between cases and controls due to the lack of matching. 
 In a very large set of cases and controls culled from 13 centers in the U.S., 
Germany, and Canada as part of the MIRAGE study, Guo et al. measured the incidence 
of head injury in NINCDS-ADRDA-diagnosed AD patients (n=2233) and compared their 
rates to both first-degree family members (parents or siblings, n=7694) and to spouses 
(n=2509) (Guo, et al., 2000).  Either the subject or the spouse reported TBI based on the 
question, “Has your relative ever had a head injury which required medical care or 
caused a loss of consciousness?”  Medical care included visiting a physician or a hospital, 
either inpatient or outpatient.  They were also queried as to the age at TBI and the 
duration of loss of consciousness (LOC), if any.  When compared with spouses, the 
presence of TBI with LOC increased the relative risk to 9.9.  This effect was seen in both 
men (RR = 5.6) and women (RR = 3.2).  Without LOC, there was still an increased risk 
(RR = 3.1).  When compared with parents and siblings, TBI with LOC increased RR = 
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4.0 (95% C.I., 2.9-5.5); without LOC, TBI still increased the risk (RR = 2.0, 95% C.I., 
1.5-2.7). 
 A prospective study looked at the presence or absence of TBI in new-onset 
dementia in non-demented, older patients (Mehta, et al., 1999).  As part of the Rotterdam 
Study, Mehta et al. began with a population of 6645 volunteer adults aged 55 years or 
older, and followed them for an average of 2.1 years from enrollment to test for new-
onset dementia (Mehta, et al., 1999).  The occurrence of TBI was ascertained by self-
report of head injury with loss of consciousness to an examining physician.  A three-stage 
assessment was conducted, consisting of the MMSE and GMS-A in the screening step.  
Then, if the MMSE < 26 or the GMS-A > 0, the CAMDEX was administered.  Finally, a 
neurological exam, MRI, and previous medical records were reviewed and diagnosis was 
made by DSM-III criteria, with subtyping by NINCDS-ADRDA criteria.  The logistic 
regression model for total dementia risk, after adjusting for age, gender and education, 
revealed no increased risk due to TBI (RR = 1.0, 95% C.I. 0.5-2.0).  Neither was there an 
effect on risk for AD, specifically (RR = 0.8, 95% C.I. 0.4-1.9).  In addition, there was 
neither an effect of ApoE4 status, nor the number of years since the injury, nor the 
duration of LOC on risk of dementia.  One weakness of this study was the short follow-
up time.  Initial assessments were conducted between 1990 and 1993, and reassessments 
between 1993 and 1994.  Another criticism of this study is that participants were all 
volunteers from the community and may have represented a bias towards better-educated, 
healthier individuals who were therefore less likely to become demented.    
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 A prospective cohort study was conducted by Plassman and colleagues on 548 
World War II Navy and Marine veterans whose military records documented a closed 
head injury (Plassman, et al., 2000).  The TBI was rated as mild, moderate or severe 
based on loss of consciousness, post-traumatic amnesia, and skull fracture.  The control 
population consisted of 1228 similar veterans who did not suffer head injury, but who 
were hospitalized for either pneumonia or laceration-type wounds.  This study made a 
standardized diagnosis of dementia and Alzheimer’s disease by a three-step process.  
First, participants were screened with the Telephone Interview for Cognitive Status, 
based closely on the MMSE.  A spouse or child verified the participant’s cognitive status.  
Further testing was then conducted using the Dementia Questionnaire.  Finally, a clinical 
evaluation including neuropsychological testing was used to make a definitive diagnosis 
of dementia by the DSM-III criteria, and AD by the NINCDS-ADRDA.  This study 
found a hazard ratio for dementia conferred by even a single, moderate TBI compared to 
no TBI (HR = 2.32, 95% C.I., 1.04-5.17).  For severe TBI, the hazard ratio was 4.51 
(95% C.I., 1.77-11.47).  The risk for dementia in general was similar to that for AD in 
particular. 
 Another, smaller prospective cohort study by Schofield et al. assessed the risk 
conferred by TBI for incident dementia in 271 community-dwelling participants.  All 
participants were at least 60 years old in a longitudinal aging study in north Manhattan 
(Schofield, et al., 1997).  At the time of enrollment, participants had no cognitive 
impairment.  Cognitive status was assessed by a neuropsychological evaluation, including 
tests of memory, orientation, abstract reasoning, language, and construction.  A CDR 
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rating was determined for each participant during a consensus conference among 
examining physicians.  The occurrence of TBI was assessed during the risk factor 
interview and by the examining physician.  During the risk factor interview, patients were 
asked about loss of consciousness and amnesia.  The examining physician asked only 
about loss of consciousness.  An informant in the home verified the occurrence of TBI.  
These participants were then followed each year for a total of 5 years and reassessed for 
cognitive status.  By the criterion of TBI as assessed by the examining physician, TBI 
conferred a risk for early-onset dementia (RR = 1.4, 95% C.I. 1.3-12.7).  However, by the 
stricter criteria of the risk factor interviewer, the risk did not reach significance (RR = 
2.0, 95% C.I. = 0.7-6.2).  If loss of consciousness was greater than 5 minutes, the risk 
increased (RR = 11.2, 95% C.I. 2.3–59.8).  If the TBI had occurred within 30 years of 
dementia onset, risk was also increased (RR = 5.4, 95% C.I. 1.5-19.5).  
 Finally, two meta-analyses were performed using data from previous case-control 
studies.  The first, published in 1991 by Mortimer and colleagues, pooled data from 7 
case-control studies conducted in the U.S., Italy, the Netherlands, and Australia.  
Individually, each of these studies found a significant increase in the relative risk for 
dementia conferred by TBI.  However, the statistical power was less than 0.2 in all 7 
studies.  When these data were pooled, however, the statistical power increased to 0.97 to 
yield an RR = 1.82 (95% C.I. 1.26-2.67) (Mortimer, et al., 1991).  When stratified by 
gender, the meta-analysis found an increased risk for dementia among males (RR = 2.67, 
95% C.I. 1.64-4.41) but not females (0.85, 95% C.I. 0.43-1.70).  Following the 
publication of this initial meta-analysis, a replication study was done by Fleminger and 
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colleagues (Fleminger, et al., 2003).  Using 8 case-control studies included in various 
analyses in the original Mortimer study as well as 7 case-control studies published since, 
this meta-analysis examined whether TBI with loss of consciousness conferred a risk for 
dementia.  Their inclusion criteria were as follows: they specified that a requirement for a 
collateral source in both cases and controls, and that the TBI had occurred some number 
of years prior to the onset of dementia.  Finally, all studies had to have used NINCDS-
ADRDA criteria for possible or probable AD, and DSM criteria for dementia of the 
Alzheimer’s type.  Overall, this study found that the odds ratio conferred by TBI for 
dementia was 1.58 (95% C.I. 1.21-2.06).  When stratified by gender, males had an 
increased risk (OR = 2.29, 95% C.I. 1.47-3.58) while females did not (OR = 0.91, 95% 
C.I. 0.56-1.47).  The authors concluded that this technique of meta-analysis of case-
control studies is replicable given the strict inclusion criteria imposed on the individual 
studies analyzed.  
 In summary, it appears that even a single incident of TBI with loss of 
consciousness or post-traumatic amnesia increases the risk for dementia later in life, 
particularly in men. 
 
Does TBI hasten the onset of AD or other dementias?   
In both studies that did and did not find an increased incidence of dementia or 
Alzheimer’s disease, a separate question can be asked regarding the age of onset in 
patients with and without a history of TBI.  For this question, we will reconsider some of 
the studies in the previous section as well as others. 
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A preliminary study published in 1989 examined a retrospective cohort to 
evaluate the specific effects of TBI on age of onset of dementia (Gedye, et al., 1989).  
Information was gathered from a pool of 148 patients with probable AD, excluding 
known familial cases, and 33 others with dementias unlikely to be AD.  All cases were 
selected from a consecutive series of 400 patients referred to an Alzheimer’s disease 
clinic.  Each received a thorough physical exam, cognitive assessment, genetics 
interview, social work interview and neurological exam.  Collateral sources were asked 
about the patient’s history of TBI and specifically about the duration of loss of 
consciousness, a feeling of being “stunned,” dizziness, confusion, and behavioral 
changes.  TBI was rated on a 7-point scale.  Cases with possible confounding factors, 
such as alcohol or medication abuse, were excluded.  Diagnosis of definite or probable 
AD was made according to the NINCDS-ADRDA criteria.  For patients who suffered a 
severe TBI before age 65, the median age of onset for AD was 8 years earlier (mean, 6.8 
years earlier) than those without a history of TBI.  A similar trend occurred in the group 
of patients with dementia unlikely to be Alzheimer’s, but the sample size was too small to 
perform statistical analysis.  A correlation was found between the severity of the trauma 
and the age of onset of probable AD (Spearman rank-order correlation r = -0.60 for 35 
patients whose TBI rated 2-7; r = -0.3 for 24 patients rated 3-7).  This study concluded 
that the mere incidence of TBI was not sufficient to cause AD or another dementia, but it 
may hasten the onset. 
Nemetz et al. examined an historical cohort from the medical records compiled as 
part of the Rochester Epidemiology Project (Nemetz, et al., 1999).  The TBI was included 
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in the study if there were documented loss of consciousness, post-traumatic amnesia, or 
focal neurologic signs.  Head trauma with skull fracture was not included.  Of 1283 
patients with recorded incidents of TBI from 1935-1984, aged 40 or older in 1988, 31 
later developed dementia.  The diagnosis was made by the patient’s own physician and 
confirmed in the medical record by a study neurologist who took the first mention of 
cognitive or behavioral difficulties that were later attributed to Alzheimer's disease as 
“time of onset.”  This study did not find an increased incidence of dementia among TBI 
patients compared to patients without a history of TBI.  However, the authors constructed 
survival curves of Alzheimer’s-free status at every age, and compared the groups of 
Alzheimer’s patients with (n=31) and without (n=689) TBI.  For patients who suffered a 
TBI before age 65, there was a twofold increase in the risk of early-onset dementia as 
compared to the expected incidence, defined as onset before the age of 75 (standardized 
incidence ratio = 2.2, 95% C.I. 1.1-4.0). 
Luukinen and colleagues asked whether fall-related TBI can hasten the onset of 
dementia in a longitudinal study from an elderly, population-based cohort (Luukinen, et 
al., 2005).  They examined 325 non-demented individuals aged at least 70 years old 
between 1991 and 1992.  Researchers then contacted participants every three months by 
telephone to inquire whether a fall had occurred, the nature of the injury and subsequent 
medical treatment.  TBI with brain involvement was specified by nausea, dizziness, 
headache, seizures, focal neurological deficits, and/or skull fracture.  The severity of the 
TBI was rated according to duration of loss of consciousness, post-traumatic amnesia, 
and initial GCS score.  A full follow-up examination was conducted eight to nine years 
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after the initial assessment in 150 of the original patients.  Participants’ cognitive status 
was assessed by the MMSE, DSM-IV, imaging and lab tests, a clinical and neurological 
exam, and a brief battery of neuropsychological exams.  A clinical diagnosis was 
determined by consensus conference between two examining neurologists.  Of the 150 
patients in the follow-up group, 8 had sustained a TBI at a mean interval of 1438 and 
1642 days from the initial and final exams, respectively.  Five patients suffered a mild 
TBI, of which three developed dementia.  Three patients suffered a moderate TBI, of 
which two became demented.  It was found that fall-related TBI in this older population 
conferred an age-specific hazard ratio of dementia (HR = 2.78, 95% C.I. 1.32–5.86).  
After adjustment for baseline low educational status and sex, TBI was still a significant 
hazard (HR = 2.80, 95% C.I., 1.35–5.81). 
Recently, McMurtray et al. published a study of patients in the V.A. system 
presenting with a memory or cognitive complaint (McMurtray, et al., 2006).  Patients 
were assessed for dementia using the criteria of deficits in two or more domains of 
cognition: a significant impairment in social or occupational functioning, and a 
significant decline from a previous level of functioning as quantified by the DSM-IV.  
Previous medical records were reviewed for a primary etiology of the complaint.  
Etiologies included TBI, alcohol abuse, HIV status, and neurological disorders: 
Alzheimer’s disease, vascular dementia, Parkinson’s disease, FTLD, or MS.  Finally, 
patients were stratified by the onset of dementia: early-onset dementia (EOD) if onset 
occurred prior to age 65 (n=268; mean age of onset, 51 ± 11) or late-onset dementia 
(LOD) if onset occurred after age 65 (n=670, mean age of 75 ± 5).  It was found that 
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among the primary etiologies, TBI, alcohol abuse, HIV status, and FTLD were 
significantly associated with an increase in frequency among the EOD group than LOD 
by a χ2 analysis.  Specifically, the X2 statistic for TBI was 71.6 with a p-value of less than 
0.0001.  By contrast, AD as an independent primary etiology was associated with an 
increased frequency in the LOD group.  This study suggests that when TBI is a primary 
etiology for dementia other than that of the Alzheimer’s type, it more frequently occurs 
as an EOD rather than an LOD.   
 In summary, most studies support the hypothesis that TBI is associated with an 
earlier onset or detection of dementia as compared to a non-injured population. 
 
What genetic factors may interact with TBI to increase risk of dementia?   
A final query of the literature might consider whether TBI interacts with certain 
other risk variables to increase the risk of dementia.  One commonly assessed risk factor 
is gender.  In several studies that demonstrated a significant increase in risk due to TBI, 
the study population was comprised of current or former military personnel and consisted 
almost entirely of males (French, et al., 1985, McMurtray, et al., 2006, Mortimer, et al., 
1985, Plassman, et al., 2000).  In studies that assessed approximately equal numbers of 
males and females, several found an increased risk in males, but not in females 
(Fleminger, et al., 2003, Himanen, et al., 2006, Launer, et al., 1999, Mortimer, et al., 
1991, Salib and Hillier, 1997).  By contrast, a large-scale study across 13 centers in North 
America and Europe found increased risk in both males and females, although risk was 
still greater in males (Guo, et al., 2000).  However, the increased rates of TBI and 
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increased severity of TBI among males as compared to females might contribute to these 
apparent disparities. 
Another putative risk factor is apolipoprotein E4 (ApoE4) status.  Possession of 
one or two ApoE4 alleles has been shown to be an important genetic risk factor for late-
onset Alzheimer’s disease (Strittmatter, et al., 1993).  Several studies have assessed its 
role in TBI-associated dementia.  Mayeux and colleagues published a case-control study 
that compared community-dwelling individuals with AD to a cognitively normal group 
aged 65 or older to measure the effects of TBI and ApoE4 on the incidence of dementia 
(Mayeux, et al., 1995).  A diagnosis of probable AD was made according to NINCDS 
criteria.  Head injury with loss of consciousness was ascertained by a semi-structured 
interview as previously described (Mayeux, et al., 1993).  Cases and controls were 
matched by age and gender, cases having 74.5% women aged 74 ± 10.5 years, and 
controls having 69.1% women aged 72 ± 9.1 years.  Ethnicity was also matched.  
However, the cases had significantly fewer years of education than controls.  As 
expected, the ApoE4 allele was significantly more frequent among cases (0.29) than 
controls (0.16; X2 = 13.4, p < 0.001), but did not differ by age, gender, or years of 
education within either group.  For ApoE4 homozygosity, the OR for AD risk was 3.9 
(95% CI, 1.2-13.2) and that associated with heterozygosity was 2.0 (95% CI, 1.2-3.6, p < 
0.01).  Of the cases, 13 or 11.5% reported a TBI with loss of consciousness occurring at 
least two years before the onset of dementia.  Of the controls, 10 or 8.1% had a history of 
TBI with loss of consciousness.  Irrespective of ApoE4 status, TBI did not confer a 
significant risk for AD (OR = 1.5, 95% CI, 0.5-3.5).  However, using the non-injured, 
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non-ApoE4+ individuals as a reference group, TBI and at least one ApoE4 allele together  
conferred a risk for AD (OR = 10.5; 95% CI, 1.3-87.8).  This study suggested that TBI 
and ApoE4 status may act synergistically to increase the risk of AD.  However, this study 
was too small to detect a significant interaction between these variables.  Additionally, 
the TBI was only required to have occurred as soon as two years prior to onset of 
dementia.  This length of time may not be sensitive enough to determine a true “onset” 
based solely on medical records. 
The synergistic effects of TBI and ApoE4 status on the development of AD 
among older individuals are supported by the findings of Luukinen et al. (Luukinen, et 
al., 2005).  In a group of individuals aged 70 or older who were cognitively normal at 
enrollment, ApoE4 status acted synergistically with fall-related TBI to confer risk for 
new-onset dementia by an age-specific hazard ratio of 7.68 (95% C.I., 2.32–25.3).    
By contrast, two large studies that examined the effect of TBI occurring at 
younger ages have found no such synergism with ApoE4 status (Mehta, et al., 1999, 
Plassman, et al., 2000).  Similar to Mayeux et al., the analysis of head injury as a risk 
factor for incident dementia in the large, community-based Rotterdam Study by Mehta 
and colleagues did not report that TBI was an independent risk factor (Mehta, et al., 
1999).  However, they did not find a synergistic effect ApoE4 genotype with TBI.  The 
prospective cohort study by Plassman et al. was also powered to detect such an 
interaction (Plassman, et al., 2000).  They reported a non-significant trend towards a 
stronger association between ApoE4 status and risk for dementia among men with a 
remote history of moderate or severe TBI.  This study maintains that moderate-to-severe 
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TBI is an independent risk factor for later development of dementia, and that one or two 
ApoE4 alleles might confer additional risk. 
 In summary, it appears that male gender and ApoE4 status might further increase 
the risk for dementia in individuals with a history of TBI.  
 
Alzheimer’s pathology in remote TBI 
 Given the evidence that TBI likely increases the risk of dementia, possibly by 
increasing the likelihood of early-onset disease or acting in synergy with genetic factors, 
what might be the histopathological basis for this increased risk?  One possibility is that 
TBI is associated with Alzheimer’s pathology; specifically, the hallmark extracellular Aβ 
plaques and intracellular neurofibrillary tangles.  One study has addressed the question of 
Alzheimer’s pathology in the setting of TBI by comparing two cohorts of autopsied 
brains (Jellinger, et al., 2001).  In the first, brains from 58 individuals aged at least 60 
years known to have residual, closed TBI were examined for coincident Alzheimer’s 
pathology.  In the second cohort, 57 age-matched samples known to have Alzheimer’s 
pathology were examined for TBI residuals.  A number of markers were examined, 
including routine stains, Bielschowsky silver stain, and immunohistochemistry for Aβ1-42, 
hyperphosphorylated tau, ubiquitin, and α-synuclein.  Within the first cohort, 7 of 57 
brains were classified as having definite, severe neuritic AD pathology, with 6 more 
diagnosed as “probable AD.”  The AD+ brains included 4 males and 3 females, ranging 
in age at death from 69-83 years old, with occurrence of TBI ranging from 10 to 30 years 
prior to death (if known).  The duration of dementia was 4-7 years.  Among the 6 brains 
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with probable AD pathology, TBI had occurred between 8 and 39 years prior to death, 
with duration of cognitive impairment ranging from 3 to 7 years.  The prevalence of AD 
pathology in this cohort was 22%, higher than expected in the general population aged at 
least 65 years old.  Within the second cohort, individuals ranged in age from 71-91 years 
old at the time of death.  Four of these 57 brains showed signs of residual TBI.  Although 
30% of all cases possessed at least one ApoE4 allele, none of the TBI brains were 
ApoE4+.  A single TBI had occurred in each of these four cases, ranging between 7-54 
years before the onset of dementia. 
 In summary, no large-scale studies have examined the true coincidence of 
Alzheimer’s pathology in documented cases of remote TBI when there is no obvious 
evidence of residual brain injury.  For example, diffuse axonal injury can be quite a 
severe TBI, but lacks the focal lesions that are grossly evident such as the contusions 
described in the Jellinger study.  Future studies are warranted to address this gap in the 
literature. 
 
 Alzheimer’s pathology in acute TBI 
If TBI increases the risk of dementia through the mechanisms of classic 
Alzheimer’s pathology, it could be asked: when does this process occur?  Is it immediate 
or delayed?  Several studies have examined the incidence of acute pathology and have 
found that Aβ deposits are present as early as 2 hours after injury in a subset of young 
TBI patients coming to autopsy or requiring decompressive surgery (Fig. 1) (Ikonomovic, 
et al., 2004, Roberts, et al., 1994, Smith, et al., 2003).  This suggests that TBI might 
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accelerate the pathophysiological processes resulting in dementia.  However, Aβ staining 
patterns following TBI differ from those associated with clinical AD, and only 1/3 of 
patients demonstrate any pathology (Ikonomovic, et al., 2004, Johnson, et al., 2009, 
Roberts, et al., 1994, Smith, et al., 2003).  These immunohistochemical studies were 
limited to single-timepoint analysis of Aβ deposits in only the most severe injuries.  It is 
unknown whether these patterns persist or evolve over longer periods of time.  
 
Figure 1. Aβ staining of patterns of deposition after acute TBI.  A, Compact, irregular 
Aβ deposits detected as early as 2h after injury.  B, plaques present at 16h after injury.  C, 
large, dispersed neuropil accumulates.  D, intracellular Aβ deposits in the cytoplasm of 
cortical pyramidal neurons.  E, intracellular Aβ deposits in axons of a plaque-negative 
case.  F, sporadic, Aβ-positive glial cells in a plaque-negative case. Scale bar 200µ (A–
C); 100µ (D–F).  G, age group distribution of cases with cortical Aβ-immunoreactivity.  
Cases were severely head-injured patients who came to autopsy 4 hours to 2.5 years after 
TBI.  A-F, From Ikonomovic et al., 2004.  G, Adapted from Roberts et al., 1994.  
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Microdialysis measures ISF Aβ dynamics in living subjects 
Immunohistochemistry can reveal deposition and accumulation of Aβ, but is 
possible only in the subset of patients who require tissue resection or who come to 
autopsy.  We wanted to understand what was happening to soluble forms of the peptide in 
the extracellular space, presumably before deposition occurs.  Essentially, we wanted to 
measure intracerebral Aβ dynamics.  For this purpose, we considered microdialysis. 
Brain microdialysis is a minimally-invasive technique that permits longitudinal 
sampling of small molecules in the extracellular space of living, awake subjects.  
Previous experimental studies from the Holtzman laboratory have demonstrated that it is 
possible to assess the dynamics of Aβ in the brain interstitial fluid (ISF) using 
intracerebral microdialysis in the brains of awake, behaving mice (Cirrito, et al., 2003). 
Additional studies uncovered a clear relationship between neuronal activity and ISF Aβ 
concentrations (Cirrito, et al., 2005, Kamenetz, et al., 2003).  In subsequent work, it was 
shown that ISF Aβ levels depend in large part on synaptically-coupled endocytosis 
(Cirrito, et al., 2008).   
Physiological manipulations of neuronal activity also affect Aβ levels.  Both acute 
and chronic stress can result in elevations of ISF Aβ levels (Kang, et al., 2007).  
Furthermore, ISF Aβ levels were found to correlate with cortical EEG measures of 
wakefulness (Kang, et al., 2009). 
Clinical microdialysis (Hillered, et al., 2005) has been used to measure interstitial 
fluid (ISF) Aβ in the brain extracellular space of human patients at multiple timepoints.  
Recently, our group published a study in which we measured the concentration of 
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amyloid-β peptide (Aβ) recovered by intracerebral microdialysis every 2 hours for at 
least 72 hours after catheter implantation in human patients who had suffered either an 
aneurysmal subarachoid hemorrhage or a traumatic brain injury (Fig. 2) (Brody, Magnoni 
et al., 2008).  We found a significant correlation between changes in microdialysis levels 
of ISF Aβ and changes in neurological status, as assessed by one or two-step changes in 
the GCS.  Aβ levels rose as neurological status improved, and fell as neurological status 
declined (Fig. 3).  Measures of impaired cerebral metabolism and physiological factors 
associated with depressed functional status were significantly correlated with reduced Aβ 
levels.  Marklund et al. presented results consistent with these findings; ISF Aβ levels 
were relatively high in a patient who did well and undetectable in a patient who died with 
severely abnormal brain metabolic parameters (Marklund, et al., 2009).   
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Figure 3.  Non-parametric correlation of fold change in Aβ levels from baseline with 
change in Glasgow Coma Score (GCS).  From Brody, Magnoni et al. 2008.   
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Figure 2.  Microdialysis in a 
severely brain-injured patient.  A, 
CT scan of study patient with 
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pericontusional location (red arrow).  
Courtesy of Sandra Magnoni, 
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Italy.  B, Aβ levels collected as 2-hour 
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Outstanding questions raised by clinical microdialysis studies 
There were several key questions generated by the results of our study.  Firstly, 
the relationship of post-injury measurements to pre-injury levels was unclear.    
Intracerebral microdialysis is indicated only for severely injured patients under close 
supervision in a hospital ICU setting.  With the exception of monitoring during an 
elective neurosurgical procedure in an otherwise healthy patient, it is impossible to 
directly measure baseline, or pre-injury, levels (Brody, Magnoni et al., 2008).  Since the 
dynamics and deposition of the Aβ is of great interest to both the Alzheimer’s and the 
TBI communities, it was critical to understand whether the post-injury levels were 
significantly increased, equal, or decreased relative to baseline levels.  Secondly, we were 
interested in the relationship of Aβ concentrations in the ISF to levels in other tissue 
compartments.  Finally, most human patients did not begin monitoring until 
approximately 12 hours or more after an insult had occurred.  We were interested to 
understand the immediate dynamics of ISF Aβ following an injury. 
The correlation between fold change in Aβ levels from baseline and change in 
Glasgow Coma Score (GCS) (Fig. 3) was an important result from this human study.  
The GCS is considered by clinicians to be a measure of neurological status.  Recent 
animal studies by our group and others have demonstrated the dependence of ISF Aβ 
levels on neuronal activity (Cirrito, et al., 2008, Cirrito, et al., 2005, Kamenetz, et al., 
2003).  Taken together, the experimental and human data strongly suggest that injury-
related changes in neuronal activity might affect ISF Aβ dynamics.  Therefore, we 
hypothesized that measurement of a surrogate of neuronal activity, such as local EEG 
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recording, would provide insight into a potential mechanism of post-injury regulation of 
ISF Aβ. 
 
Need for an animal model: combined CCI-MDA in wild-type animals 
For these reasons, we turned to an animal model of a standardized brain injury 
and microdialysis probe placement.  Our group has previously published a well-
characterized model of controlled cortical impact (CCI) using a precise 
electromagnetically driven device (Brody, et al., 2007).  We combined the CCI technique 
with intracerebral microdialysis using a hippocampal probe placement.  This combination 
of techniques permitted us to measure Aβ before and after an injury and in sham-injured 
animals.  We used a wild-type mouse in which murine Aβ is cleaved from full-length 
amyloid precursor protein (APP) under endogenous promoter control.  These experiments 
demonstrated a trend towards decreased endogenous Aβ in the injured brain.  A set of 
complete results and analysis of these experiments are described in the body of a 
submitted manuscript included in Chapter 5 of this thesis.   
 
Use of transgenics to measure human sequence Aβ in CCI-microdialysis model 
Because this combined CCI-microdialysis model was optimized to address 
specific questions that arose from the human study, we wanted a more direct comparison 
of the dynamics of a human-sequence Aβ in the interstitial fluid and better time 
resolution, at least every two hours as was done in the human study.  For these reasons, 
we employed two transgenic mouse models, Tg2576 and PDAPP mice.  We hypothesized 
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the feasibility of this approach based on previous literature.  Firstly, the histological and 
functional sequelae of CCI in PDAPP mice have been extensively characterized (Brody 
and Holtzman, 2006, Nakagawa, et al., 1999, Nakagawa, et al., 2000, Smith, et al., 1998).  
Although direct cortical impacts were not yet described in the Tg2576 mice, they had 
been studied using a model of repetitive-concussive closed-skull injury (Uryu, et al., 
2002, Yoshiyama, et al., 2005).  Secondly, intracerebral microdialysis of human-
sequence Aβ has been described in both PDAPP and Tg2576 (Cirrito, et al., 2008, 
Cirrito, et al., 2003, Cirrito, et al., 2005, Kang, et al., 2007, Kang, et al., 2009).  This 
allowed us better time resolution as well as the measurement of human-sequence peptide, 
whose dynamics may significantly differ than the non-aggregating mouse homologue.  
As in the wild-type mice, ISF levels of human-sequence Aβ in PDAPP mice were 
significantly decreased compared to baseline.  Complete results of experiments with all 
transgenic mice are described in the submitted manuscript (Ch. 5) and elsewhere as 
appropriate.  
 
Addition of local EEG to test the potential correlation with ISF Aβ dynamics 
Given the correlation between changes in Aβ with changes in neurological status 
as demonstrated by the human study, we decided to incorporate measurement of local 
neuronal activity in our animal model.  Others in the group had used a simple two-
electrode recording system to measure potential differences in the vicinity of a 
microdialysis probe (Cirrito, et al., 2008, Cirrito, et al., 2005, Kang, et al., 2007, Kang, et 
al., 2009).  We determined that this system would provide a suitable way to test the 
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hypothesis that TBI-induced changes in local neuronal activity might be related to post-
injury Aβ dynamics.   
 
Final considerations of mechanism 
What other factors are associated with the acute decrease in interstitial levels of 
Aβ?  Previous studies from the group have shown that ISF Aβ levels are dependent in 
large part on synaptically-coupled endocytic activity (Cirrito, et al., 2008).  Might the 
changes we observed in our initial experiments be due to changes in neuronal or synaptic 
activity following TBI?  We designed and tested several of these potential mechanisms, 
which will be described in later chapters of this thesis.  The next chapter will present the 
model of injury, electromagnetic-controlled cortical impact, previously characterized in 
the lab. 
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Chapter 2. 
 
Experimental TBI and functional evaluation 
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Types of experimental TBI 
There are a number of well-characterized animal models of experimental 
traumatic brain injury (Morales, et al., 2005).  Experimental TBI can be subdivided into 
focal, diffuse, and mixed types of injury.  Focal models include weight-drop, controlled 
cortical impact, midline fluid percussion, and optic nerve stretch.  Diffuse models include 
impact acceleration and inertial acceleration injuries.  Mixed injury is modeled by the 
lateral fluid percussion technique.  A novel type of injury, commonly termed “blast,” 
results from exposure to the explosive devices employed in military conflict and terrorist 
activity (Cernak and Noble-Haeusslein, 2009).  Blast injury has profoundly devastating 
systemic effects, acting simultaneously on the brain and body.  Efforts are ongoing to 
fully characterize this injury in the clinical realm and to develop appropriate animal 
models. 
Controlled cortical impact (CCI) is achieved by a metal impounder “tip” driven 
by a column of compressed air (pneumatic CCI) or electromagnetic discharge (EM-CCI).  
As the name implies, the cortex is directly contacted by the impounder tip.  To do this, 
the skull is removed by trephinning (craniotomy) prior to impact.  Injury severity is 
graded primarily by varying the depth, but also velocity and dwell time of the impact.  
The resultant injury is a focal contusion.  In humans, this type of injury is also usually 
described as a contusion. 
As an experimental model, CCI recapitulates salient features of clinical 
contusions, including acute hemorrhage, axonal injury, contusion, blood–brain barrier 
dysfunction and, in some species, coma.  Early spontaneous seizures within 24 hours 
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after CCI have been observed in rats (Nilsson, et al., 1994).  A very recent report suggests 
the occurrence of post-traumatic epilepsy 6-10 weeks after injury in CD-1 mice (Hunt, et 
al., 2009).  The histological and functional effects of CCI have been described in wild-
type mice (Saatman, et al., 2006, Smith, et al., 1995) and in PDAPP mice (Brody and 
Holtzman, 2006, Nakagawa, et al., 1999, Nakagawa, et al., 2000, Smith, et al., 1998).   
 
Controlled cortical impact: details of the technique 
CCI is conducted only on deeply anesthetized animals.  The cortex is first 
exposed by removing the bone above the area that will be impacted.  The bone may be 
drilled by a hand trephine or microdrill.  Dura mater is left intact.  The diameter of the 
craniotomy usually depends on the size of the impactor tip.  For example, a widely used 
combination is a 5.0 mm craniotomy for a flat-tip 3.0 mm impactor tip.  Stereotaxic 
coordinates are used to precisely orient the drill and tip relative to fiduciary landmarks on 
the skull, such as bregma, sagittal, and lambdoid sutures.  Then, the impactor tip is 
centered over the region of interest and a reference depth is established.  In our lab, we 
use a low-voltage touch sensor that produces both light and sound when the impactor tip 
just touches the dura.  The tip is then withdrawn into a cocked position, lowered to the 
desired depth of impact, and discharged to full extension to impact the cortex.  Impactor 
velocities typically range from 2-7 m/s with a dwell time on the order of 100s of 
milliseconds.  Our impactor discharges at 5 m/s, with a dwell time of 100 ms.  
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Figure 4.  Electromagnetic impactor mounted on stereotactic frame with microdrill 
and 5.0 mm trephine.  Inset, 3.0 mm impactor tip.  From Brody et al., 2007.   
 
 
 
Advantages of the electromagnetic controlled cortical impact (EM-CCI) 
Because we use transgenic mice, it was important to have a system that was 
reliable and precise in order to reduce the variability, thereby reducing the number of 
mice needed to detect significant differences.  Original versions of this model employed a 
pneumatic system, whereby the flat-tip metal impounder was driven by a column of 
compressed air.  In conjunction with a professor of mechanical engineering, Philip Bayly, 
the lab designed an electromagnetic coil-based system operated by a custom MATLAB 
program (Fig. 4; hereafter referred to as “EM-CCI”).  A chief advantage of EM-CCI 
device over pneumatic impactors is the relative absence of overshoot (Brody, et al., 
2007).  A range of injury severities were characterized by gross histology, stereological 
cell counting, Morris water maze testing, and rotarod testing.  These results were 
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compared to those described for injuries produced by a pneumatic impactor.  It was 
determined that the increased control in the impactor’s trajectory yielded more precise, 
reproducible injuries.  As a consequence, a lesser number of mice per group was required 
to detect significant differences (Brody, et al., 2007).   
 
Usefulness of the hippocampus as an experimental test structure 
Because we wanted to recreate important aspects of clinical TBI in the CCI 
model, an appropriate behavioral evaluation was necessary.  Sensitive functional tests for 
CCI-injured mice include composite neuroscore, wire grip, beam balance, beam walk, 
rotarod, grid walk, forelimb use, Barnes maze, and Morris water maze tasks (Fujimoto, et 
al., 2004).  These tests assess a range of functions, including sensorimotor and memory 
functions.  Due to our overarching interest in TBI-related dementia, we chose to model 
memory impairments.  Many brain-injured patients suffer debilitating deficits in implicit 
and explicit memory (Vakil, 2005).  Functional MRI and PET studies suggest that 
different types of memory functions depend on different networks of structures and tracts 
(Gabrieli, 1998, Mizumori, et al., 2004).  Likewise, human TBI is typically of a diffuse 
nature, affecting multiple structures.  How do we isolate a testable memory function in 
our animal model? 
In rodents, spatial learning and memory were first believed to localize to the 
hippocampus  based on in vivo recording of “place cells” of the CA1 and CA3 regions 
(O'Keefe and Dostrovsky, 1971).  Based on these initial observations and an extensive 
literature, it is well documented that selective damage to the hippocampus results in 
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impaired spatial learning and memory in rodent models.  Such impairments are evaluated 
by various maze assessments (Paul, et al., 2009).     
CCI is an appropriate injury model to create hippocampal damage and deficits in 
spatial learning and memory.  The epicenter of impact can be stereotactically positioned 
over the hippocampus.  There are a range of depths that will damage the hippocampus in 
a graded manner as quantified by cell loss, IgG extravasation, reactive gliosis, and MAP2 
immunoreactivity within 15 minutes to 7 days post-injury (Saatman, et al., 2006) and 
atrophy at 30-45 days post-injury (Brody, et al., 2007).  It has previously been shown that 
CCI-induced damage affects spatial learning and memory as assessed by the Morris water 
maze in various strains of wild-type and transgenic mice (Fox, et al., 1999, Nakamura, et 
al., 1999, Scherbel, et al., 1999, Sinz, et al., 1999).  The Morris water maze can also 
reveal deficits in executive functions such as search strategy, particularly in mice that 
express various forms of human APP (Brody and Holtzman, 2006, Janus, 2004). 
 
The Morris water maze: set-up and brief procedural details 
The Morris water maze is a well-characterized, widely used model of spatial 
learning and memory in rodents (Crawley, 2000, Morris, et al., 1982).  It has been 
employed in various areas of neuroscience research, including experimental TBI 
(Fujimoto, et al., 2004).  The task is predicated on the observation that mice can swim, 
but are motivated to escape water.  The apparatus consists of a pool (diameter, 118 cm) 
filled to within 10 cm of the upper edge with water made opaque by white nontoxic 
tempera paint (Fig 5).  The pool contains a round platform (diameter, 11 cm) that the 
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mice can climb on to escape the water.  The pool is located in a well-lit room that 
contains different visual “cues” in fixed locations.  For example, we use colorful posters 
and worklights.  Mice are first trained in the escape task with a marked, visible platform 
during 60 s-trials.  Then, during similar timed trials, mice are required to learn and 
remember the location of a platform hidden just below the surface of the opacified water.  
To track and record the mouse’s trajectory, an overhead video camera records the 
animals' swim paths (Fig 5; San Diego Instruments, San Diego, CA). 
 
Figure 5.  Morris water maze.  Pool filled with opacified water during the HIDDEN 
task.  Trajectories recorded by the software are superimposed on a photograph.  From 
http://www.iop.kcl.ac.uk/iopweb/blob/downloads/locator/l_622_watermaze.jpg. 
 
 
 
Specific tasks in the MWM assess learning and memory 
For the training period, also called CUED or VISIBLE task, the platform is 
visibly marked by a bright orange, 1-foot tall stick.  The platform surface is also slightly 
above the water level.  Mice are placed into the pool by hand at one of four release 
points.  The mouse can then see the platform and learns to swim to the platform and 
climb on it to escape the water.  Importantly, the mice are released from each of 4 
different quadrants in each trial.  The novelty of the start location requires the mouse to 
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rely on multiple cues, including the orange stick and cues around in the room, to 
construct a complex spatial configuration.  For most experiments, 4 trials per day, 1 
quadrant per trial, for each of 3 days of CUED training are sufficient for the mice to learn 
to quickly and directly swim to the platform.  The mice are then allowed two days of rest 
and consolidation.  Next comes the testing period, which often consists of two main 
tasks: the HIDDEN or SPATIAL task, and the PROBE trial.  In the HIDDEN task, the 
orange stick is removed and the platform surface is submerged 0.5 cm below the surface 
of the water such that it is not directly visible to a swimming mouse.  The HIDDEN task 
is often conducted at a rate of 4 trials per day for each of 5 days.  Mice must again learn 
and remember the location of the platform using only the visual cues in the room (the 
colorful posters and worklights).  At the end of the 5th day, the PROBE trial is conducted.  
In this test, the platform is removed entirely from the pool and the mice will swim around 
in the vicinity of the platform.  Mice are allowed only 30 s and are then removed from the 
pool.  Mice that have learned the location of the platform will spend a greater proportion 
of the time in the quadrant that formerly held the platform.     
 
Training for the MWM: Hartman study 
 To better learn the execution and analysis of Morris water maze testing, I was 
recruited to conduct an experiment to complete a study by a previous postdoctoral 
candidate in the Holtzman laboratory, Richard Hartman.  He assessed the effects of long-
term administration of pomegranate juice with respect to amyloid plaque burden, Aβ 
tissue levels, and assessment of spatial memory (Hartman, et al., 2006).  In this study, 
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mice expressing a prion-promoter controlled transgene for the Swedish mutant human 
amyloid precursor protein (referred to in the paper as APPSw; also called Tg2576 mice) 
were given pomegranate juice (PJ) at a concentration equivalent to that of an adult human 
consuming 1 or 2 8-oz glasses of juice per day.  The treatment regimen began at 6 months 
of age and continued until 11.5 months, when behavioral testing was initiated.  Treatment 
was continued throughout testing.  The control group received sugar water in an identical 
composition and concentration of that found in PJ.  APPSw mice fed PJ demonstrated 
superior learning in the Morris water maze, finding the platform more quickly in the 
CUED task and spending more time in the vicinity of the platform in contrast to APPSw 
mice fed sugar water.  To determine whether or not the effects of PJ were specific to the 
tissue levels of human Aβ and amyloid plaque formation, the same experiment was 
conducted on wild-type (littermate) mice.  I was assigned to conduct all treatment and 
MWM testing in the wildtypes.  There were no differences between groups given either 
PJ or sugar water, neither in distance traveled nor in swim speed (Fig. 6).  This result 
means that the mice learned and remembered platform location equally, and their 
physical abilities and motivation to escape the water were also equal.  This suggested that 
the effects of PJ on MWM learning were specifically mediated through effects on Aβ and 
amyloid plaque burden. 
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Figure 6.  MWM testing.  Wildtype controls were fed either pomegranate juice (PJ, dark 
circles) or sugar water (vehicle, open circles) for six weeks and tested in the MWM using 
CUED and SPATIAL tasks.  A, total distance recorded in the CUED and SPATIAL 
tasks.  B, swim speed calculated in the CUED and SPATIAL tasks.  Neither total distance 
nor swim speed differed between groups.  From Hartman et al., 2006.   
 
 
 
 
Learning assessment of CCI-injured mice in the MWM: Brody study 
Secondly, in response to a manuscript review for the lab’s paper describing the 
characterization of the EM-CCI device, we were asked to evaluate an additional, milder 
injury severity in terms of MWM (Brody, et al., 2007).  I was recruited to perform 
injuries and assess mice in the MWM.  Three groups of B6SJL mice (wild-type) were 
pseudo-randomly assigned to a sham, 1.5 mm, or 2.5 mm injury.  These mice were 
allowed to recover for 12 days, and tested in the MWM by myself and a senior 
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technician, Michael Spinner.  A similar experimental design as in the previous study was 
used: 3 days of visible testing, 2 days of rest, and 5 days of hidden testing with a probe 
trial at the end of the 5th day.  Shown below is a figure describing the lack of an effect in 
the MWM of 1.5 mm depth (Fig. 7).  Not shown are data for the 2.5 mm injury; deficits 
in MWM tasks were similar to the previous two investigators’ groups, also presented in 
this paper.   
 
Figure 7.  B6SJL (wildtype) mice injured at 1.5 mm depth show no significant 
differences from sham-injured animals in the visible and hidden tasks in MWM.  
From Brody et al., 2007.   
 
 
 
 
The concordance of the results of these behavioral experiments in wild-type mice 
with others in the lab suggested that we were prepared to combine CCI with 
microdialysis, first in wild-type and then in APP-transgenic mice, towards our ultimate 
goal of measuring hippocampal Aβ dynamics before and after brain injury.  The next 
chapter will provide some background on brain microdialysis in research and clinical 
applications. 
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Chapter 3. 
 
Brain microdialysis in research and clinical studies 
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Microdialysis: origins in the push-pull canula 
The origins of microdialysis were first described in the early 1960s, when push-
pull canulas were inserted into animal tissues to sample from the extracellular space 
(Myers, 1986).  Before in vivo sampling was possible, it was difficult if not impossible to 
measure specific neurotransmitters in discrete anatomical regions.  Most techniques 
relied on biochemical extraction and analysis of post-mortem tissue.  To improve the 
specificity for region-specific physiological activity, push-pull canulas were developed 
for use in the brain.  Two canulas, usually metal but sometimes glass or plastic, are 
placed side by side into tissue.  Early designs employed large-bore syringe needles, for 
example.  A syringe or peristaltic pump pushes fluid through one canula, and a separate 
pump pulls fluid from the second canula at the same rate.  Using an adaptation of a 
design originally to measure bradykinin in the skin of human volunteers (Fox and Hilton, 
1958), Delgado and colleagues measured acetylcholine (ACh) release in the caudate 
nucleus and motor cortex in unanesthetized monkeys (Delgado and Rubinstein, 1964).  In 
addition, they placed an electrode next to the canulas and were able to measure the effects 
of local electrical stimulation on neurotransmitter levels (Fig. 8). 
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Figure 8.  Push-pull canulation in the awake monkey.  Two #27 stainless steel tubes 
(1), soldered together with electric recording probes (5).  Figure from J.M.R. Delgado, 
1966.  Intracerebral perfusion in awake moneys.  Arch. Int. Pharmacodyn. Ther. 161: 
442-462. 
 
 
 
 
 
In the same year, a colleague reported measurements of ACh and dopamine in the 
caudate nucleus of anesthetized cats, and enhanced ACh release upon thalamic 
stimulation (McLennan, 1964).  Perfusion became a critical technique to study discrete 
brain regions in living animals.  Not only could cerebral metabolites, neurotransmitters, 
and hormones be measured under physiological conditions, the response to homeostatic 
challenges such as temperature and appetite could be documented.  For example, cross-
perfusion experiments revealed the solubility and sites of production and action of 
hypnogenic, appetitive, and satiety factors (Drucker-Colin, 1973, Yaksh and Myers, 
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1972).  Further, the effect of drugs and electrical stimulation on endogenous species 
could be investigated.  These initial studies established push-pull perfusion as an 
invaluable experimental tool.   
 
Limitations of push-pull canulas 
However, push-pull canulas were limited by their tendency to cause tissue 
damage and the lack of controls for effects of technical design details.  Firstly, even in the 
absence of perfusion, simple insertion of the rigid canula into soft tissues such as brain 
parenchyma was enough to cause a measureable lesion along the tract (Yaksh and 
Yamamura, 1974).  Secondly, at perfusion rates 50-100 times faster than are typically 
used in modern probes, fluid pressure could damage tissue as reflected in dialysate 
protein concentration (Yaksh and Yamamura, 1974).  A lesion could also result from 
pressure differences due to a mismatch in push and pull flow rates.  In this case, 
dislodged tissue fragments could occlude the canula lumen (Myers, 1986).  Finally, there 
were very few controlled experiments to determine the effects of repeated insertions of 
the canula, the size of the device, the perfusion rate, separation between the tips of the 
push and pull tubes, and the longevity of perfusion (Myers, et al., 1998). 
 
Evolution of the modern microdialysis probe 
In contrast to an open push-pull canula system in which neural tissue is bathed 
directly in perfusate, other configurations consisted of a “dialysis bag.”  This was a 
permeable membrane attached to the end of the canulae, filled with perfusion fluid and 
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left to equilibrate with the surrounding medium (Bito, et al., 1966, Delgado, et al., 1972).  
This is equivalent to the “zero flow method” for which complete equilibration across the 
membrane is allowed to occur over a theoretically unrestricted period of time.  However, 
for longitudinal measurements in the same subject, samples need to be collected after a 
finite period of time.  Furthermore, the exchange surface needs to be constantly refreshed 
with new perfusion fluid.  A flow of perfusate would thus permit partial equilibration of 
solutes across the membrane, but also allow samples to be collected in discrete time 
intervals.  These ideas were realized by the “hollow-fiber” configuration (Delgado, et al., 
1984).  In 1974, Ungerstedt and Pycock reported on the use of hollow fibers in their study 
of dopamine transmission in the rodent brain (Ungerstedt and Pycock, 1974).  The fibers 
were composed of semi-permeable material.  A perfusion fluid was flowed through the 
hollow fibers.  Only molecules that could diffuse across the material, the membrane, were 
collected in the dialysate.  The method had many advantages over the push-pull 
canulation systems.  While sampling was selective for small, easily diffusible species, 
tissue damage using a soft, flexible membrane probe was minimal and measurements 
were more reliable than push-pull canulation (Myers, et al., 1998).  These prototypes 
evolved into modern versions of the microdialysis probe.  An example of a rodent 
research probe is shown in Figure 9.      
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Figure 9.   Bioanalytical Systems BR-2 38 kD cutoff microdialysis probe and guide 
canula for rodents.  Left, microdialysis probe has inlet (yellow) and outlet (green) ports.  
The 2.0 mm-long, 0.320 mm diameter exchangeable membrane is seen at the tip of the 
probe.  Right, corresponding guide canula with plastic shaft.  The probe fits by tongue-
and-groove through guide canula, shown with dummy stylet.  When inserted into guide 
canula, only the 2.0 mm probe membrane protrudes.    
 
 
  
 
Theory of microdiaylsis sampling 
Microdialysis sampling primarily depends on several factors: concentration 
gradient of the molecule of interest, flow rate of the perfusate, and the area and diffusion 
characteristics of the membrane (Benveniste and Huttemeier, 1990).  Another 
consideration is the configuration of the inlet and outlet ports with the exchange 
membrane.  A number of arrangements have been described, including side by side 
tubing, loop dialysis probes and linear or “transverse” configurations (Fig. 10) 
(Benveniste and Huttemeier, 1990, de Lange, et al., 1997). 
  
 
 
 
 Figure 10.  Different probe geometries used for intrac
or vertical, U-shaped membrane.  
linear or horizontal/transverse membrane.  From de Lange et al.,1997.
 
 
Most commercially-available probes use a c
 
Figure 11.  A concentric configuration of inlet and outlet tubings in a probe 
designed for intracerebral sampling
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B, side-by-side or vertical, L-shaped membrane.  
 
 
oncentric configuration (Fig. 11).  
.  Adapted from Beraldi Ribeiro, 2009.
 
.  A, loop 
C, 
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The choice of probe configuration depends on the specific application.  For example, 
long-term experiments to measure circadian fluctuations of melatonin in the pineal gland 
have been facilitated by a linear or transverse probe (Borjigin and Liu, 2008). 
The first principle is that molecules move according to their concentration 
gradient, from areas of higher to lower concentration (Fig. 12).  For example, if a 
molecule is to be infused into tissue, there should be a much higher concentration in the 
perfusate than in the surrounding tissue.  Likewise, if an endogenous molecule is to be 
sampled from the tissue, its concentration in the perfusate should be much lower than the 
region of interest. 
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Figure 12.  Schematic of a research microdiaysis probe schematic demonstrating 
inflow and outflow pathways, and exchange of small molecules across the 
membrane.  The perfusate contains an infused molecule (black circles) that can 
exchange across the membrane into the tissue.  Simultaneously, an endogenous molecule 
(white circles) exchanges across the membrane into the outflow dialysate.  Adapted from 
Chaurasia et al.  AAPS-FDA Workshop White Paper: Microdialysis Principles, 
Application, and Regulatory Perspectives Report From the Joint AAPS-FDA Workshop, 
November 4-5, 2005, Nashville, TN.  AAPS Journal. 2007; 9(1): E48-E59. 
 
 
 
  
The second principle is that recovery is inversely related to perfusion rate.   Based 
on theoretical models of diffusion and informed by empirical data, a mathematical 
function can be used to predict recoveries based on flow rate (Jacobson, et al., 1985, 
Outflow 
(dialysate)
Inflow 
(perfusate)
Shaft
Semi-permeable 
membrane
IN
OUTOUT
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Johnson and Justice, 1983, Menacherry, et al., 1992).  Often, this function takes the form 
of a first-order exponential decay, although empirical data should always be used to 
determine the best-fit function.   
Thirdly, the choice of membrane material will influence the types and quantity of 
sampled species.  Materials are described as “semi-permeable” or “porous.”  Beyond that, 
materials vary considerably in their electrostatic nature.  Some are more hydrophilic 
(cellulose acetate, polycarbonate, polyacrylonitrile), whereas others are more 
hydrophobic (polysulfone-based materials).  While the recovery of some small 
molecules, such as urea, does not appear to differ meaningfully among membranes, 
material composition can have a dramatic effect of recovery of large species, such as β2 
microglobulin (Ouseph, et al., 2008).  Proteins pose a particular challenge.  Not only can 
they adsorb to the synthetic polymer materials, they can accumulate in pores.  Pores 
resemble tunnels relative to the size of most relevant proteins when examined at the 
resolution of a scanning electron micrograph (Fig. 13, from Rosenbloom et al., 2005). 
Figure 13.  Scanning electron micrograph of CMA 20 (PES) microdialysis 
membrane.  Left, close en face view of material porosity.  Scale bar, 2 µm.  Right, cross-
sectional view at lesser magnification.  Scale bar, 50 µm.  From Rosenbloom et al., 2005. 
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Hydrophobic materials are especially adsorptive for proteins.  One solution is to 
create an intermediate composition by the addition of a polymer such as 
polyvinylpyrrolidone (PVP) to impart hydrophilicity.  Such a material then has 
hydrophilic-hydrophobic “microdomains,” such as polyarylethersulfone (PAES). 
Related to material composition is the molecular weight cutoff (MWCO).  The 
MWCO is a boundary beyond which approximately 80% of dextrans of that size are non-
exchangeable (CMA literature).  Because the MWCO rating is empirically determined 
using the exchange characteristics of dextrans, it is nominal with respect to biological 
macromolecules.  The MWCO rating often fails to accurately describe the recovery of 
proteins.  For example, a recent study concluded that proteins larger than 43 kD were 
mostly irrecoverable using a CMA 20 probe of nominal cutoff 100 kD (Rosenbloom, et 
al., 2005).  This study recommended the CMA 20 be rated at 29 kD for most proteins.   
Membrane pore sizes in high MWCO membranes are often orders of magnitude 
larger than the expected radius of individual proteins.  The discrepancy between 
apparently favorable pore-to-protein size ratios and the low recovery of higher molecular 
weight species may seem paradoxical.  However, the path through a network of pores to 
reach the inside of probe is tortuous, and may be 10,000 times longer than the protein’s 
diameter.  The relationship of each protein to each membrane material must be 
individually characterized. 
A related factor in the recovery of large molecular weight species in a high 
MWCO probe is that of volume recovery.  Volumes of the dialysate can either be 
increased due to ultrafiltration (fluid flow into the probe from tissue) or decreased due to 
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loss of perfusate into the tissue.  In a low MWCO probe, given the isotonicity and ionic 
balance between perfusate and tissue, net fluid exchange does not usually occur.  
However, in higher MWCO probes with pore sizes on the order of microns, net fluid 
exchange can be problematic.  The balance between hydrostatic pressure of the fluid 
column through the membrane and oncotic pressure on the dialysate from the tissue will 
dictate the net gain or loss of water from the microdialysis probe.  Because of the 
relatively large pore size in the high MWCO membranes, and the back-pressure imposed 
by the perfusion rate, fluid will escape from the system into the lower pressure tissue 
without any colloidal forces to maintain net zero pressure. 
Finally, many proteins tend to bind synthetic surfaces, including membranes, 
tubing and at junctions.  For example, despite a molecular weight of approximately 4 kD 
for monomeric Aβ, this species is irrecoverable without the addition of albumin to the 
perfusate.  It is thought that albumin coats or carries this highly “sticky” peptide across 
the membrane and through the tubing, preventing its binding to synthetic surfaces.   
 
Clinical applications of microdialysis 
Since the first publications from Ungerstadt and colleagues in the mid-1980s, the 
clinical cerebral microdialysis literature has amassed hundreds of studies describing 
measurement of metabolic molecules such as lactate, pyruvate, glucose, and urea; the 
neurotransmitters, glutamate, GABA, glycine, acetylcholine, dopamine, serotonin, and 
histamine; and other molecules.  The full range of clinical applications has not been fully 
explored and is under active investigation.  Although cerebral microdialysis is used 
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routinely in some centers in Europe to monitor surrogates of cerebral metabolism, it is 
not commonly used in the U.S.  The delayed adaptation of new monitoring technology is 
not uncommon in intensive care, as is demonstrated by the case of invasive intracranial 
pressure monitoring (Hillered, et al., 2005).  In the case of microdialysis, there are a few 
well-studied markers of clinical events that would merit widespread adaptation of this 
technique.  Most notably, microdialysis measurement is very sensitive to disturbed 
glucose metabolism as detected by glucose, lactate, pyruvate, the lactate/pyruvate ratio, 
the lactate/glucose ratio, and pH (Hillered, et al., 2005).  These studies have provided 
otherwise inaccessible information about metabolic disturbances in the extracellular 
space in a variety of neurological insults (Hillered, et al., 2005).   
Not only can microdialysis aid in the characterization of physiological events, it 
can help to monitor the effectiveness of interventions.  For a drug treatment, these 
methods are pharmacokinetics (the measurement of drug metabolism) and 
pharmacodynamics (the measurement of a drug’s effect on a particular target).  The 
targets in published pharmacodynamic studies are often the same molecules and 
neurotransmitters first described in studies of basic physiology (Hillered, et al., 2005). 
However, many drugs target larger peptides and proteins.  In 2005, our lab was 
actively testing anti-Aβ strategies such as passive immunotherapy and γ-secretase 
inhibitors.  Therefore, we conceived the microdialysis experiments as a novel technique 
for pharmacodynamic studies of such anti-Aβ strategies.  At this time, we were also 
developing an interest in proteins thought to be increased in the CSF after TBI and 
subarachnoid hemorrhage, such as tau and neurofilament, and began to explore the 
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technology available to measure the ISF levels of these species by microdialysis.  As 
these proteins are approximately 50 and 68 kD, respectively, their detection would be 
unlikely using the standard clinical catheters.  Fortunately, a high MWCO human catheter 
had recently been introduced (Fig. 14). 
 
Figure 14.  CMA-71 100 kD cutoff patient microdialysis catheter. 
    
 
Measurement of higher-molecular weight species using human catheters 
 The only catheters that are FDA-approved for use in human patients are 
manufactured by CMA Microdialysis of Sweden.  Measurement of small molecules in 
the brain has been extensively studied using the CMA70 model, which has a 20 kD 
MWCO rating (Hillered et al., 2005).  The exchange membrane of a CMA70 consists of a 
polyamide material.  More recently, the introduction of the CMA71 catheter with a 100 
kD MWCO rating has permitted detection of larger species such as cytokines, as well as 
peptides and proteins implicated in neurodegenerative disease (Brody, et al., 2008, 
Marklund, et al., 2009).  The exchange membrane is composed of the synthetic material, 
polyarylethersulphone (PAES), and is approximately 10.0 mm long with a diameter of 
0.50 mm.  Using a standard flow rate of 0.3 µL/min, the lab was able to measure tau and 
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neurofilament light-chain in some patient microdialysis samples (Magnoni, 2009).  The 
recovery of small molecules is similar to the CMA 70 (Hillman, et al., 2005).  However, 
very few studies have been able to measure detectable levels of such large proteins, and 
none have conducted controlled experiments to quantify relative recovery.  
The challenges of microdialysis with high molecular weight membranes have 
been described in the literature (Clough, 2005, Rosenbloom, et al., 2005).  Recently, a 
study used scanning electron microscopy to compare a CMA 71 probe used in only an in 
vitro solution (the in vitro probe) with another CMA 71 probe that had been placed in a 
human patient for 48 h (the  ex vivo probe).  These images demonstrate the invasion of 
pores by biological debris in the ex vivo probe (Helmy, et al., 2009).  In contrast to an in 
vitro probe (Fig. 15), the ex vivo probe appears to be clogged or “biofouled” (Fig. 16).  
Figure 15.  Scanning electron micrograph at various magnifications of CMA 71, 
after 48h in vitro experiment bathed in CNS perfusion fluid + recombinant IL-1. A, 
PAES outer membrane showing large pores and occasional merged pores. B, inner shaft 
of non-porous material polyurethane. C, higher magnification view of porous material. D, 
on-end view of pores within outer PAES membrane. From Helmy et al., 2009. 
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After 48 hours in vivo, it appears there may be some invasion of the pores by large 
biological debris, such as cells (Fig. 16). 
Figure 16.  Scanning electron micrograph of CMA 71 after 48h in vivo. A, on-end 
view of isolated membrane.  The inner tube has fallen out.  Note larger pore size on the 
outer surface, compared to the inner surface. B, higher magnification view of outer 
membrane showing pores of diameter several microns with occasional particulates, 
possibly cells. C, D, E, highest magnification view of outer surface membrane 
demonstrating material in pores. F, pores on the inner surface of the membrane appear to 
have a much smaller diameter than on the outer surface.  From Helmy et al., 2009. 
 
 
57 
 
Cytokines: example of recovery of higher molecular weight species 
 One example of recovery of higher molecular weight species in cerebral 
applications is that of inflammatory cytokines.  Since 2005, several groups have reported 
the recovery of cytokines using the CMA 71 100 kD catheter (Hillman, et al., 2005, 
Hillman, et al., 2007, Hutchinson, et al., 2007, Mellergard, et al., 2008).  Using a standard 
pump rate of 0.3 µL/min, perfusion solutions contained either 3.5% human albumin or 
Ringer-dextran 60 (RD60) to avoid net volume loss.  In particular, levels of IL-6 tracked 
with changes in the L/P ratio and glycerol levels in patients with severe TBI or 
subarachnoid hemorrhage (Hillman, et al., 2005).  IL-6 has a molecular weight of ~24 
kD.  A follow-up study validated these initial results using 3.5% human albumin 
exclusively in the perfusate as an oncotic agent.  It was determined that interstitial levels 
of IL-6 corresponded better than IL-1β to ischemic events and general brain “stress” 
(Hillman, et al., 2007).  Additionally, this paper described the measurement of vascular 
endothelial growth factor (VEGF) and cathepsin-D in one or two patients, indicating that 
recovery of these proteins is also possible.  VEGF exists as a homodimer of molecular 
weight 45 kD, and as a monomer of approximately 23-26 kD.  Cathepsin-D has multiple 
mature isoforms, with molecular weights detected at 15 kD (light chain) and 28-35 kD 
(heavy chain).  Further studies looked at the roles of other cytokines: IL-1α, IL-1β, and 
IL-1ra, and again compared their dynamics to the L/P ratio as a marker of anaerobic 
stress (Hutchinson, et al., 2007).  The molecular weights of IL-1α, IL-1β and IL-1ra are 
approximately 17 kD.  Finally, another group looked at concentrations of a number of 
other cytokines as well as VEGF and basic fibroblast growth factor (bFGF, molecular 
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weight ~17 kD) (Mellergard, et al., 2008).  They compared two probe locations, one in 
macroscopically normal tissue and one in pericontusional tissue.  All probes were 
perfused with Ringer dextran 60 (RD60).  As expected, ISF levels of cytokines were at a 
detectable level throughout the monitoring periods.  In contrast, VEGF was undetectable 
in the sickest patients.  FGF was detectable in the first 6-12 hours immediately after 
microdialysis catheter was implanted, but rapidly dropped off to a plateau and remained 
close to the limit of detection over the course of 36 hours.              
Experimental probes have been custom-built to study other, larger proteins in 
human patients.  Recently, one group reports that use of a 3000 kD MWCO probe 
(Metalant, Sweden) with peristaltic push-pull perfusion permits the in vivo measurement 
of the inflammatory cytokines, IL-1β and IL-6, and nerve growth factor (NGF) from 
patients with severe TBI (Winter, et al., 2002, Winter, et al., 2004).  NGF is secreted into 
the extracellular space and exists in vivo as a 26-29 kD dimer.  As endogenous controls, 
total protein and albumin levels measured in dialysate remained relatively constant over 
periods of up to 5 days.    
 
Importance of pumping method: push-pull vs standard pumping 
Despite these promising results, measurement of larger proteins has been 
challenging in the CMA 71 probes using the standard, constant-flow clinical pump.  
Studies have been done in other tissues, such as skin, with the CMA 60 catheter (Sjogren, 
et al., 2002).  Like the CMA 71 designed for cerebral monitoring, the CMA 60 has a 100 
kD MWCO rating.  This study compared push-pull pumping with standard pumping at 
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the same flow rates.  Recovery of the cytokine IL-6 was undetectable until ~120 minutes 
after implantation of the probe in the standard conditions, whereas it was detected by 100 
minutes under push-pull conditions.  Levels of IL-6 remained elevated throughout the 
rest of the experiment (~210-270 minutes) in both conditions, but were higher in push-
pull conditions.  Notably, this study did not correct for volume loss through the probe 
with an oncotic agent, such as albumin or dextrans. 
 
Motivation and rationale for higher molecular weight species in TBI 
 In the search for “biomarkers” of traumatic brain injury, there are several 
compartments that can be sampled.  Two are accessible by routine methods: plasma, by 
simple arterial or venous blood sampling, and CSF, by ventricular drain or lumbar 
puncture if increased ICP is not a concern.  Proteomic studies in these compartments 
have revealed significant changes in many species, including higher molecular weight 
species (Hanrieder, et al., 2009, Ottens, et al., 2007, Prieto, et al., 2008).   
While it was clear that measurement of pre- and post-injury dynamics of Aβ was 
possible, we were also interested in known protein markers of traumatic axonal injury 
described in studies of post-injury CSF samples.  For example, ventricular CSF 
measurements show that the microtubule-stabilizing protein, tau (50 kD), is increased in 
the setting of acute injuries and correlates with 1-year outcome (Ost, et al., 2006).  
Similarly, various isoforms of neurofilament-heavy chain are acutely increased in the 
CSF after injury (Siman, et al., 2009).   
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Although CSF profiles from injured patients can be significantly different than 
healthy controls, the meaning of these changes with respect to the injured brain is less 
straightforward.  The passage of proteins such as tau and neurofilament from the ISF into 
the CSF is complex.  CSF levels may not accurately reflect changes in brain parenchyma.   
Direct measurement of tau and neurofilament in the ISF would be preferable.  Such 
proteins posed a significant challenge to our mouse model, however.  Until this point, we 
had been using the BAS BR-2 probe designed for mice, which had a molecular weight 
cutoff rating of 38 kD.  To begin, we turned to the rodent research version of the CMA 
71, the CMA12, to attempt dynamic measurement of tau.        
 
Initial studies with CMA 12 probes 
 We first characterized the CMA 12 probe’s recovery characteristics in vitro.  The 
CMA 12 was chosen because its probe membrane material was made of polyethersulfone 
(PES) and is currently made from PAES, identical to the CMA 71 probes used in our 
initial human studies.  This basic research version of the CMA 71 is 2 mm long and 0.5 
mm diameter (Fig. 17).  
 
Figure 17.  CMA-12 100 kD cutoff research probe. 
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First, the issue of perfusate fluid loss was addressed.  Addition of a bulk solute to 
the perfusate is a common strategy to correct for an imbalance between hydrostatic and 
oncotic pressures, thereby preventing the loss of fluid into the surrounding tissue through 
the pores.  The CMA product literature recommended using 3% dextran solution.  Since 
we were already using 1.5% human albumin (hAlb) in the human studies, we decided to 
substitute hAlb for dextran.  A range of hAlb concentrations was compared at a single 
flow rate, 0.5 µL/min: 0.15%, 1.5%, 3%, and 4%.  This flow rate was chosen based on 
the recommendations from the CMA product literature, that an acceptable flow rate range 
was 0.5 – 2.0 µL/min.  We used our standard syringe pump.  Volumes were estimated by 
a mass measurement of the returned volume. Of these flow rates, 0.15% and 1.5% 
returned ~50-67% of the expected volume across at least 6 hours of testing.  The higher 
concentrations of albumin returned 90-100%, with 4% hAlb giving 100% return.  The 
results of this experiment suggested that 4% hAlb was the optimal amount of solution to 
avoid fluid loss. 
Then, we wanted to repeat Aβ microdialysis using the CMA 12 probe in mice that 
we had already characterized using the BR-2 38 kD cutoff probe: PDAPP and Tg2576 
transgenics.  Later, we planned to use the 3X Tg mouse model because it overexpresses a 
human (mutant) form of tau prone to deposition (Oddo, et al., 2003).  Ultimately, we 
wanted to know if we could measure tau dynamics after TBI in these mice. 
Using the CMA 12 probe with 4% hAlb at a flow rate of 0.5 µL/min, the Aβ 
measurements in PDAPP and Tg2576 mice were not as consistent both in terms of 
absolute levels and dynamics during baseline as well as post-injury periods.  We 
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attempted Aβ microdialysis in young Tg2576 (#90), with baseline levels of 500, 200, and 
380 pg/mL and post-TBI levels at 100, then nearly zero over 120 h.  In a second 
experiment again using a young Tg2576 mouse, only one baseline measurement of 800 
pg/mL was measureable on the ELISA standard curve, suggesting a major probe 
malfunction.  After injury, levels ranged between 400-500 pg/mL for approximately 48 h, 
then began to rise to overshoot the baseline (from 800 to a peak of 1600 pg/mL between 
48 and 108 hrs.  These dynamics were abnormal and suggested that the CMA 12 probe 
was not behaving in a predictable way. 
Below are results of the experiments with older PDAPP, young Tg2576, and older 
Tg2576 mice (Fig. 18).  The general conclusion from these initial studies is that the 
concentrations and dynamics measured using the CMA 12 probe with 4% hAlb at a flow 
rate of 0.5 µL/min were less reliable than our standard protocol, using the BR-2 probe 
with 0.15% hAlb at a flow rate of 1.5 µL/min, as described in Chapter 5. 
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Figure 18.  % baseline Aβ in transgenic mice implanted with CMA 12 probes, 
before and after 1.5 mm TBI.  All experiments conducted at 0.5 µL/min.  4% human 
albumin was added to perfusion fluid except in (A).  A, 3% hAlb in an older PDAPP 
mouse. B, an older PDAPP mouse.  C-D, young Tg2576 littermates.  E, a 20-month-old 
Tg2576 mouse.  F, a young Tg2576 mouse.  
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After these unsuccessful in vivo experiments in the summer of 2007, we returned to using 
the BR-2 probe with 0.15% hAlb. 
The following spring, we reattempted in vivo microdialysis with the CMA 12 
probe.  On the hypothesis that some of our issues may have resulted from the high 
percentage of hAlb in the solution, and the possibility that hAlb was clogging the 
membrane, we decided to substitute high-concentration (hyperosmolar) saline solution.  
We determined that 455 µM NaCl was equivalent to 3% human albumin in terms of 
molarity.  Below is a plot of the recovered volumes.  From the time of implantation over 
the course of the next 18-21 hours, volume recovery reached only 40% of expected.  As it 
is plainly evident, hyperosmolar saline solutions do not resolve the fluid loss issues with 
the CMA 12 probe (Fig. 19). 
 
Figure 19.  % volume recovery using hyperosmolar NaCl at an equivalent molarity 
to 3% hAlb (455 µM) .  Volume recovery is initially low at 10% of expected.  Volume 
rises over time, but plateaus by 18 h at 40%. 
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We returned to using 3% hAlb as was done in the original tests in PDAPP and 
Tg2576 mice.  We then thought perhaps the volume recovery might be dependent on the 
flow rate.  Since the back-pressure from the syringe pump might vary according to flow 
rate, we compared 0.3 and 1.5 µL/min in the same animal, before and after TBI.  
Similarly to the BR-2 probe, recovery of Aβ varied with flow rate.  According to our 
zero-flow extrapolation experiments using the BR-2 probe, it was determined that a flow 
rate of 1.5 µL/min yields approximately 6-7% recovery, while 0.3 µL/min yields 
approximately 30% recovery.  Theoretically, the dialysate concentrations collected at 0.3 
µL/min should be approximately 5 times greater than that measured at 1.5 µL/min. Using 
the CMA12 probe, the average Aβ concentration over 24 hours at 1.5 µL/min was 19.4 
(standard deviation, ± 9.5 pg/mL), while Aβ concentration over 24 hours at 0.3 µL/min 
was 108.9 (standard deviation, ± 42.1 pg/mL).  The relative recovery at 0.3 µL/min as 
compared with 1.5 µL/min is 5.6, which is similar to the BR-2 probe (Fig. 20). 
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Figure 20.  Effect of flow rate on Aβ concentration and dynamics using the CMA12 
probe perfused with 3% hAlb in a 3X Tg mouse.  Levels were low and at times 
undetectable at 1.5 µL/min, but increased at 0.3 µL/min.  Levels did not appear to reach 
steady state at 0.3 µL/min over 20 hours.  Taken as a 24-hour average, recovery was 
approximately 5.6 times higher at 0.3 µL/min than at 1.5 µL/min. 
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 Next, we wanted to determine whether we could measure tau using the CMA 12 
probe.  Using the standard syringe pump at a flow rate of 0.5 µL/min, we performed in 
vitro experiments using a variety of tau-containing solutions.  Additionally, due to 
concern that the hAlb (molecular weight, ~50-70 kD) might be clogging this probe, we 
decided to use a higher molecular weight species than the MWCO rating for our oncotic 
agent.  We chose 150 kD dextran at a concentration of 3%.  For the tau-containing in 
vitro solution, we chose a PBS-extracted brain homogenate from an aged 3X Tg mouse.  
This mouse produces a human form of tau, which could be compared with other 
experiments using human microdialysis and ventricular CSF samples.  Below are the 
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results of that experiment (Fig. 21).  Briefly, there were significant fluid losses in the 
initial samples, which eventually normalized over 18 hours.  
Figure 21.  % volume recovery using the CMA12 probe perfused at 0.5 µL/min with 
3% 150 kD dextrans.  Probe was immersed in a 3X Tg mouse brain homogenate. 
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The concentration of Tau in microdialysate samples was quite high in the first two 
samples, but quickly dropped off to near limits of detection by 4.5 h (Fig. 22).   
Figure 22.  Tau recovery in vitro using the CMA12 probe perfused at 0.5 µL/min 
with 3% 150 kD dextrans.  Probe was immersed in a 3X Tg mouse brain homogenate. 
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As with in vivo Aβ microdialysis, there is likely a period of equilibration.  If we consider 
the first 3 hours (first 2 samples) to be a kind of equilibration period, and look at the tau 
dynamics beginning at 4.5 h, we can see they are still detectable (Fig. 23). 
 
Figure 23.  Tau recovery in vitro using the CMA12 probe perfused at 0.5 µL/min 
with 3% 150 kD dextrans.  Probe was immersed in a 3X Tg mouse brain homogenate. 
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However, given that the volumes recovered were constantly changing, the meaning of 
these measurements is uncertain.  Secondly, when the concentration of tau was measured 
for the in vitro solution, it was clear that the efficiency of recovery was quite low.  Pre 
and post-experiment measurements of tau in the homogenate were 810 ng/mL and 897 
ng/mL, respectively.  Comparing the pre-experimental value with the concentration 
measured in the first sample of microdialysate, 4218 pg/mL, this is only a 0.52% 
recovery.  The second sample had a tau concentration of 746 pg/mL, which is a 0.09% 
recovery.  Clearly, the results of this experiment indicate that our methods are insufficient 
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for proper dialysis technique using the CMA 12 high molecular weight probe for 
recovery of larger proteins.    
Very recently, as of the writing of this thesis, the Holtzman lab has reported the 
successful measurement of tau protein in mice using the CMA 12 probes, using push-pull 
perfusion technique and the addition of 4% human albumin to the perfusate.  Previous 
experiments have shown push-pull perfusion to be a superior method for the recovery of 
IL-6 both in vitro and in vivo (Sjogren, et al., 2002).  Future experiments using high 
molecular weight catheters such as the CMA 12 in this lab should test the push-pull 
strategy.   
The following chapter will elaborate on development of the combined CCI-
microdialysis model. 
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Chapter 4. 
 
Development of the combined CCI-microdialysis model 
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Previous studies and specific requirements for site, study length, robustness  
Experimental TBI combined with pre and post-injury microdialysis has been 
described in rat models.  Most experiments combined microdialysis with Marmarou 
weight drop or fluid percussion injury (Alves, et al., 2005, Bramlett and Dietrich, 2001, 
Busto, et al., 1997, Chen, et al., 2000, Chen, et al., 2000, Globus, et al., 1995, Headrick, 
et al., 1994, Jiang, et al., 2004) or a weight drop model (Alessandri, et al., 2000, Koizumi, 
et al., 1997).  Others combined CCI with microdialysis (Bell, et al., 1998, Krishnappa, et 
al., 1999, Marklund, et al., 2001, Marklund, et al., 2001, Marklund, et al., 1997, Palmer, 
et al., 1993, Rose, et al., 2002, Stover, et al., 2003).  The successful combination of the 
techniques was encouraging for our project, and the geometry of a craniotomy in tandem 
with an implanted guide canula seemed feasible. 
However, there were additional challenges to achieve this combination in our 
model.  Firstly, all previous studies had been done in rats.  The rat skull is significantly 
larger than the mouse cranium.  Secondly, most of the previous work had measured acute 
timepoints, ranging from 3 hours to just 15 minutes before an injury to hours following 
an injury.  Thirdly, rats are relatively robust animals and survive experimental TBI with 
minimal mortality.  Transgenic mice can be remarkably sensitive to experimental TBI.  
Our task, therefore, was threefold.  Firstly, the hippocampal microdialysis placement site 
would need to be ipsilateral to a CCI.   The CCI impactor site also was required to be 
identical to the site used in standard EM-CCI experiments (Fig. 24).  Secondly, we 
wanted to achieve longer periods of baseline and post-injury measurements, at least 12 
hours of baseline measurement and 24 hours following an injury.  Thirdly, we wanted an 
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injury that showed a robust effect compared to sham with minimal-to-no complications 
and mortality that could be used in fragile transgenic mice.  
 
Figure 24.  Standardized impact sites with and without microdialysis.  A, EM-CCI 
impact at 2.0 mm depth with 5.0 mm craniotomy shown immediately after impact.  
Courtesy of C. Mac Donald.  B, stereotactically-placed, 3.8 mm craniotomy to 
accommodate microdialysis guide canula. 
 
  
 
Geometrical requirements and implementation 
First, using the Franklin and Paxinos atlas, we chose a site for probe placement 
that would best fit a 2-mm long, 35 kD BR-2 probe from Bioanalytical Systems (BAS, 
West Lafayette, IN).  This probe had been extensively characterized by John Cirrito in his 
pioneering studies of Aβ microdialysis in transgenic mice (Cirrito, et al., 2008, Cirrito, et 
al., 2003, Cirrito, et al., 2005).  The requirements for this placement were twofold: firstly, 
the guide canula could not block the trajectory of the impact; secondly, the probe needed 
to sample a region that was known to be damaged on histological and behavioral criteria.  
Additionally, this site must remain intact as a distinct tissue structure.  For example, the 
A B
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loss of architectural integrity and massive degeneration that occurs in the overlying 
cortex would not provide a representative tissue medium for microdialysis sampling. 
Given ours and previous studies, the ipsilateral hippocampus was the best 
candidate.  Other studies have established that CCI injury causes acute and subacute CA3 
cell loss and hippocampal atrophy (Brody, et al., 2007, Nakagawa, et al., 1999, 
Nakagawa, et al., 2000, Saatman, et al., 2006, Smith, et al., 1998, Smith, et al., 1995).  
Additionally, injury severity is reflected by graded deficits in Morris water maze 
assessments (Brody, et al., 2007, Saatman, et al., 2006, Smith, et al., 1995).  A guide 
canula placement that crossed midline was chosen so that the cement crown could attach 
to the contralateral skull, leaving the ipsilateral skull clear for craniotomy and impact.  
Again using the Franklin and Paxinos atlas, placement at -2.54 mm from bregma along 
the long axis of the hippocampus would serve our purposes (see Figure 25A).  
Coordinates were calculated for stereotaxic placement of the canula, and probe location 
was verified by T2 MRI and postmortem histology (Figure 25C, D).  As in the original 
studies, mice are tethered in the electronic swivel cage (Rat Turn) with the affixed guide 
canula and microdialysis tubing, but are generally free to move about, eat, drink, and 
sleep (Figure 25B).  The cement crown and guide canula did not appear to appreciably 
impair the animal’s behavior in the RatTurn. 
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Figure 25.  Microdialysis probe placement for combined studies with experimental 
traumatic brain injury.  A, schematic of microdialysis probe placement and craniotomy 
for controlled cortical impact TBI.  A rigid guide canula was inserted via a stereotaxically 
placed burr hole. Then, the microdialysis probe was placed through the guide canula into 
the left hippocampus. A 3.8 mm-diameter craniotomy was performed to allow controlled 
cortical impact TBI.  Modified from Franklin and Paxinos (2001). B, photograph of 
awake, moving mouse with implanted canula and probe affixed with dental cement. The 
mice were tethered to an electronic swivel system to prevent tangling of the microdialysis 
tubing.  C, a T2-weighted MR image of living mouse brain with implanted canula and 
probe.  D, post-mortem staining of probe tract with Evans blue dye and counterstained 
with Neutral Red.  Scale bar, 2.0 mm.  
 
 
 
Refinement of the technique: craniotomy placement and sequence 
As part of the model development, we needed to know whether necessary 
manipulations during the CCI injury would affect our measurements of Aβ.  First, the 
craniotomy was assessed.  Initially, we allowed the dental cement to cover the entire skull 
on the assumption that the trephine could drill through.  This strategy was unsuccessful. 
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We then attempted to leave the ipsilateral skull clear by using a plastic ring to sequester 
the cement on the contralateral hemisphere.  It soon became clear that a 5.0 mm-diameter 
trephine was inconvenient and difficult to use given the amount of glue necessary to 
create a stable structure.  Because the 3.0 mm diameter impactor tip would still be used, 
we chose a smaller trephine of diameter 3.8 mm.  This modification permitted a more 
consistent and clean craniotomy that is critical for a reliable and reproducible impact 
(Fig. 26). 
 
Figure 26.  Simultaneous craniotomy and guide canula placement.  A, 3.8 mm 
craniotomy.  B, craniotomy cap covers ipsilateral hemisphere only.  C, guide canula, 
plastic ring to guide cement on contralateral hemisphere, and bone screws to anchor 
cement crown. 
 
 
 
Controls for post-injury Aβ measurement: craniotomy and probe removal 
Finally, we wanted to know whether or not the craniotomy and probe removal 
caused a change in Aβ levels as compared to no further manipulation after guide canula 
implantation and probe insertion.  To assess the effect of a craniotomy, we implanted 
PDAPP+/- mice with guide canulas and microdialysis probes, allowed them to recover for 
approximately 12 hours, and collected baseline samples every 90 minutes for 9 hours.   
Then we reanesthetized the mice, opened the sutures, exposed the skull, removed the 
A B C
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microdialysis probe and placed it is a vial of perfusion fluid, and performed a craniotomy.  
The skull defect was sealed with a plastic cap as per usual, the skin was resutured around 
the glue cap, and microdialysis probe replaced.  The entire procedure took 20-25 minutes.  
It was found that, for n = 4 mice, the craniotomy caused a modest but significant decrease 
in microdialysis levels of Aβ in the first 6 hours following the procedure (Fig. 27A).  
Therefore it was concluded that the craniotomy should be included in the initial 
implantation procedure, such that any changes it induced in microdialysis levels of Aβ 
were included in baseline measurements.  A similar assessment with simple probe 
removal and replacement did not cause a significant change in levels (Fig. 27B).  It was 
determined that this necessary manipulation during the CCI procedure would have no 
effect on post-injury measurements.  
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Figure 27.  Effects of craniotomy and probe removal/reinsertion on ISF Aβ.   A, 
effect of craniotomy on ISF Aβ.  Young PDAPP +/- mice (n=4) were implanted with a 
microdialysis probe only and allowed to equilibrate.  Then, baseline samples were 
collected for 7.5 hours.  Mice were reanesthetized and a craniotomy was performed.  The 
probe was removed just before the craniotomy was drilled, placed in a vial of perfusion 
fluid, and reinserted as soon as the plastic skull cap was secured.  This procedure lasted 
approximately 20 minutes.  Mice were returned to their swivel cages and samples were 
collected for an additional 6 hours.  Aβ1-x in the pre and post-craniotomy samples was 
measured by ELISA.  Although the difference between pre and post-craniotomy levels 
was not statistically significant (p=0.0556, Mann-Whitney U-test).  B, effect of probe 
removal-reinsertion on ISF Aβ.  Young PDAPP +/- mice (n=4) were implanted with a 
microdialysis probe and baseline samples were collected for 10.5 hours after 
equilibration.  Mice were then briefly reanesthetized, the probe was removed for 
approximately 10 s, and immediately reinserted.  Samples were collected for an 
additional 4.5 hours.  Aβ1-x in pre and post-probe removal samples was measured by 
ELISA.   There was no significant difference in Aβ1-x levels before vs. after probe 
removal (p=0.667, Mann-Whitney U-test). 
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Preliminary experiments: measurement in Tg2576 / ApoEX mice 
 Having established these controls, we then attempted to measure pre- and post-
TBI Aβ levels in the hippocampus.  Preliminary experiments were conducted using 
transgenic mice that expressed the APPSw gene under the control of the prion promoter 
(Hsiao, et al., 1996) and that had human-sequence ApoE lipoprotein “knocked in” to the 
mouse ApoE locus (Xu, et al., 1996).  These mice are referred to as “Tg2576 / ApoEX” 
where X stands for 2, 3, or 4 depending on the particular isoform.   Typically, these mice 
were implanted and microdialysis sampling occurred over 24 hours prior to injury 
(baseline).  Mice were then injured and sampling continued for the next 3-5 days.  
 
Difficulties in survival and recovery after CCI: no effect of modified injury depth 
A number of difficulties in recovery and survival of the mice after either 
implantation surgery or CCI injury were encountered during this time.  The effects were 
seen in some mice during baseline sampling, in some only after injury, and in some, not 
at all.  Our initial observations were that the mice appeared lethargic, failed to eat, drink, 
or move appropriately, lost weight, and became hypothermic.  We measured temperatures 
as low as 24º or 25º C in some mice.  These abnormalities strongly suggested a profound 
metabolic disturbance.  Initially, we had been using an injury depth of 2.0 mm, which 
was characterized as mild-moderate in the wild-type B6SJL strain.  We modified the 
depth to 1.5 mm.  This did not significantly improve the morbidity and mortality. 
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Possible effect of age and / or particular transgenes 
Since modification of the injury depth failed to improve morbidity, we considered 
the age and transgene expression in the mice independently of the TBI.  Firstly, the mice 
were usually older.  All were at least 6 months, usually 9-12 months, but some up to 15 
months old.  The Tg2576 (Swedish mutation in the amyloid precursor protein, APPSw) 
transgenic mouse model of AD develops parenchymal plaque pathology and prominent 
CAA beginning at 9 months of age (Hsiao, et al., 1996).  Expression of human ApoEX 
under endogenous promoter control delays Aβ deposition by months, such that 12-month 
old mice have little or no plaques compared with animals expressing endogenous murine 
ApoE (Fryer, et al., 2005).  Despite the relative lack of Aβ deposition in these mice 
compared with Tg2576 mice, we thought the Tg2576 / ApoEX animals might be fragile 
in other ways due to their age and multiple genetic manipulations.  Additionally, because 
of their age, the older transgenic mice might have been more susceptible to anesthesia 
and injury.  These mice also had a number of systemic health problems, including sores 
and bacterial infections.  Rectal prolapse was common, especially in older animals.  This 
condition indicates abnormal bacterial colonization of the gut.  Their fur was often matted 
and patchy, suggesting underlying skin or connective tissue disorder.   
   
Diagnosis of colonic perforation and peritonitis by autopsy 
To fully evaluate the pathology of these sick mice, we sent a recently deceased 
exemplar to the Division of Comparative Medicine for veterinary autopsy.  They found 
evidence of peritonitis resulting from colonic perforation, which likely accounted for the 
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behavioral and metabolic disturbances observed.  As this had not occurred in other strains 
of mice, we hypothesized that it might be related to the particular combination of 
transgenes expressed by these animals.  We confirmed our observations of sepsis with a 
former graduate student, John Fryer, who had previously characterized Tg2576 / ApoEX 
(Fryer, et al., 2005).  Therefore, we concluded that the lethargy and sickness observed in 
some of our mice was not due to the implantation surgery or the CCI injury, but to the 
sepsis resulting from perforation by the rectal temperature probe. 
 
Modified temperature control to avoid perforation  
Temperature control in anesthetized mice is achieved using a feedback system in 
which a rectal probe monitors the animal’s temperature, and a heating pad directly 
underneath the mouse’s body warms until the probe reads the desired temperature.  
Previous use of the rectal probe in all earlier experiments with B6SJL (wildtype) mice 
had been successful in maintaining body temperature during anesthesia, without incident.  
We hypothesized that the probe caused colonic perforation and subsequent peritonitis, 
resulting in septic shock and death when it was used in these older Tg2576 / ApoEX 
transgenics.  To avoid the risk of colonic perforation and peritonitis, we decided to use 
passive heating.  The probe would be taped directly to the heating pad and would sense 
its temperature.  The pad itself would be maintained at 37º C.  Passive heating would 
ensure the mouse be kept warm during anesthesia. 
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Successful data collection: initial findings with Tg2576 / ApoE2 mice 
After making this change to the protocol, we achieved better success with survival 
and microdialysis collection.  In addition, we were able to collect data for 3-5 days post-
TBI.  The details of Aβ microdialysis sampling and ELISA detection are described in the 
next chapter.  Our initial findings were shared with the Holtzman group during a lab 
meeting and with this Thesis Committee during the initial proposal in November 2007 
(Fig. 28). 
 
Figure 28.  Pre and post-TBI levels of Aβ measured in Tg2576 / ApoE2 mice.  A 1.5-
mm CCI was given at t=0.  Samples were normalized to individual baseline levels, and a 
group of 5 mice were averaged.  Error bars, standard error of the mean.   
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minutes; and that possibly, levels began to rise again around 72 hours post-injury.  These 
were consistent with previous, unpublished observations in the lab that when an animal 
was very sick, microdialysis levels of Aβ decreased and became undetectable near death.   
I had also measured a similar decline in Aβ levels as septic Tg2576 / ApoEX mice 
sickened and died. 
 
Further controls necessary: switch from old Tg2576 / ApoEX to young PDAPP mice  
There were several outstanding issues with this initial dataset, however.  Firstly, 
there were no controls for injury and for probe function.  We had focused on establishing 
whether or not there was a significant effect of TBI on ISF Aβ, and had encountered 
significant problems with the temperature control.  By the time we had completed 5 
successful experiments with Tg2576 / ApoE2 mice, the supply of this and the other 
ApoEX genotypes were nearly gone.  There were not enough mice to complete a similar 
set of sham animals.  In addition, we were concerned about the age of the mice.  For 
these reasons, we decided to switch genotypes to the PDAPP mouse previously 
characterized by John Cirrito in his PhD thesis and described in his 2003 paper (Cirrito, 
et al., 2003).  There was an ample supply of young, pre-plaque animals that were actively 
reproducing in the Washington University colony.  Moreover, at younger ages the 
PDAPP mice showed none of the systemic health problems seen in the Tg2576 / ApoEX 
mice.  It was therefore decided to switch to this transgenic line. 
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PDAPP mice 
The PDAPP mouse possesses a transgene for human APP with a V717F mutation 
under the PDGF-β chain promoter (Games, et al., 1995).  This promoter is specific for 
neuronal cell bodies, and a transgene under its control is expressed primarily in the 
cortex, hippocampus, and cerebellum (Sasahara, et al., 1991).  The V717F mutation shifts 
the γ-site cleavage to longer isoforms, particularly the 42-amino acid length but some as 
long as 50-54 amino acids (Esh, et al., 2005). 
Our mice were originally obtained from Eli Lilly and Company and bred at 
Washington University on a C57BL6 background.  They were used for all initial 
experiments to establish the technique of Aβ microdialysis in transgenic mice.  Given the 
previous experience with these mice and the abundance of young animals, we were 
confident that we could complete multiple experiments in different injury severities, 
including the critical sham controls. 
 
Preliminary probe function control: use of urea in clinical microdialysis studies 
The second outstanding issue was that of probe function.  Others in the lab had 
seen unexplained increases in Aβ after a number of days; the meaning of its occurrence in 
the initial dataset was unclear.  Were levels returning to baseline?  This rise did not occur 
in all animals in contrast to the immediate decrease.  Did this signify heterogeneity in 
recovery, or did it reflect variable permeability or changes in local tissue architecture and 
diffusion characteristics?  It became obvious that an additional control was necessary.  
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Based on the clinical microdialysis literature, measurement of endogenous urea was 
chosen for the initial probe control (Ronne-Engstrom, et al., 2001). 
 
Urea as endogenous, exchangeable marker of probe function 
Urea is a small molecule naturally produced in the liver by the nitrogen cycle.  It 
rapidly equilibrates throughout all tissues of the body and in all types of tissue spaces: 
intracellular, interstitial, and vascular.  It is thought that if urea can exchange across the 
probe membrane, and if the levels are constant compared to other tissues, then the probe 
is permeable.  There were definite instances of blockage by an air bubble or mechanical 
disruption in which we observed a sharp drop-off in urea levels.  Similarly, we found that 
microdialysis urea was quite a sensitive marker for renal failure when we first began to 
use it in the Tg2576 / ApoEX mice.  As the animals became septic and especially when 
death was imminent, urea levels might double or triple in the microdialysis samples, 
suggesting poor clearance by the kidneys. 
 
Final modifications: preventing dural disruption on craniotomy cap removal 
We began to use the PDAPP mice and to routinely measure urea in all samples.  
However, there were a few issues to be resolved before we designated the model 
“complete” and began to collect data in earnest.  One issue had to do with the craniotomy 
cap.  We were drilling the craniotomy as part of the initial implantation surgery.  This 
necessitated a plastic cranitomoy cap to protect the underlying dura.  In standard injury 
protocols, this cap is placed only after injury and is coated only with the VetBond 
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adhesive.  It is not designed to be removed, although removal from the skull is not 
difficult.  What was problematic was removal from the dura in preparation for the CCI 
injury.  Often, the dura would be pulled off along with the plastic cap.  This created a 
swollen, bleeding cortex to be impacted.  A reference position from which to measure the 
depth of the injury was impossible to obtain with accuracy.  To overcome this issue, we 
put PureLube petrolatum eye ointment on the middle region of the skull cap that was in 
contact with the dura, restricting the VetBond to just the outer edges of the cap.  In this 
way, the cap did not stick to the dura when it was pulled off the skull before impact.  The 
dura remained intact and reference positions could be determined as easily as in a simple 
CCI study (Fig. 24). 
 
Final modification: probe removal technique 
One final issue was that of probe removal.  While it was clear from ours and 
previous studies that the probe needed to be removed prior to the impact to avoid 
shearing damage to the surrounding tissue, it was not clear exactly how to do this.  We 
tried three ways: one, removal for the entire TBI procedure from anesthetic induction to 
recovery; two, “partial” removal whereby the stylet was pulled out just 2 mm, the length 
of the semi-permeable membrane resting in the guide canula shaft during impact; and 
finally, complete removal just before impact and immediate reinsertion following impact.  
In the cases of complete removal, the probe was always immersed in a vial of CMA CNS 
perfusion fluid and was never exposed to air longer than 60 seconds.  We found that the 
brief but complete removal and reinsertion gave the best sham results, and decided to 
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conduct all experiments in this manner.  Typically, the probe was immersed for no longer 
than 5 minutes at a time during a sham or injury procedure. 
 
Model development complete 
Once the geometry was designed and confirmed, and the exact details of the 
technique had been worked out to yield to most reproducible injury, we considered our 
combined CCI-microdialysis model complete.  The written protocol we used on a routine 
basis for implantation surgery and CCI procedure is included along with a pictorial guide 
in Appendix 1.  The written protocol for intraparenchymal EEG experiments is attached 
as Appendix 2  
The main body of the proposed experiments is presented in the next section, 
which was submitted as a manuscript to Experimental Neurology in October 2009. 
 
 
 
 
 
 
 
 
 
87 
 
 
 
 
 
 
 
 
 
Chapter 5. 
Submitted manuscript with main results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
88 
 
ABSTRACT 
 
The amyloid-β peptide (Aβ) plays a central pathophysiological role in 
Alzheimer’s disease, but little is known about its dynamics in the brain’s extracellular 
space. A recent microdialysis-based study in human patients with severe brain injuries 
found that extracellular Aβ dynamics correlate with changes in neurological status.  
Because neurological status is generally diminished following injury, this correlation 
raises the possibility that extracellular Aβ is reduced relative to baseline. However, 
human studies cannot assess pre-injury Aβ levels, very early post-injury Aβ levels, nor 
the relationship between extracellular Aβ levels as measured by microdialysis and total 
tissue Aβ levels.  Therefore, we developed a mouse model that combines experimental 
TBI with microdialysis to address these gaps.  In this model Aβ levels were stable at 
baseline and after sham-injury.  Following controlled cortical impact TBI, we found that 
Aβ levels as measured by microdialysis were immediately and persistently decreased in 
the ipsilateral hippocampus. These results were found in both wild-type mice and young 
pre-plaque PDAPP mice that produce human-sequence Aβ.  Similar decreases were 
observed in PBS-soluble hippocampal extracts, but no changes were found in carbonate 
or guanidine extracts.  Reductions in Aβ were not due to changes in microdialysis probe 
function, APP levels nor Aβ deposition.  Hippocampal depth electrode recordings 
demonstrated that electroencephalographic activity was decreased over 24 hours 
following TBI.  Thus, we propose that in mice and likely human patients with TBI, post-
injury extracellular Aβ levels are acutely decreased relative to baseline. Reduced 
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neuronal activity may contribute, though the underlying mechanisms have not been 
definitively determined.  
 
INTRODUCTION 
 
Brain microdialysis is a minimally-invasive technique that permits longitudinal 
sampling of small molecules in the extracellular space of living, awake subjects.  
Previous experimental studies have demonstrated that it is possible to assess the 
dynamics of Aβ in the brain interstitial fluid (ISF) using intracerebral microdialysis in the 
brains of awake, behaving mice (Cirrito, et al., 2003). Additional studies uncovered a 
clear relationship between neuronal activity and ISF Aβ concentrations (Cirrito, et al., 
2005, Kamenetz, et al., 2003).  In a subsequent study, it was shown that ISF Aβ levels 
depend in large part on synaptically-coupled endocytosis (Cirrito, et al., 2008).   
Physiological manipulations of neuronal activity also affect Aβ levels.  Both acute 
and chronic stress can result in elevations of ISF Aβ levels (Kang, et al., 2007).  
Furthermore, ISF Aβ levels were found to correlate with cortical EEG measures of 
wakefulness (Kang, et al., 2009). 
Recently, our group published a study in which we measured the concentration of 
amyloid-β peptide (Aβ) recovered by intracerebral microdialysis every 2 hours for at 
least 72 hours after catheter implantation in human patients who had suffered either an 
aneurysmal subarachoid hemorrhage or a traumatic brain injury (Brody, et al., 2008).  We 
found a significant correlation between changes in microdialysis levels of ISF Aβ and 
changes in neurological status, as assessed by one or two-step changes in the GCS.  
Measures of impaired cerebral metabolism and physiological factors associated with 
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depressed functional status were significantly correlated with reduced Aβ levels.  
Marklund et al. presented results consistent with these findings; ISF Aβ levels were 
relatively high in a patient who did well and undetectable in a patient who died with 
severely abnormal brain metabolic parameters (Marklund, et al., 2009). 
As is generally the case for clinical microdialysis studies, we could not measure 
pre-injury levels in our subjects.  Intracerebral microdialysis is indicated only for 
severely injured patients under close supervision in a hospital ICU setting.  Therefore, the 
question of the relationship of post-injury to pre-injury levels remained open to inquiry.    
Secondly, the relationship of Aβ concentrations in the ISF to levels in other tissue 
compartments could not be assessed in the human study.  Finally, the dynamics of ISF 
Aβ immediately following an injury were not determined; most human patients did not 
begin monitoring until 12-24 hours or more after injury.  
To address these gaps, we turned to an animal model that combined a 
standardized brain injury with standardized microdialysis catheter placement.  We 
adapted methods successfully employed in rats (Alves, et al., 2005, Bell, et al., 1998, 
Krishnappa, et al., 1999, Palmer, et al., 1993, Rose, et al., 2002) to mice.   Our group has 
previously published a well-characterized model of controlled cortical impact (CCI) 
using a precise, electromagnetically-driven device (Brody, et al., 2007).  This 
combination of techniques permitted us to measure Aβ before and after an injury, and in 
sham-injured animals.   
  Given the findings in brain-injured human patients, we hypothesized that ISF Aβ 
would be reduced following experimental CCI-TBI compared to baseline.  In agreement 
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with this hypothesis, we found that hippocampal levels of ISF Aβ were immediately 
decreased by approximately 30-50% after TBI.  Similar changes were found in PBS-
soluble tissue extracts, but not other tissue fractions.  Furthermore, significant reductions 
in local electroencephalographic (EEG) activity after injury suggest a mechanistic 
relationship with reduced neuronal activity (Cirrito, et al., 2005, Kamenetz, et al., 2003).    
 
MATERIALS and METHODS 
 
Mice 
Most experiments used male and female PDAPP+/- mice (Games, et al., 1995) on 
a C57Bl6 background at 3-6 months of age.  These mice were originally obtained from 
Eli Lilly and Co., and have been bred at Washington University.  Wild type mice used 
were C57Bl6 littermates of the PDAPP+/- mice.  The mice were housed in standard cages 
at 3–5 mice per cage under standard laboratory conditions prior to the experiment.  They 
were individually housed in Rat Turn electronic swivel cages (Bioanalytical Systems) 
during combined microdialysis-CCI experiments.  All experiments were approved by the 
Animal Studies Committee at Washington University. 
 
Combination microdialysis and controlled cortical impact (CCI) model of TBI 
To allow for baseline Aβ microdialysis measurements, mice underwent an initial 
surgery for implantation of a microdialysis guide canula (MD-2250, Bioanalytical 
Systems) and craniotomy placement 24 hours prior to CCI.  Isoflurane anesthesia was 
induced at 5% and maintained between 1.5 - 2% during the procedure.  Following 
anesthesia, mice were placed on a stereotactic frame (David Kopf) on a thermoregulated 
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heating pad kept at 37º C for the duration of the 60-minute surgery.  The scalp was 
shaved, 10% povidone-iodine applied to the skin and allowed to dry, and the skin opened 
to expose the skull.  The mouse’s head was fixed in place by cupped head holders (David 
Kopf) mounted on the stereotactic frame.  The skull was leveled along the anterior-
posterior and lateral axes to a tolerance of 0.10 mm with a digital stereotactic device 
(Benchmark Digital).   
For microdialysis guide canula implantation, a 0.7-mm burr bit mounted an on an 
electric drill (Foredom) was used to create a groove beginning at 2.54 mm posterior to 
bregma suture, 0.0 mm midline through 1.0 mm left of midline, at a depth to visualize but 
not breach dura mater and the sagittal sinus.  Three additional holes were placed for bone 
screw anchors at 1.0 mm right of midline, 0.75 mm posterior to bregma; 3.0 mm right, 
0.75 mm posterior to bregma; and 3 mm right, 3.5 mm posterior to bregma.  Finally, 
fiduciary markers for a 3.8 mm-diameter craniotomy were made at 3.6 mm left of 
midline, 1.1 mm anterior to lamboid suture and 1.7 mm left of midline, 3.0 mm anterior 
to lamboid suture.   
The left craniotomy required for CCI-TBI was performed during the same 
surgical procedure as guide canula implantation.  Our control experiments indicated that 
there was a small decrease in the microdialysis concentration of Aβ1-x after craniotomy 
(Fig. 11A, see above).  Although this difference was not statistically significant at the 
95% confidence level (p=0.0556, Mann-Whitney U-test), we included the craniotomy as 
part of the baseline procedure to separate its effect on levels of Aβ1-x from those due to 
the CCI-TBI.  The craniotomy was created with a cylindrical, air-vent cooled, 3.8 mm-
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diameter micro-trephine (Xemax Surgical) angled between 12-15º to create an even, 
circular groove through the skull.  Once the skull bone under the trephine became 
translucent, the bone flap was carefully removed using a 1.0 mm cup rongeur and spatula.  
A plastic cap was immediately placed over the exposed dura.  The central part of the cap 
touching the dura was coated with petrolatum-based veterinary ointment (Purelube) and 
the peripheral part was secured to the skull with veterinary adhesive (VetBond, 3M).   
Bone screw anchors were inserted into the previously drilled holes at the 
minimum depth required for secure placement, typically between one-half and one full 
turn.  The bone screw anchors provided necessary support for the dental cement crown to 
secure the guide canula to the skull.   
The microdialysis guide canula was mounted on the right arm of the stereotactic 
frame, and the arm was positioned at 38º relative to the sagittal plane.  The guide canula 
was introduced into the left cortex to a depth of 1.3 mm through the groove at 0.5 mm left 
of midline, 2.54 posterior to bregma (Ch. 4, Fig. 25A).  The depth was measured from 
where the rightmost (bottom) edge of the guide canula contacted the dura.  Then, the 
guide canula was secured using dental cement.  A ½-circumference cap from a 1.7 mL 
microcentrifuge tube was placed just to the left of the canula to protect the craniotomy 
skull cap from the dental cement crown.  Dental cement (DuraLay inlay pattern resin, 
Reliance) was carefully placed around the canula and bone screw anchors for maximum 
security and allowed to dry 10-15 minutes.  Once dry, the head holders were released and 
skin sutured around the resultant cement crown using 4-0 interrupted nylon suture.  Triple 
antibiotic ointment was applied to the entire area.   
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The guide canula stylet was removed and a primed, 2 mm microdialysis probe 
(MD2200 BR-2, Bioanalytical Systems) was carefully inserted by hand with visualization 
of the guide canula tract.  The mouse was then removed from the stereotaxic frame, 
placed in the automatic swivel cage and allowed to wake from anesthesia.  Most mice 
were alert and moving within 20 minutes.  An adjustable plastic collar was loosely placed 
around the mouse’s neck, and attached to the suspended tether of the automatic swivel 
arm.  Microdialysis tubing was secured to the tether arm to prevent tangling.  Standard 
cob bedding, mouse chow pellets, and fresh water were provided daily (Ch. 4, Fig. 25B).   
Approximately 24 hours later, mice underwent a single, moderate left lateral 
controlled cortical impact with craniotomy, as described previously (Brody, et al., 2007).  
Briefly, mice were anesthetized with isoflurane, placed in the stereotaxic frame and 
maintained at 37°C as before.  Head holders were used to secure the skull in a level 
position.  The sutures were opened, plastic skull cap removed to expose underlying dura, 
and impactor tip aligned in the center of the craniotomy.  Just prior to impact, the 
microdialysis probe was removed from the guide canula and immersed in a vial of CMA 
CNS perfusion fluid.  Brief removal of the probe from the guide canula does not affect 
microdialysis levels of Aβ1-x (Ch. 4, Fig. 27B; p=0.667, Mann-Whitney U-test).  Mice 
were subjected to controlled cortical impact (CCI) in which a 3 mm-diameter, flat metal 
tip impounder was driven by an electromagnetic device at a velocity of 5 m/s to various 
depths (1.0, 1.5, or 2.0 mm) into the cortex.  In part because this electromagnetic device 
does not overshoot the way some pneumatic controlled cortical impact devices can, these 
impact depths produce less severe injuries than those produced by some pneumatic CCI 
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devices at the same nominal depth (Brody, et al., 2007).  Sham-injured mice underwent 
identical procedures, except the impactor tip was discharged into the air and did not 
contact the dura.  The microdialysis probe was re-inserted immediately after the impact 
such that entire duration of probe removal was 4-5 minutes.  The wound was then cleaned 
by gentle irrigation with sterile-filtered phosphate-buffered saline (PBS), and a plastic 
skull cap replaced and again secured with VetBond.  Skin was resutured around the 
cement crown using 4-0 interrupted nylon sutures and triple antibiotic ointment applied to 
the entire area.  As before, mice were allowed to wake and recover in the electronic 
swivel cages where they were monitored by microdialysis for an additional 24 hours.  
 
Microdialysis 
Microdialysis parameters were based on previously published methods designed 
for the measurement of interstitial fluid (ISF) Aβ in PDAPP mice (Cirrito, et al., 2003).  
Microdialysis probes had a 2 mm-long, 320 µm outer diameter, 38 kDa molecular-weight 
cutoff membrane (MD2200 BR-2 probes; Bioanalytical Systems) and were connected to 
an infusion syringe pump (KDS 101, KD Scientific).  The inlet tract of the probes were 
attached to the syringe pump via a 1.0 m-long, Teflon (FEP) tubing (inner diameter, 0.12 
mm; SciPro) and primed for 1-2 hours with 0.15% sterile human albumin (diluted from 
25% Human Albumin, Grifols) in sterile, isotonic saline solution (147 mM NaCl, 2.7 mM 
KCl, 1.2 mM CaCl2, and 0.85 mM MgCl2; CNS perfusion fluid, CMA, Sweden).  During 
most experiments, flow rate was maintained at 0.3 µL/min for wild-type mice, and 1.5 
µL/min for PDAPP+/- mice.  Samples were collected every 90 minutes.  The outlet tract 
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of the probe was connected to a second 1.0 m-long piece of FEP tubing.  The outflow 
was collected in low-protein-binding polypropylene tubes housed in a 4ºC-refrigerated, 
automated fraction collector (Univentor 820 Microsampler, SciPro).   
For the initial baseline sampling period, sampling was begun after the dead 
volume had cleared the outflow line.  Similarly, microdialysis samples were collected as 
soon as the post-TBI dead volume had cleared the outflow lines.  All samples were 
tightly capped and stored at 4ºC for 48 hours or less prior to analysis by ELISA. 
 
MR imaging and histological verification of probe placement 
To verify probe placement in the living animal, T2-weighted magnetic resonance 
(MR) images were acquired (Mac Donald, et al., 2007) (Ch. 4, Fig. 25C).  Mice were 
implanted with a guide canula and probe as described above and allowed to wake and 
recover for 6-8 hours.  Mice were re-anesthetized (induction, 5%; maintenance, 0.75-1%) 
and placed in an MR-compatible stereotaxic frame in a 4.7T scanner (Oxford Instruments 
200/330).  Scan duration was approximately 3.5-4 hours, after which the mice were 
allowed to wake and recover before sacrifice. 
To verify probe placement post-mortem in a separate set of animals, 2 mg/mL 
Evans blue dye (Direct Blue 53, Sigma) in PBS was perfused through the microdialysis 
probe for a total volume of 50 µL.  Mice were transcardially perfused with ice-cold PBS -
0.3% heparin, and the whole brain was extracted.  After overnight fixation in 4% 
paraformaldehyde at 4°C, the brains were transferred to 30% sucrose for 72 hours of 
equilibration.  Brain sections (50 µm) were cut in the coronal plane on a freezing 
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microtome and counterstained with Neutral Red.  Sections were mounted, dried and 
coverslipped according to standard methods.  Regions of interest demonstrating presence 
of Evans blue into tissue adjacent to the microdialysis probe were identified and 
photomicrographs acquired at 1× power with a light microscope (Nikon Eclipse E800; 
Ch. 4, Fig. 25D). 
 
Aβ
 
quantification 
Microdialysis and tissue samples were analyzed for Aβ using a denaturing, 
sandwich ELISA specific for human Aβ1-x according to established methods (Cirrito, et 
al., 2003).  The capture antibody is directed against amino acids 13-28 (m266, courtesy of 
Eli Lilly and Co.).  The detection antibody is biotinylated and directed against N-terminal 
amino acids 1-5 (3D6, courtesy of Eli Lilly and Co.).  The PDAPP+/- tissue samples and 
wild-type microdialysis samples were assayed for Aβx-40 using a capture antibody 
specific for amino acids 33-40 (HJ2, courtesy of Hong Jiang and David Holtzman). 
PDAPP+/- tissue samples were assayed for Aβ1-42 using a capture antibody specific for 
amino acids 33-42 (21F12; see Cirrito, 2003).  For the m266 and 21F12-based assay, we 
used biotinylated 3D6 as a detection antibody.  For the HJ2-based assay, a biotinylated, 
middle-domain capture antibody directed against amino acids 13-28 (HJ5.1, courtesy of 
Hong Jiang and David Holtzman) was used.  All secondary antibodies were followed by 
streptavidin-poly-horseradish peroxidase-20 (SA-HRP20, Research Diagnostics).  Super 
Slow ELISA TMB (Sigma) was used for colorimetric detection and analyzed on a BioTek 
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Synergy 2 (BioTek) microtiter plate reader. Aβ40 and Aβ42 standard curves were 
generated from synthetic, human sequence Aβ peptide (American Peptide). 
For analysis of microdialysis samples, PBS-soluble tissue extracts and carbonate-
soluble tissue extracts, samples were diluted in a final buffer of 0.25% bovine serum 
albumin (BSA), 500 mM guanidine, 200 mM Tris-PBS, pH 7.4; for analysis of the 
guanidine-soluble tissue extracts, an equal volume of PBS substituted for the guanidine in 
the original sample buffer.  
All microdialysis samples were loaded on 96-well plates in duplicate at a dilution 
factor of 2 for wild-type mice or in triplicate at a dilution factor of 3 for PDAPP+/- mice.  
Depending on the number of samples to be analyzed, samples were systematically 
dithered among two or three plates per experiment.  We used strict inclusion criteria for 
the determination of acceptable ELISA values.  Firstly, all raw concentration values were 
interpolated, rather than extrapolated, from the standard curve.  Secondly, at most one of 
the three replicates was masked, and the values were only accepted if the coefficient of 
variation was less than 20%.   
To quantify the differences in Aβ microdialysis levels between sham and TBI 
groups in PDAPP+/- mice over time, two approaches were taken.  Firstly, raw 
concentration values were corrected for the dilution factor but not for fractional recovery. 
Then, these concentrations were averaged by group (TBI vs sham) at each 90-minute 
sampling period, and plotted as a function of time with standard error of the mean shown.  
Secondly, we compared normalized Aβ concentrations between groups.  To perform this 
analysis, we first computed a mean baseline value for each experimental subject on each 
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96-well plate.  The baseline was defined as the 12-hour period prior to the sham or TBI 
procedure, typically 6-12 hours after the initial implantation.  Then, all baseline and post-
TBI or post-sham measurements were normalized to their respective mean baseline 
values.  Using our strict inclusion criteria, there were scattered missing data such that the 
most reliable analysis could be performed on 6-hour epochs. The normalized values from 
each experiment were binned into 6-hour epochs, and a group average for each epoch 
was computed.  A repeated-measures ANOVA was used to test for differences between 
groups over time in these normalized data binned into 6 hour epochs.   
For wild-type microdialysis, four 90-minute samples were pooled for Aβ40 
measurement over a 6-hour interval, and normalized to the mean of the three baseline 
values.  Group mean data were plotted as a function of time for each 6-hour interval.  All 
post-injury data were then averaged over time and a two-tailed Mann-Whitney U-test was 
used to compare sham and TBI groups.    
 
Urea assay 
After the volume required for Aβ quantification was removed from the 
microdialysis collection tubes, urea concentration was measured in the remaining volume 
using a commercially-available kit (Quanti-Chrom Urea Assay Kit, BioAssay Systems).  
If an experiment showed fluctuating or significantly decreased urea levels > 20%, it was 
excluded on the basis of probe malfunction.  Approximately 1 in 15 experiments was 
excluded due to abnormal urea levels. 
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Zero-flow extrapolation 
Flow rates were varied systematically and the concentration of Aβ was measured 
at each flow rate using the Aβ1-x ELISA.  For each animal, a flow rate of 1.5 µl/min was 
used for the first 4.5 hours (3 samples) after probe insertion.  An equilibration period of 
4-5 hours has previously been described for microdialysis measurement of Aβ in the 
hippocampi of PDAPP+/- mice (Cirrito, et al., 2003).  Then, the flow rates were changed 
in a systematic fashion to 0.1, 0.3 and 0.5 µl/min.  These particular flow rates were used 
because they yielded the most efficient fit to an exponential curve among a set of 8 test 
flow rates in pilot experiments (not shown).  After each flow rate change, the dead 
volume (12 µl) was allowed to clear the tubing before the sample was collected for 
analysis.  This required 8 minutes at 1.5 µl/min and 120 minutes at 0.1 µl/min.  Samples 
were collected for 90-540 minutes, and ELISA dilution factors were varied between 3-8.  
The same pattern of flow rate variation was followed in all animals.  After TBI, an 
identical set of flow rate changes and ELISA dilutions were performed.  Except for flow-
rate variation, these experiments were conducted in an identical manner to other 
combined CCI-microdialysis experiments. 
All Aβ concentrations were normalized to the 0.1 µL/min pre-TBI concentration 
for each mouse ([Aβ] / pre-TBI [Aβ]
 0.1 µL/min), and the resultant ratios were averaged to 
derive a group mean for each flow rate before and after TBI.  The concentration as a 
function of flow rate was fit to a decaying exponential relationship (Jacobson, et al., 
1985) using the Excel Solver tool:  
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C = C0[1 – e-K0A/F]       (Equation 1) 
 
where C is the concentration at a given flow rate, C0 is the zero-flow concentration, K0 is 
the mass transfer coefficient, A is the microdialysis probe membrane surface area (160.85 
µm
2) and F is the flow rate.  
For comparison of pre- and post-TBI mass transfer coefficients, the natural logs 
of the mean ratios were plotted against their corresponding flow rates and a linear 
regression of the relationship was performed with a statistical analysis package 
(GraphPad Prism 5.0).  The best-fit slope of this semi-log plot is equal to the -K0A term 
in Equation 1.  The 95% confidence intervals of the best-fit slope were used to determine 
the significance of differences between pre- and post-TBI mass transfer coefficients. 
 
Retrodialysis 
An N-terminal-biotinylated, synthetic, human-sequence Aβ1-40 peptide (rPeptide) 
was continually infused through the inlet port before and after CCI-TBI in PDAPP-/- 
wild-type littermates at a concentration of 3000 pg/mL in the standard 0.15% albumin-
CMA CNS perfusion solution.  To ensure that a loss of infused peptide could be reliably 
detected when comparing the infused and outflow concentrations, we used a slower flow 
rate of 1.0 µL/min.  Microdialysis samples were analyzed by ELISA using m266 as the 
capture antibody and incubation with SA-HRP20 for detection of biotinylated Aβ1-40.  
Percentage loss was calculated as the ratio of the concentration in each sample to the 
concentration in the infused substrate ([Aβ] / [Aβ]IN).  Both infused and outflow samples 
were measured on the same ELISA plates. 
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CA3 cell counts following TBI with and without microdialysis 
 Four groups of PDAPP+/- mice were assessed histologically for CA3 cell counts: 
sham with microdialysis, sham without microdialysis, 2.0 mm TBI with microdialysis, 
and 2.0 mm TBI without microdialysis. 4 mice per group were assessed in a blinded 
fashion. Brains were sacrificed at 24 hours after injury and prepared for histology.  Every 
6th section was mounted on a Fisher Superfrost slide, dried, and stained with Neutral Red.  
Stereological methods were used to quantify the number of cells remaining in the 
inferior blade of the CA3 region.  The inferior blade was defined within the region of 
CA3 in coronal sections approximately between the anterior-posterior dimension 
coordinates of Bregma -1.2 to -2.5 (Franklin and Paxinos, 2001), and extending from the 
midline to the most lateral edge (Fig. 29).  The Optical Fractionator method was used to 
estimate the number of cells.  First, the CA3 inferior blade was outlined at low power 
(4×). Individual cells were then visualized at high power (60×: oil immersion) within 
systematic, randomly sampled sites chosen by the StereoInvestigator 8.0 software 
(MicroBrightfield), and counted.  Non-viable cells were excluded from counting as 
determined by the criteria of shrunken volume, abnormally dark staining, and irregular 
borders.  To meet the prespecified criterion for the Gundersen coefficient of error (CE < 
0.10, m=1), a 100 × 100 µm sampling grid and 40 × 40 µm counting frame was used, and 
a 15 µm dissector region was sampled.   
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Tissue homogenization and extractions 
To compare microdialysis measurements of ISF Aβ with tissue levels after an 
acute TBI, we measured Aβ1-x, Aβx-40 and Aβ1-42 in serial homogenate extracts of 
hippocampus and cortex in separate animals that did not undergo microdialysis.   
Two hours after the injury, deep anesthesia was induced with isoflurane, and mice 
were transcardially perfused with ice-cold PBS-0.3% heparin.  The whole brain was 
quickly removed and divided along the sagittal plane into left (ipsilateral) and right 
(contralateral) halves.  The cortex and hippocampus were dissected, immediately frozen, 
and stored at -80ºC.  For the homogenization-extraction procedure, frozen tissues were 
weighed and 10 µl per mg of ice-cold PBS with protease inhibitors was added at a 
minimum volume of 200 µL.  Tissues were then dounce-homogenized using a blunt-tip 
Teflon homogenizer in an ice-cold 1.7-mL microcentrifuge tube for a total of 75 up-and-
down strokes.  Tubes were spun at 14,000 rpm for 20 minutes at 4ºC in a refrigerated 
microcentrifuge.  The supernatant (PBS-soluble extract) was carefully removed.  This 
extract was stored at -80º C.  The resultant pellet was resuspended in 200 uL of 0.1M 
carbonate buffer, pH 11.5 with protease inhibitors, and dounce-homogenized in the same 
manner as in the PBS extraction step.  Tubes were spun at 14,000 rpm for 20 minutes at 
4ºC.  The supernatant (carbonate-soluble extract) was carefully removed and stored at -
80ºC.  Finally, the resultant pellet was extracted with 200 µL of 5M guanidine-HCl, pH 
8.0 added to the tube, mixed 15-20 times with a P1000 pipettor, and rotated end-over-end 
at room temperature for three hours.  The resultant extract (“guanidine-soluble”) was 
stored at -80ºC.  There was no visible tissue or particulate matter in this extract.  Tissue 
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sample concentrations were normalized to protein concentration as measured by Micro 
BCA Assay (Pierce). 
 
APP measurement by Western blot analysis 
 Two groups (n=3 sham and n=4 2.0 mm-injured) of PDAPP mice were sacrificed 
at 2 hours post-injury for biochemical analysis of APP levels.  Brains were perfused and 
quickly removed.  Ipsilateral and contralateral hippocampi and cortices were dissected on 
an ice-cold glass plate and immediately frozen at -80ºC.  The following day, tissues were 
weighed and immersed in 200 µL of ice-cold, modified RIPA buffer optimized for 
Western blotting (50 mM Tris-HCl, pH 7.4; 1% NP-40 substitute, 0.25% sodium 
deoxycholate, 150 mM NaCl, 1 mM EDTA) with protease inhibitors (20 µg/mL aprotinin 
and 10 µg/mL leupeptin).  Tissues were then dounce-homogenized with a small, Teflon-
coated conical tip in a 1.7 mL-microcentrifuge tube for a total of 45 strokes (15 easy, 15 
hard, 15 easy), with attention paid to minimize bubble formation of the detergent buffer.  
The homogenates were spun at 13,000 rpm at 4ºC for 20 minutes.  The supernatant was 
removed and assayed for protein content using the Micro-BCA Assay (Pierce).  Samples 
were diluted to 1 mg/mL of protein. 10 µg protein per well was loaded on a 4-12% Bis-
Tris, 1 cm x 10 well mini-gel (Invitrogen).  Following electrophoresis, gels were blotted 
onto nitrocellulose membranes, washed for 4-5 hours in TBS, blocked for 60 minutes at 
room temperature with 2.5% nonfat dry milk in TBS-0.125% Tween-20 (2.5% milk TBS-
T), washed 3 times for 5 minutes each (same wash protocol hereafter), and incubated 
overnight at 4ºC with an anti-APP polyclonal rabbit antibody, Zymed 512700 
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(Invitrogen) at a concentration of 1:1000 in 2.5% milk in TBS-T.  Blots were then 
washed and incubated with the Licor Odyssey infrared imaging system secondary 
antibody, goat anti-rabbit IR 680 at 1:10,000 (Licor). To probe the same membranes for 
β-tubulin as a loading control, membranes were exposed to Restore Western Blot 
Stripping Buffer (Thermo Scientific) for 10 minutes at room temperature, washed in PBS, 
blocked for 1 hour at room temperature with 4% milk-PBS, incubated for 3 hours with an 
anti-tubulin primary antibody at 1:5000 (Sigma-Aldrich T5168), washed, and incubated 
for 60 minutes with the Licor Odyssey infrared imaging system secondary antibody, goat 
anti-mouse IR 800 at 1:10,000 (Licor).  Membranes were washed in PBS and imaged 
using the Licor Odyssey infrared imaging system.  The average intensity of each band 
complex (APP) or single band (tubulin loading control) was quantified by the user-
defined background subtraction tool in the Licor Odyssey V3.0 acquisition and analysis 
software.  Identical rectangular area templates were used to calculate band intensity for 
each band complex or single band on the blot. The average band intensity for APP was 
normalized to that of the tubulin loading controls from the same sample to account for 
inhomogeneities between lanes. 
 
Aβ immunohistochemistry  
A randomly-selected subset of brains was chosen for Aβ immunohistochemistry.  
All mice were sacrificed at 24 hours after injury, and brains perfused, fixed and sliced 
coronally into 50 µm sections and placed immediately in TBS.  Free-floating sections 
were treated with 0.3% H2O2 for 10 minutes at room temperature to inactivate 
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endogenous peroxidases and washed 3 times in TBS for 5 minutes each (hereafter, all 
washes are 3 times, 5 minutes each in TBS).  Sections were then blocked at room 
temperature with 3% nonfat dry milk in TBS-0.125% Triton-X (3% milk in TBS-X) for 
60 minutes, washed, then incubated overnight at 4ºC in 0.75 µg/mL of a biotinylated, 
monoclonal antibody directed against the N-terminus of human Aβ (HJ3.4, courtesy of 
Hong Jiang and David Holtzman) in 1% milk-TBS-X.  Sections were washed, incubated 
for 60 minutes at room temperature with a 2.5% solution of the Vectastain Elite ABC kit 
(Vector Labs; 2.5% avidin-biotin complex in TBS), washed, and developed using 0.25% 
diaminobenzidine (DAB) chromagen substrate.  The reaction was judged to be complete 
when Aβ deposits on the positive controls became visible at low power on a light 
microscope.  Sections were then immediately washed and mounted on Fisher Superfrost 
slides, allowed to dry overnight in ambient conditions, dehydrated and coverslipped.  
Representative images were taken at 2× and 4× with a Nikon Eclipse E800 light 
microscope. 
 
Intraparenchymal EEG recording 
The EEG recording protocol was adapted from previous studies of combined 
EEG-microdialysis (Cirrito, et al., 2005).  Two Teflon-coated platinum-iridium recording 
electrodes (Cat. No. 777000, 0.0055-inch diameter, A-M Systems; Fig. 6A) (Cirrito, et 
al., 2005, Kang, et al., 2007) were attached to either side of the cylindrical guide canula 
using an epoxy-cement (Elmer’s Super-Fast Epoxy Cement).  The electrodes extended to 
2 mm past the end of the guide canula, the same distance as the probe, such that they 
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recorded potential differences in the vicinity of the probe membrane.  They were cut on-
end at a 45º angle such that the bare metal tip was exposed at the end of the 2 mm 
extension.  These electrodes and a zero-reference to cerebellar dura were soldered to a 
three-pin prong.  A custom-built head stage amplifier was used to eliminate external 
electrical noise (courtesy of the Washington University Electronics Shop).  The signal 
was then amplified (P511 AC Amplifier, Grass Instruments) and digitized (MiniDigi 1A, 
Axon Instruments) for acquisition (Axoscope 9.2, Axon Instruments) and offline analysis 
(Clampfit 9.2, Axon Instruments) on a PC.  The raw signal was filtered between 0.1 Hz 
and 0.1 kHz.  The Clampfit 9.2 statistics package was used to quantitate RMS amplitude 
over 6 artifact-free, 1-2 min epochs per microdialysis sampling period.  These amplitudes 
were averaged and data normalized to the mean baseline RMS amplitude.   
 
Statistical methods 
Statistica 6.0 was used for repeated-measures ANOVA testing for differences in 
microdialysis Aβ for sham vs. TBI by group and by time (Fig. 2B) (StatSoft, Tulsa, OK).  
Significance was determined at p < 0.05.  Statistical analysis for other tests was 
performed using Prism version 5.00 for Windows (GraphPad, San Diego).  Again, 
significance level was determined at p < 0.05.  Two-tailed Mann-Whitney U-tests were 
used to test for differences in Aβ levels between sham and TBI groups.   Mass transfer 
coefficients for pre and post-TBI exponential curves in the zero-flow control experiment 
were evaluated for statistical difference using overlap of the 95% confidence intervals, as 
calculated from a linear regression analysis of the natural log of group-mean normalized 
108 
 
concentrations at each flow rate.  Two-tailed, paired t-tests were used to compare pre vs. 
post TBI levels of infused Aβ during retrodialysis and urea measurement control 
experiments.  Comparison of EEG amplitude changes over the 24 hours following sham 
or TBI was also performed using the two-tailed Mann-Whitney U-test.   
 
RESULTS 
Intracerebral microdialysis combined with controlled cortical impact TBI  
 We initially established that experimental controlled cortical impact (CCI) TBI 
could be successfully combined with intracerebral microdialysis in mice (Ch.4, Fig. 25).  
This method was designed to allow microdialysis sampling from a large region of the 
hippocampus without hindering placement of the ipsilateral craniotomy required for CCI 
(Ch. 4, Fig. 25A).  The microdialysis guide canula was affixed to the skulls of the mice 
with dental cement and they were tethered to an automatic swivel cage (Ch. 4, Fig. 25B).  
This allowed microdialysis to occur while the mice were freely moving before and after 
injury.   To verify probe placement in vivo, three separate mice were anesthetized and 
imaged using magnetic resonance technology with a T2-weighted sequence (Ch. 4, Fig. 
25C).  This confirmed that the probe tract extended into the hippocampus, whereas the 
guide canula was restricted to the cortex.  Additionally, we infused the probe with Evans 
blue dye just prior to sacrifice to again verify placement on histology.  The blue tract of 
the probe was restricted to an area along the long axis of the hippocampus in the coronal 
plane (Ch. 4, Fig. 25D).  These results established the accuracy of the placement of the 
microdialysis probe both in vivo and post mortem. 
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To evaluate the similarity of the CCI injury performed in conjunction with 
microdialysis and injury without microdialysis we made two comparisons.  First, we 
consistently observed a 10-20% weight loss within the first 24 hours after CCI injury 
with or without microdialysis.  Second, the CCI injury consistently results in neuronal 
cell loss in the CA3 region of the hippocampus in PDAPP mice.  We found no significant 
difference in cell loss in the inferior blade of the CA3 region between injury with (24.5%) 
and without microdialysis (30.9%; p=0.572, unpaired, two-tailed t-test comparing cell 
counts; Figs. 29, 30).  Importantly, there was no difference in inferior blade CA3 cell 
counts in sham mice with and without microdialysis (Fig. 29, 30; p=0.693, unpaired, two-
tailed t-test).  The CA3 cell loss in CCI-injured PDAPP mice was concordant with 
previous results (Hartman, et al., 2002, Smith, et al., 1998). 
 
Figure 29.  CA3 cell loss and cortical lesion at 24 hours post-injury in young, 
PDAPP+/- mice: injury with microdialysis vs. without microdialysis.  Coronal sections 
from young PDAPP+/- mice sacrificed at 24h following TBI or sham injury were stained 
with Neutral Red. Representative images used to count CA3 cells are shown at 4× power 
(A-D) with the region of interest, CA3 inferior blade, bordered by arrows.  A-D: scale 
bar, 500 µm.  Corresponding views are shown at 2× power (E-H).  E-H: scale bar, 1 mm.  
A, E. Sham with microdialysis.  B, F. Sham, no microdialysis.  C, G. 2.0 mm TBI, with 
microdialysis.  D, H. 2.0 mm TBI, no microdialysis. 
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Figure 30.  CA3 cell loss at 24 hours post-injury in young, PDAPP+/- mice: injury 
with microdialysis vs without microdialysis.  Mean cell counts with standard errors 
plotted for each group, n=4 per group: no significant differences between 2.0 mm-injured 
mice with and without microdialysis (p = 0.572, two-tailed t-test), nor between sham-
injured animals with and without microdialysis (p=0.693, two-tailed t-test).  
 
 
Microdialysis levels of Aβ decrease immediately following CCI 
In 3-6 month old wild-type C57BL6 mice, we collected baseline microdialysis 
samples over 18-24 hours, then performed either sham (n=4) or 2.0 mm CCI TBI (n=4) 
(Fig. 31A, B).  Measurements of endogenous Aβ40 were made every 6 hours for 24 hours 
before and 42 h following an injury.  Absolute levels during the baseline period were 
68.0 ± 19.5 pg/mL.  Levels of endogenous Aβ
 
were low relative to the limits of detection, 
which averaged 28.6 pg/mL in this ELISA.  Thus, time resolution better than 6 hours was 
not possible in wild-type mice.  
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There was a trend for Aβ levels to be decreased in the wild-type TBI group. They 
remained close to baseline in the wild-type sham group (Fig. 31A).  Over the entire 42-
hour post-TBI interval, Aβ40 levels were 67.1% ± 4.6% of baseline in 2.0 mm-injured 
mice and 96.1% ± 5.0% of baseline in sham-injured mice (p=0.200, two-tailed Mann-
Whitney U-test).  It was not possible to measure Aβ42 in microdialysates from wild-type 
mice. 
In principle, human sequence Aβ could show dynamics in ways that differ from 
murine Aβ, i.e. due to aggregation or deposition.  In order to address the dynamics of 
human sequence Aβ in the ISF after TBI, we turned to a transgenic mouse model, the 
PDAPP+/- mouse. Additionally, the ELISAs used to detect human Aβ is considerably 
more sensitive than the ELISA used to detect murine Aβ (typically 1.6-4.4 pg/ml). This 
permitted an improved time resolution from 6 hours to 90 minutes. We collected baseline 
microdialysis samples for Aβ1-x measurement over 18-24 hours, then performed either 
sham (n=6) or 2.0 mm CCI TBI (n=6) in 3-6 month old in PDAPP+/- mice (Fig. 31C).  
Baseline Aβ1-x values in sham and injured groups were relatively stable, showing little 
variation during the 12 hours preceding sham or TBI (Fig. 31C).  For PDAPP+/- mice, 
baseline Aβ1-x values measured in microdialysates were 90 ± 53 pg/ml (mean ± SD) in 
the sham groups and 108 ± 57 pg/ml in the TBI group.  These were not significantly 
different (p=0.6991, two-tailed Mann-Whitney U-test).  Following injury the TBI group 
demonstrated an immediate and persistent decrease in Aβ1-x (Fig 31C). Taken in 6-hour 
epochs and normalized to baseline, levels fell to approximately 67 ± 23% of baseline 
during the first 6 hours, then 46 ± 13% over 6-12 hours, 37 ± 8% over 12-18 hours, and 
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34 ± 7% from 18-24 hours after injury (Fig 31D).  Aβ1-x levels in the sham-injured group 
remained at or above baseline values.  Overall, Aβ1-x levels were significantly different 
between TBI and sham groups (Fig. 31D) (repeated measures ANOVA p < 0.00239 for 
main effect of group).   
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Figure 31.  Hippocampal Aβ dynamics before and after traumatic brain injury as 
measured by microdialysis.  A, wild-type mice. Aβx-40 by ELISA beginning 18 hours 
before injury though 42 hours after injury in 3-6 month old C57BL6 mice. Sham-injured 
animals underwent the same procedures, except the impactor was discharged without 
contacting the cortical surface.  Error bars represent the standard error of the mean for the 
group.  B, data were normalized to each individual animal’s baseline and averaged by 
group over the entire 42-hour, post-TBI interval.  Error bars represent the standard error 
of the mean for the group.  Injured animals showed a non-significant decrease in Aβx-40 
compared to sham (p = 0.200, two-tailed Mann-Whitney U-test). C, PDAPP mice.  Aβ1-x 
measured in 90-minute microdialysis samples by ELISA beginning 12 hours before 
injury though 24 hours after injury in 3-6 month old PDAPP+/- mice. Error bars represent 
the standard error of the mean for the group.  D, data were normalized to each individual 
animal’s baseline and binned into 6-hour epochs.  Error bars represent the standard error 
of the mean for the group.  Injured animals showed a statistically significant decrease in 
Aβ1-x compared to sham (**p < 0.004 for main effect of group, p < 0.00004 for group by 
time, repeated measures ANOVA).  
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Decreases in Aβ1-x likely reflect physiological sequelae of TBI 
A key assumption underlying the reliability of measurements made by 
microdialysis is that the probe is functioning normally throughout the experiment.  For 
example, the probe should never be clogged or otherwise blocked from free exchange 
with the surrounding interstitial fluid (ISF).  To address this concern, we used three 
approaches to test for consistent probe function: zero flow extrapolation, retrodialysis, 
and measurement of urea.  
We performed zero-flow extrapolations during baseline periods and again during 
post-TBI periods in 4 PDAPP+/- mice undergoing 2.0 mm CCI injury (Fig. 32A).  The 
zero-flow extrapolation method involves varying the flow rate over time and assumes that 
the underlying ISF concentration remains constant.  Because the levels of post-TBI Aβ 
decreased by 4.5-6 hours after injury and remained relatively stable over the next 18 
hours (Fig. 31C), we were able to vary the flow rate during the post-injury period.  We 
plotted the Aβ levels before and after TBI as a function of flow rate, and fit this data to 
decaying exponential curves.  The mass transfer coefficients for these exponential curves 
were not significantly different before and after TBI (K0, pre-TBI = 9.5 ± 2.2 
mL/(min*mm2) and K0, post-TBI = 10.2 ± 1.6 (mL/min*mm2) as indicated by overlapping 
95% confidence intervals.  This result indicates that there was no significant change in 
the fractional recovery of Aβ before and after TBI.  Normalized to the respective zero-
flow concentrations, the mean fractional recoveries at 1.5 µL/min were 0.0527 ± 0.00129 
(pre-TBI) and 0.0642 ± 0.00286 (post-TBI); these were not significantly different (two-
tailed Mann-Whitney U-test, p = 0.1333).  
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 Next, probe function was evaluated using retrodialysis of Aβ in the perfusion 
solution.  For simple diffusion, Aβ diffusion rates from the microdialysis probe into the 
brain should be similar to diffusion rates from the brain into the microdialysis probe.  
Wild-type mice were subjected to the combined CCI-microdialysis procedure with 
perfusion of 3000 pg/ml of synthetic, biotinylated Aβ1-40 through the inlet tubing.  There 
was an average Aβ loss of approximately 20-25% both before and after a 2.0 mm CCI 
injury (Fig. 32B).  Pre and post-injury levels were not significantly different (p=0.1944, 
paired t-test).  This experiment further indicates that there were no changes in the 
diffusion of Aβ across the microdialysis probe after TBI. 
 Finally, the recovery of urea was used as a third control for probe function.  Urea 
is a small molecule produced in the liver that rapidly equilibrates throughout all tissue 
compartments, and is frequently used as a control for probe function in human cerebral 
microdialysis (Ronne-Engstrom et al., 2001; Brody, Magnoni et al., 2008).  Urea levels 
were comparable in all microdialysis samples (Fig. 32C).  There were no significant 
differences between pre and post-TBI urea levels (p=0.1747, paired t-test).   
Of note, in some animals in which microdialysis was performed for more than 24 
hours after TBI, urea levels became inconsistent.  Therefore, Aβ measurements were 
considered potentially unreliable after the first 24 hours.  Thus, we restricted our analyses 
to measurements during the first 24 hours after of injury.    
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Figure 32. Controls for changes in microdialysis probe function following TBI.  A, 
zero-flow extrapolation.  Flow rates were changed systematically at baseline (left) and 
after 2.0 mm TBI (right) in 4 PDAPP+/- mice.  Exponential fits to these data allow 
comparison of pre and post-TBI fractional recovery of Aβ.  Statistically indistinguishable 
mass transfer coefficients (K0 pre-TBI, K0 post-TBI) suggest unchanged probe recovery before 
and after TBI.  B, retrodialysis of biotinylated Aβ in wild-type mice did not differ before 
vs. after 2.0 mm TBI (n=4; p=0.1944, paired t-test); inset, averaged data for all samples 
pre and post-TBI. C, recovery of urea by microdialysis in PDAPP+/- mice was stable 
before and after TBI (p=0.1747, paired t-test).  
 
 
 
Decreases in microdialysate levels of Aβ1-x are reflected in tissue lysates 
Post-TBI changes in microdialysate levels of Aβ might reflect changes in overall 
tissue levels or be specific to ISF Aβ.  To assess these alternative hypotheses, we used a 
serial tissue extraction protocol in a separate set of PDAPP+/- mice sacrificed 2 hours after 
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TBI.  Because the mice used for tissue homogenization did not undergo microdialysis, 
the similarity of injury with and without microdialysis was first assessed histologically 
(Fig. 29), including stereological quantification of cells in the inferior blade of the CA3 
region of the hippocampus (Fig. 30).  No significant differences were found between 2.0 
mm injured mice with and without microdialysis qualitatively (Fig. 29) or stereologically 
(Fig. 30; p=0.572, unpaired, two-tailed t-test). This indicates that 2.0 mm impact depth 
injuries were similar in severity with and without microdialysis.  Likewise, there were no 
differences between sham-injured mice with and without microdialysis (p=0.693, 
unpaired, two-tailed t-test; Fig. 30).   
Aβ1-x levels in tissue lysates were reduced in both the hippocampus and cortex.  
For ipsilateral hippocampus, significant differences were measured in the PBS-soluble 
pool of Aβ1-x between sham and injured groups (Fig. 33A; p=0.0286, Mann-Whitney U-
test).  Specifically, after injury, tissue levels were reduced to approximately 50-60% of 
that found in sham-injured animals.  This change is of the same magnitude as was 
measured by microdialysis (Fig. 31).  Although Aβ1-x measurements in carbonate and 
guanidine-soluble extracts of ipsilateral hippocampus were not significantly different 
between sham and TBI, mean levels were decreased ~25-50% at the 2-hour timepoint 
(Fig. 33D, G). 
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Figure 33.  Effects of experimental TBI on Aβ levels in ipsilateral hippocampal 
homogenates.  PDAPP+/- mice underwent 2.0 mm injury or sham and were sacrificed 
after 2 hours (n=5 per group).  Levels of Aβ isoforms were measured in serial extracts, 
and values were normalized to total protein in each homogenate.  Data plotted for 
individual mice: Aβ1-x (A, D, G), Aβx-40 (B, E, H), Aβ1-42 (C, F, I) levels in PBS (A, B, 
C), carbonate (D, E, F), and guanidine-soluble extracts (G, H, I).  Significant differences 
were observed in the PBS-soluble pool of Aβ1-x between sham and TBI groups 
(p=0.0286, Mann-Whitney U-test); PBS-soluble levels of Aβx-40 also differed between 
sham and TBI groups (p=0.0159). 
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For ipsilateral cortex, there was a statistically significant difference of 
approximately 50% between sham and injured groups in Aβ1-x levels in all three 
homogenates: PBS-soluble extracts (Fig. 34A; p=0.0079), carbonate-soluble extracts 
(Fig. 34D; p=0.0159), and guanidine-soluble extracts (Fig. 34G; p=0.0079).   
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Figure 34.  Effects of experimental TBI on Aβ levels in ipsilateral cortical 
homogenates.   Cortical homogenates from the same mice as in Fig. 18. Values 
normalized to total protein in each homogenate plotted for individual mice: Aβ1-x (A, D, 
G), Aβx-40 (B, E, H), Aβ1-42 (C, F, I) in PBS (A, B, C), carbonate (D, E, F) and 
guanidine-soluble extracts (G, H, I).  Differences were detected in the PBS-soluble pool 
of Aβ1-x between the sham and TBI groups (p=0.0079, Mann-Whitney U-test), in the 
carbonate-soluble pool of Aβ1-x (p=0.0159), and the guanidine-soluble pools of both Aβ1-x 
(p=0.0079) and Aβ1-42 (p=0.0159). 
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Decreases in Aβ40 and Aβ42  
Aβx-40 and Aβ1-42 were measured individually in tissue homogenates of ipsilateral 
hippocampus and cortex.  Levels of PBS-soluble Aβx-40 in the ipsilateral hippocampus 
were significantly different between sham and TBI groups in (Fig. 33B; p=0.0159).  
There was also a significant difference in Aβ1-42 levels in guanidine-soluble cortical 
extracts (Fig. 34I, p=0.0159).  While changes in the levels of these specific isoforms in 
other PBS, carbonate and guanidine-soluble extracts did not reach statistical significance, 
levels of Aβ were decreased in injured tissues 25-50% compared to sham.  No extracts 
showed evidence of increased Aβ.   
We did not measure Aβx-40 and Aβ1-42 separately in individual microdialysis 
samples due to the low sample volumes and lesser sensitivity of the isoform-specific Aβ 
ELISAs.   
 
No changes in the amount of APP in the injured brain 
 Reductions in hippocampal Aβ1-x measured by microdialysis and in hippocampal 
and cortical homogenates could in principle be related to changes in the expression of the 
amyloid precursor protein (APP) in the brain after injury.  To test the hypothesis that APP 
levels were affected in the acute post-injury period, we used Western blotting to quantify 
the amount of full-length APP in RIPA-extracted tissues from additional injured and 
sham PDAPP+/- mice.  APP levels were found not to be significantly different between 
sham and TBI groups at 2 hours after injury in ipsilateral and contralateral hippocampi 
and cortices (Figs. 35, 36). 
 Figure 35. Measurement of full
for full-length APP in RIPA extr
the RIPA-soluble pool of full
quantified by the average intensity per band, normalized to tubulin loading control.  
Tissues were loaded in the same order on each gel such that each lane co
the same mouse on each blot (S=sham, T=TBI).  
Contralateral hippocampus.  C.
 
 
Figure 36. Quantification of average band intensities,
in RIPA-extracted tissues at 2 hours post
average band intensities of APP (normalized to tubulin), quantified by the user
background method on the Licor Odyssey
each (see Fig. 35 for blot).  No 
and injured.  Standard errors 
all comparisons. A. Ipsilateral hippocampus (p = 0.419).
(p=0.553). C. Ipsilateral cortex (p=0.382). 
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No Aβ deposits observed at 24 hours after injury in the young, injured mouse brain 
 Acute Aβ deposits have been observed as early as 2 hours in the brains of 
approximately 1/3 of adult human TBI patients not otherwise expected to have plaques 
(Fig. 1). We did not expect to see Aβ deposits after TBI in these animals based on 
previous results (Smith, et al., 1998) and our guanidine extract ELISA data (Figs. 33, 34). 
However, to explicitly test the hypothesis that Aβ deposition might underlie the decrease 
in the exchangeable pool of Aβ, we stained sections throughout the hippocampus, every 
300 µm, from two groups of mice (n=5 2.0 mm TBI, n=5 sham) at 24 hours after injury 
or sham with a biotinylated anti-Aβ
 
antibody (HJ3.4B, courtesy of Hong Jiang and David 
Holtzman).  No deposition could be seen in any of the sections at this timepoint in young 
PDAPP+/- mice (Fig. 37, A-D).  As positive controls, sections from 10 and 20-month old 
PDAPP+/- mice were stained with HJ3.4B.  The 10-month old mouse showed nascent 
deposition in hippocampus and cortex (Fig. 37E), while the 20-month old mouse 
displayed widespread plaques throughout cortex and hippocampus (Fig. 37G).  These 
patterns confirmed the sensitivity of the immunohistochemical methods.   
Figure 37. Aβ immunohistochemistry. Coronal sections from animals sacrificed at 24h 
following 2.0 mm TBI or sham injury were stained with HJ3.4B, a monoclonal, 
biotinylated antibody directed against the N-terminus of human Aβ.  Every sixth section 
was stained with HJ3.4B (A, C, E, G, I).  The series adjacent to the stained series 
underwent the same processing, with omission of the primary antibody (B, D, F, H, J).  
Scale bar on all images, 2.5 mm.  A. 4-5 month old PDAPP+/-, 2.0 mm TBI with 
microdialysis.  B. Same brain as (A), without primary antibody.  C. 4-5 month old 
PDAPP+/-, sham with microdialysis.  D. Same as (C), without primary.  E. 10 month old 
PDAPP+/- sham with microdialysis.  F. Same as (E), without primary.  G. 20 month old 
PDAPP+/-, 2.0 mm TBI with microdialysis.  H. Same as (G), without primary.  I. 4-5 
month old wild-type C57BL6 mouse underwent 2.0 mm TBI.  J. Same as (I), without 
primary.    
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Reduced EEG activity in the injured hippocampus  
 Previous animal studies suggest that extracellular Aβ dynamics are highly 
correlated with neuronal activity (Cirrito, et al., 2008, Cirrito, et al., 2005, Kamenetz, et 
al., 2003).  We asked whether the changes seen in microdialysis levels of Aβ in our 
model might be associated with changes in local neuronal activity using intra-
parenchymal EEG.  Using a modified guide canula with two affixed electrodes (Fig. 
38A), EEG amplitude was continuously recorded during the baseline monitoring (Fig. 
38B) and post-injury periods (Fig. 38C).  Filtered tracings were sampled for statistical 
analysis of root-mean square (RMS) amplitude, and average baseline values 
corresponding to each microdialysis sampling period were plotted over time (Fig. 38D).  
EEG amplitude was stable during the baseline period.  After TBI, the EEG amplitude was 
decreased compared to baseline (Fig. 38B, C; Fig. 38D).  The extent of the reduction in 
EEG amplitude over the 24-hour period following sham or 2.0 mm injury was 
significantly different between groups (two-tailed Mann-Whitney U-test, p = 0.0182) 
(Fig. 38E).  Taken together with the previous studies of extracellular Aβ dynamics and 
neuronal activity, our measurement of an overall reduction in EEG amplitude suggests a 
possible mechanism for the observed reduction in ISF Aβ in the injured hippocampus. 
 
 
 
 
 
 
 
 
 
 
 Figure 38. Measurement of EEG changes following experimental TBI.  A.
Photograph of modified guide canula with Teflon
attached.  Scale bar, 5 mm.  Inset demonstrates relationship of leads to probe membrane.  
Scale bar, 2 mm.  B. Exemplar EEG tracing before injury.  
minutes after 2.0 mm TBI. D
changes following a 2.0 mm 
over the 24-hour period following sham (n = 6) or 2.0 mm TBI (n = 11) (p = 0.0182, two
tailed Mann-Whitney U-test).  
 
DISCUSSION  
In both wild-type and young PDAPP
found that ISF Aβ levels in the ipsilateral hippocampus were immediately reduced after 
experimental traumatic brain injury and remained low over the next 24 hours.  Further, 
we measured a similar reduction of A
ipsilateral hippocampus in injured PDAPP mice compared to sham
hours after injury.  We found no significant differences in APP levels in RIPA
tissue extracts, indicating that changes in post
127 
-coated platinum-iridium EEG leads 
C. Exemplar EEG tracing 60 
. Time course of EEG root mean square (RMS) amplitude 
TBI in an individual mouse. E. Change in EEG amplitude 
 
+/- 
mice without Aβ plaque depositi
β1-x and Aβ40 in the PBS-soluble tissue extracts of 
-injured animals 2 
-injury levels of Aβ1-x are not likely due to 
 
-
 
on, we 
-soluble 
128 
 
acute reductions in APP.  Immunohistochemistry revealed no intracellular or extracellular 
accumulations of Aβ.  There were no significant changes in hippocampal carbonate or 
guanidine-soluble extract Aβ levels.  This indicates that reductions in the hippocampal 
ISF and PBS-soluble tissue extract levels were not due to acute aggregation or deposition 
of Aβ.  Finally, we measured a significant post-injury reduction in local EEG activity 
over 24 hours.  Taken with our observed reductions in both ISF Aβ and Aβ in tissue 
extracts, our finding is consistent with earlier reports that extracellular Aβ levels are 
correlated with neuronal activity.   
 Previous studies that combined experimental TBI with pre- and post injury 
microdialysis have been performed in rats.  Our study extends this approach to mice, 
broadening the scope of possible microdialysis assessments to include a wide variety of 
transgenic animals.   
These experimental results complement the findings from recent clinical 
microdialysis studies of Aβ dynamics in human brain injury patients (Brody, Magnoni et 
al., 2008; Marklund et al., 2009) in three ways: first, pre-injury Aβ levels were measured 
prior to experimental TBI.  This baseline measurement allowed us to clearly determine 
that ISF Aβ levels were reduced following injury.  Second, Aβ levels were measured at 
very early times following injury, and these were also found to be immediately decreased 
within the first 90 minutes of TBI.  In human patients, microdialysis catheters were 
typically placed 12-24 hours after injury, thus very early Aβ measurements were not 
possible.  Third, Aβ levels in tissue compartments other than the ISF pool sampled by 
microdialysis were assessed in comparably injured animals.  Levels of Aβ in 
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hippocampal PBS-soluble extracts were also found to be decreased at the 2-hour 
timepoint, but there were no changes in the hippocampal carbonate or guanidine-soluble 
extracts.  Extrapolating these results to previous human studies, we suggest that post-
injury extracellular Aβ levels are likely immediately decreased following TBI and then 
increase or decrease further in parallel with recovery or deterioration of neurological 
status in patients with acute brain injury.  
What is the underlying cause for the trends in ISF Aβ dynamics described here?  
It has previously been demonstrated in vitro as well as in vivo that neuronal activity, and 
more specifically, synaptically coupled endocytic activity, is directly correlated with Aβ 
release (Cirrito, et al., 2008, Cirrito, et al., 2005, Kamenetz, et al., 2003).  During the 24-
hour period after 2.0 mm CCI-TBI, there was a significant reduction in EEG activity.  
However, this observation does not prove a causative link between neuronal activity and 
ISF Aβ in the setting of brain injury.  The changes in the two measures might both be 
caused by a common post-insult factor, such as neuronal cell death.  Future studies to test 
hypotheses regarding these mechanisms will be required to address the role of neuronal 
and synaptic activity as it relates to Aβ levels in the context of TBI. 
Caveats associated with extrapolation from transgenic mouse models to human 
patients warrant consideration here.  The mechanics of experimental TBI in rodents are 
different from those in human TBI patients.  In contrast, some experimental TBI models 
in pigs are biomechanically more similar to human TBI (Smith, et al., 1999).  
Microdialysis measurements of other analytes have been performed in conjunction with 
TBI in pigs (Alessandri, et al., 2003), but Aβ has not yet been measured.  Extension of 
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these methods to pigs could significantly advance current experimental understanding of 
Aβ dynamics following TBI.  
The PDAPP mouse overexpresses a rare form of human APP, the V717F 
mutation, and this may affect Aβ dynamics.  However, the similarity of post-injury Aβ 
dynamics in wild-type and transgenic mice indicates that the observed decrease is not 
unique to transcriptional control under the PDGF promoter used in the PDAPP mice, nor 
does it depend on absolute levels of the peptide or the specific assay used to measure Aβ.  
Our experimental approach is not without limitations.  First, the pool of Aβ in 
interstitial fluid is but one of many in the living brain.  Our longitudinal microdialysis 
measurements were limited to the interstitial space.  Second, levels of ISF Aβ are lower 
in PDAPP mice as compared to some other hAPP models, such as the Tg2576 mouse 
(Cirrito et al., 2005; Kang et al., 2007; Cirrito et al., 2008; Kang et al., 2009; and our 
unpublished results).  Measurement of reduced ISF Aβ levels was bounded by the 
sensitivity of our ELISA assay.  Future experiments using other lines of transgenic mice 
with higher ISF Aβ levels could increase time resolution and allow more detailed 
assessment of underlying mechanisms.  Third, we were restricted to the first 24 hours 
after injury for microdialysis monitoring due to the apparent inconsistent probe function 
at later times.   
Our findings fit well with a previous study that described a marked decrease in 
amyloid plaque burden in older PDAPP mice at 5 and 8 months after injury (Nakagawa, 
et al., 1999).  We therefore suggest that reduced extracellular concentrations of Aβ after 
TBI resulted in diminished deposition at chronic timepoints in this mouse model.  
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However, our results differ from other descriptions of post-injury Aβ dynamics in tissue 
homogenates (Abrahamson, et al., 2006, Loane, et al., 2009, Smith, et al., 1998).  
Methodological differences preclude a direct comparison of our findings with these 
studies.   
In conclusion, further studies of both experimental models and human TBI 
patients will be required to address these mechanisms underlying the observed Aβ 
dynamics.  This mouse model demonstrates the potential experimental approaches to 
complement human microdialysis measurements.  
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Chapter 6. 
 
Synaptosomes to examine post-TBI localization of Aβ 
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Serial tissue extractions reveal decrease or trend to decrease at 2h 
Based on the results from serial tissue extractions, hippocampal Aβ was 
significantly decreased in the PBS-soluble fraction, and trended towards decrease in the 
carbonate and guanidine fractions.  Likewise, there was a significant decrease in ISF Aβ 
levels by microdialysis.  It seemed to us that this selective decrease in extracellular and 
highly soluble compartments might be in part due to reduced synaptic activity, and 
subsequently, decreased release of the peptide into the extracellular space. 
 
Other mechanisms: decreased production and/or increased clearance? 
Because the carbonate and guanidine fractions trended towards decrease, 
suggesting an overall decrease in soluble and insoluble Aβ tissue content, it was also 
possible that decreased enzymatic production might contribute to our measurements.  We 
did not detect a change in protein levels of APP at early timepoints, so we did not suspect 
decreased precursor proteins contributed to our measurements.  However, failed APP 
transport to its sites of cleavage by β and γ-secretases, or impaired enzymatic activities 
themselves might lead to an overall decrease in Aβ tissue levels.  We did not rule out 
increased clearance from the ISF as a contributing factor.  Other experiments to address 
these possibilities were initiated and will be presented in the next chapter. 
 
Disrupted synaptic homeostasis post-TBI  
 Previous studies had established a very early failure of synaptic homeostasis after 
CCI in rats (Sullivan, et al., 1998).  To isolate the nerve terminals, the authors prepared 
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synaptosomes from ipsilateral and contralateral hemispheres of CCI-injured animals.  As 
compared to the contralateral hemisphere, they measured reduced ATP levels within 30 
minutes after injury with a significant increase in lipid peroxidation (Sullivan, et al., 
1998).  ATP is required for endocytosis at the synapse (Heidelberger, 2001), and lipid 
peroxidation impairs synaptic membrane functions (Braughler, 1985, Cohadon, 1984). 
We hypothesized that disruption in homeostatic release and uptake of Aβ at the 
synapse might be one mechanism by which ISF Aβ levels are decreased in microdialysis 
measurements.  In a complementary fashion, the synaptic compartment might have 
increased levels. 
 
Previous studies of Aβ measurement in synaptosomes 
It was unknown whether we would be able to measure Aβ in a synaptic location. 
Earlier studies had detected Aβ at the synapse in aged Tg2576 mice using gold-labeled 
immunogold electron microscopy (EM) (Takahashi, et al., 2008).  This suggested that Aβ 
accumulates in a synaptic location and can be detected.  Two recent reports describe a 
crude synaptosome preparation in conjunction with flow cytometry to quantify the Aβ, 
tau, and cholesterol content at the synapses of human brain tissue in AD and control cases 
(Fein, et al., 2008, Gylys, et al., 2007).  These studies suggested to us that it was possible 
to detect Aβ in such a preparation if it were present.  We wanted to explicitly test the 
notion that Aβ might be retained in a synaptic location after experimental TBI and chose 
a synaptosome preparation for our model system.   
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Synaptosomes: theory and technique 
 Synaptosome preparation was first described in the neuroscience literature by 
Hebb and Whittaker (Hebb and Whittaker, 1958) and employed in many studies, 
particularly involving neurotransmitter distribution and function, during the following 
decades (Whittaker, 1993).  Essentially, these structures are detached, sealed presynaptic 
terminals.  A portion of the target cell, such as a dendritic spine, can adhere to the 
synaptosome surface (Fig. 39).   
 
Figure 39. Theoretical and actual structures of synaptosomes.  Left, schematic from 
Gylys et al., 2004.  Nerve terminals and axonal processes are sheared from axonal 
attachments and resealed.  Right, a synaptosome imaged by transmission electron 
microscopy.  Presynaptic terminal contains vesicles; closely apposed to the post-synaptic 
density.  Electron micrograph by Marilyn Levy, Washington University Histology Core. 
 
 
 
It has been shown that these structures can be prepared from a variety of neural tissues, 
including spinal cord, retina, sympathetic ganglia, myenteric plexus and electric organs 
(Whittaker, 1993).  These structures have also been shown to respire, take up oxygen and 
glucose, release Na+, take up K+, maintain a normal membrane potential and, release 
neurotransmitter in a Ca2+-dependent manner.   
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Crude preparation 
In the first versions of the protocol, brains or brain regions are extracted 
immediately following decapitation.  The tissue is coarsely chopped using a blade and 
placed in a glass vial.  Using a strategy the originally termed “osmotic shock,” a 0.32M 
hypertonic sucrose solution is added at various steps and washings to preserve cell 
membrane integrity.  Then, a glass pestle, also called the dounce-homogenizer, is driven 
up and down to smear the tissue against the glass vial.  This action shears nerve terminals 
from their axons.  When these membranes reseal, synaptosomes are created.  The 
remaining steps isolate and purify these structures from the rest of the tissue.   
  
Ultracentrifugation across a sucrose gradient 
Isolation of synaptosomes is achieved by gradient fractionation.  The original 
versions utilize ultra-high speed centrifugation across a sucrose-based gradient.  The 
main disadvantages of this technique are the amount of mechanical disruption during 
resuspension, and the fact that it often takes over 4-5 hours to complete all the steps.  
Traditional procedures often lead to a loss of functional integrity and low yields (De 
Robertis, et al., 1961, Fleming, et al., 1980, Gray and Whittaker, 1962).  We were also 
concerned about the fundamental fragility of CCI-injured tissue.  One way for reseachers 
to decrease the amount of time and manipulation is to simply use the crude mitochondrial 
fractions (P2) for their functional experiments, rather than to risk damage during the 
purification by fractionation of the pellet.  In this way they can avoid hypertonic 
conditions and ultracentrifugation.  The entire length of preparation is also reduced to 30-
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40 minutes total.  However, the P2 fraction is contaminated with myelin and 
extrasynaptosomal mitochondria, and these elements can interfere with biological assays 
(Dodd, et al., 1981). 
 
High-speed centrifugation across a Percoll gradient 
For these reasons, we chose an abbreviated procedure that eliminates the need for 
ultracentrifugation by substituting Percoll for sucrose in the discontinuous gradient.  The 
methods were first described for isolation of white and red blood cells (Gutierrez, et al., 
1979, Kurnick, et al., 1979, Rennie, et al., 1979, Ulmer and Flad, 1979).  The use of 
Percoll gradients to isolate synaptosomes was first described in 1986 (Dunkley, et al., 
1986), modified to an even shorter protocol in 1988 (Dunkley, et al., 1988, Harrison, et 
al., 1988) and published in full detail in 2008 (Dunkley, et al., 2008). 
Percoll is a slurry of synthetic polyvinyl, pyrrolidone-coated silica particles of a 
uniform 17 nm diameter.  A major advantage of Percoll over other gradients, such as 
sucrose and Ficoll, is its low viscosity.   As a result, sedimentation occurs more rapidly at 
lower centrifugal forces using Percoll.  In addition to blood elements, Percoll gradients 
have been used to isolate many other types of cells and subcellular organelles (Pertoft, 
2000). 
Dunkley et al. first applied this rapid Percoll gradient to isolate functional 
synaptosomes (Dunkley, et al., 1986).  The crude P2 pellet was applied to a 4-layer 
discontinuous gradient and centrifuged for 5 minutes at 32,500 g, excluding acceleration 
and deceleration times.  Fractions were collected at the interfaces between different 
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layers and were each resuspended to dilute Percoll contaminant, and concentrated by 
centrifugation at 15,000 g.  Functional viability was tested by uptake assays for calcium, 
phosphate, and noradrenaline; and by the effects of depolarization on metabolism, 
calcium uptake, and protein phosphorylation.  The purity of the synaptosomal content of 
each of the fractions was assessed by electron microscopy. 
Soon after the first report, this same group modified the procedure slightly to 
apply the first supernatant, S1, directly to the Percoll gradient, instead of a second 
centrifugation step (Dunkley, et al., 1988, Harrison, et al., 1988).  This both reduced the 
total time of the procedure and the possible mechanical damage resulting from 
resuspension.  These methods were published in explicit detail in a more recent paper, 
which provided us the protocol for preparation of synaptosomes from CCI-injured brain 
(Dunkley, et al., 2008).  The exact protocol used in the experiments described in this 
chapter is detailed in the Appendix 3 (Synaptosomes: materials and protocol). 
 
Initial verification of the discontinuous Percoll gradient: colored layers 
 Upon the recommendation and instruction by a committee member, Dr. Timothy 
Miller, we first verified that our Percoll gradient was “clean” and that we could create 
separate layers by the use of food coloring.  This was an important control.  Without good 
technique to create separate layers, we would be unable to separate different fractions and 
therefore unable to isolate synaptosomes (Fig. 40). 
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Figure 40.  Discontinuous Percoll gradient.  Each layer, beginning with 23%, was 
carefully hand-poured using a 1-mL transfer pipette for 2 mL each in a 12 mL Sorvall 
polycarbonate centrifuge tube.  Layer interfaces are marked with black Sharpie on the 
outside of the tube.  Food coloring added prior to pouring indicates various 
concentrations of Percoll in each layer.  With kind assistance from Tim Miller, MD, PhD. 
 
 
 
Once it was clear that we could prepare a consistent discontinuous gradient, we then 
attempted to separate fractions prepared from whole brain.  Eventually, we would use 
isolated, ipsilateral hippocampi, one per gradient.  Because an ipsilateral hippocampus 
was often less than 10% by weight of the total brain, we wanted to confirm our 
techniques with whole brain before moving on to a more challenging tissue. 
Briefly, wild-type mice were deeply anesthetized and their brains were quickly 
perfused with 10 mL of homogenization buffer by transcardial perfusion using a large 
bore syringe (18-gauge needle).  The skull was opened, brain removed and coarsely 
chopped into smaller pieces with a sharp #10 Exacto blade.  Cerebellum and brain stem 
were not included in the homogenization.  These pieces were suspended in 3 mL of 
homogenization buffer and dounce-homogenized in a 15 mL Teflon Wheaton 
3%
10%
15%
23%
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homogenization vial.  We used a total of 10 up-and-down strokes, making sure that no 
gross particles of brain tissue remained.  This solution was spun down briefly at a low 
speed (1000 g) to remove gross matter and large nuclei.  The supernatant from this 
fraction, S1, contains synaptosomes, subcellular organelles and isolated membranes.  
This supernatant is fractionated by the Percoll gradient.  Depending on the protein 
concentration, the supernatant was sometimes diluted for optimal centrifugation.  A 
volume of 2 mL of the S1 supernatant was loaded on top of the gradient prior to the high-
speed spin, shown on the left in Figure 41.  The centrifuge tubes were spun down in a 
Sorvall SS34 rotor at 20,000 g, resulting in the fractionation of different sizes of 
subcellular organelles and membranes, as depicted in Figure 41 (right).  The fractions 
enriched in synaptosomes are Fraction 4 (most pure) and Fraction 3 (less pure, but more 
abundant). 
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Figure 41.  Discontinuous Percoll gradient before and after high-speed 
centrifugation.  Left, loaded with 2 mL S1 supernatant just prior to 5 minute high-speed 
centrifugation at 20,000 g.  Right, after high-speed centrifugation.  Fractionation of S1 
occurs at layer interfaces, marked here on the tube with black Sharpie.  Fractions 2, 3, 
and 4 are indicated (F2, F3, F4, respectively). 
 
 
  
Finally, we removed each fraction by careful pipetting with a long-bore pipette tip, first 
removing Fraction 3, then Fraction 4 (Fig. 42). 
 
Figure 42.  Sequential removal of fraction 3 (left) and fraction 4 (right). 
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Synaptosomes prepared from mouse brain: verification by electron microscopy   
 Because the previous protocols used transmission electron microscopy (TEM) to 
verify the morphology and concentration of synaptosomes in each of the resultant 
fractions, along with any contamination, we wanted to compare our fractions to validate 
the similarity of our technique (Dunkley, et al., 1988, Dunkley, et al., 1986, Dunkley, et 
al., 2008, Harrison, et al., 1988).  To do this, we enlisted the help of Marilyn Levy at the 
Washington University Histology Core.  As a specialist in the technique of TEM, she was 
able to recommend the best method for preparing and fixing our fractions.  Briefly, we 
spun down the fractions at low speed into a pellet, gently washed the pellet with 0.9% 
NaCl, and resuspended the pellet in ice-cold, 2.5% gluteraldehyde in PBS.  These fixed 
pellets were then embedded in plastic, sliced, and stained with osmium tetroxide.  We 
examined these slices using the electron microscope, and were able to validate our 
technique against published results in a qualitative fashion.  Below are images we took of 
fractions 3 and 4, separately, at different magnifications (Figs. 43-45).  
 
143 
 
Figure 43.  Fractions 3 (left) and 4 (right) at 7X power.  Scale bars as marked. 
 
 
 
 
Figure 44.  Fraction 3 at 12X (left) and 20X power.  Scale bars as marked. 
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Figure 45.  Fraction 3 at 20X power.  Scale bars as marked. 
 
 
 
 
By a qualitative assessment, we determined that our homogenization, fractionation, and 
purification protocol yielded morphological synaptosomes, with the greatest proportion in 
Fraction 3.  Because we were ultimately going to measure Aβ content in a single, 
ipsilateral hippocampus, we decided to combine Fractions 3 and 4 for the greatest 
possible yield based on these electron micrographs. 
 
Preparation of synaptosomes from single hippocampus 
 Having shown that we could prepare synaptosomes from whole brain, we now 
wanted to know whether we could prepare them from a single ipsilateral hippocampus 
(both sham and injured).  In this experiment, we perfused mice and extracted the brains 
300 nm350 nm
250 nm 350 nm
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as before, except we dissected and isolated each side (left and right) of the hippocampus.  
Notably, these tissues were much smaller than the whole brain.  The coarse chopping step 
became very brief as there was little tissue to parse.  We also substituted a smaller 
dounce-homogenizer (5 mL) for the 15 mL vial used to homogenize the whole brain.  
After spinning the crude homogenate at 1000 g, we were able to pellet out gross matter 
and derive an S1 supernatant for fractionation (Fig. 46). 
Figure 46.  S1 supernatant prepared from single hippocampus, left and right.  Pellet 
is seen at the base of the each tube.   
 
  
 
Fractionation with this supernatant was possible, albeit at low yield.   
 Next, we wanted to demonstrate that Fractions 3 and 4 were enriched for 
synaptosomes.  To do this, we chose a highly conserved presynaptic marker, SV2 
(Bindra, et al., 1993, Feany, et al., 1992).  Using a Western blot, we compared SV2 
content in S1, the original supernatant, with combined fractions 3 and 4 for each single 
hippocampus.  For a positive control, we used a RIPA-extract whole brain homogenate 
(Fig. 47).  In the same blot, using a strip-reprobe method, we looked at the APP content 
(Fig. 48). 
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Figure 47.  SV2 protein in S1 as compared to combined fractions 3 and 4.  “A” and 
“B” represent left and right sides of a hippocampus.  Enrichment of SV2 in fractions 3 
and 4 suggests the enrichment for presynaptic terminals, as compared with crude 
homogenate.  Positive control, RIPA-extract from whole brain of a PDAPP mouse.  All 
lanes were loaded with 10 ug of total protein. 
 
  
 
Figure 48.  APP in S1 as compared to combined fractions 3 and 4.  APP is present in 
both crude homogenate supernatant S1 and in the synaptosome-enriched fractions.  
Positive control, RIPA-extract of whole brain from a PDAPP mouse.  All lanes were 
loaded with 10 ug of total protein. 
 
 
 
 
Having shown now that our fractions were enriched for synaptic structures, we wanted to 
test the hypothesis that Aβ might be retained within a synaptic terminal in injured tissue 
rather than be released into the extracellular space.  Again, this was a proposed 
mechanism for the observed reduction in the ISF Aβ levels in the ipsilateral hippocampus 
immediately after a 2.0 mm CCI injury. 
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 To test this hypothesis, we performed either a sham or 2.0 mm CCI injury on 
young, pre-plaque PDAPP mice.  Mice were allowed to recover for 2 hours, then quickly 
perfused.  Synaptosomes were prepared as described in Appendix 3 from ipsilateral and 
contralateral sides of the hippocampus.  The purified suspensions were subject to either 
of two conditions.  In the first, synaptosomes were simply diluted in standard Aβ ELISA 
buffer, without guanidine, as described in Chapter 5 and loaded onto ELISA plates for 
measurement of Aβx-40 and Aβ1-42.  Secondly, we hypothesized that if indeed Aβ were 
retained within a membrane-bound presynaptic terminal such as a synaptosome, the lysis 
of such a structure might liberate total intra-synaptic content.  To do this, we treated 
synaptosomes for 10 minutes in the same carbonate buffer at pH 11 that was used in the 
serial extractions as described in Chapter 5.  We chose a volume that was approximately 
half that of the total volume required for triplicate measurement on the ELISA.  After the 
short incubation, we completed the volume with standard Aβ ELISA buffer and loaded 
the samples onto coated plates for measurement of Aβx-40 and Aβ1-42.  Finally, we 
measured the protein content of each sample prior to loading on the ELISA plates so all 
values could be normalized to protein content.   
 The results of those measurements are reported below for synaptosomes diluted in 
ELISA buffer only (Fig. 49) and in carbonate buffer pH 11 first, then ELISA buffer (Fig. 
50).  Firstly, there were no significant differences for either condition between the levels 
of Aβx-40 and Aβ1-42 in synaptosomes prepared from sham and injured animals, either in 
the ipsilateral or the contralateral sides of the hippocampus.  However, the carbonate 
buffer-treated synaptosomes yielded Aβ
 
levels that were approximately tenfold increased 
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as compared to the ELISA buffer-only preparation, suggesting that indeed most of the Aβ 
is inside these structures and requires the lysis of membranes for detection of Aβ from the 
presynaptic terminal. 
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Figure 49. Aβ content, normalized to total protein levels, in synaptosomes 
resuspended in ELISA buffer only.   Aβx-40 and Aβ1-42 measured separately for each 
animal, for ipsilateral and contralateral sides of the hippocampus (top two panels) and 
added for an estimate of total Aβ (bottom panel).  No significant differences between 
sham and TBI animals in either isoform, nor when added together. 
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Figure 50. Aβ content, normalized to total protein levels, in synaptosomes incubated 
in ½ volume of carbonate buffer pH 11 before completing with ½ volume of ELISA 
buffer.   Aβx-40 and Aβ1-42 measured separately for each animal, for ipsilateral and 
contralateral sides of the hippocampus (top two panels) and added for an estimate of total 
Aβ (bottom panel).  No significant differences between sham and TBI animals in either 
isoform, nor when added together. 
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Finally, we repeated this experiment in a separate group of mice and pooled the results of 
the first and second experiments.  Shown in Figure 51 are the results for Aβ40 in 
carbonate-treated synaptosomes from ipsilateral and contralateral sides of the 
hippocampus.  Again, no significant differences were seen, although there might be a 
trend towards increased Aβ40 in synaptosomes prepared from the injured hippocampus. 
 
Figure 51.  Aβ content, normalized to total protein levels, in synaptosomes incubated 
in ½ volume of carbonate buffer pH 11 before completing with ½ volume of ELISA 
buffer.  Aβx-40 measured in ipsilateral and contralateral sides of the hippocampus of each 
animal.  Results of two experiments have been pooled here, one performed in April and 
one in June 2009.  No significant differences between sham and TBI groups, although a 
possible trend towards increased Aβx-40 in the injured ipsilateral hippocampus. 
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We also attempted to measure APP in the fractions by ELISA, guided by the hypothesis 
that if Aβ were increased in this compartment, it might be due to a proportional increase 
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in APP.  An ELISA kit from R & D Systems allowed quantification of APP.  We began 
by comparing the S1 supernatant with combined fractions 3-4 (Fig. 52): 
Figure 52.  APP content in synaptosomes incubated in RIPA-extracted 
synaptosomes and diluted in standard Aβ ELISA buffer.  APP measured in S1 
supernatant and synaptosomal F3-F4 fractions from naïve hippocampi.  A trend towards 
enrichment for APP in F3-F4 as compared to S1, but levels are not significantly different.    
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In conclusion, while our efforts to prepare synaptosomes from single hippocampi 
were successful, the results of this experiment suggest that there are no significant 
differences in synaptosomal Aβ levels at the 2h timepoint between sham and TBI groups.  
The conclusions that can be drawn from this result are less clear.  Because the 
synaptosome is an artificial, prepared structure, it may not be representative of synaptic 
terminals in vivo.  Membranous compartments abound in fractions 3 and 4, and it is 
possible that soluble Aβ
 
may have been artificially trapped or redistributed during the 
homogenization procedure.  To further test the hypothesis that Aβ might be retained at 
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the synaptic terminal, an immunogold technique might be considered as demonstrated in 
previous studies of aged Tg2576 mice (Takahashi, et al., 2008). 
If a 2.0 mm injury was sufficient to reduce Aβ levels by ~50% and average RMS 
amplitude ~30% in the 24 hours following TBI, what might a less severe injury do?  
Others have demonstrated that 2.5 and 2.0 mm injuries produce deficits in the Morris 
water maze visible and hidden tasks in a B6SJL (wild-type) mouse, but 1.5 mm injury 
does not.  We wanted to know if there was an effect on ISF Aβ dynamics and local 
electrical activity in less-severe injuries, and if so, was there a correlation between these 
two variables across different injury severities?  The following chapter will address the 
elaboration of the original findings using a graded response approach. 
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Chapter 7. 
 
Effect of injury severity on ISF Aβ, tissue levels, and activity 
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 One way to determine how injury affects both ISF Aβ levels and neuronal activity 
is to compare the effects of different severities of injury (graded response).  Previous 
studies of CCI-injured mice have used a graded-response approach for histological and 
behavioral measures (Brody, et al., 2007, Saatman, et al., 2006).  We applied this method 
for the microdialysis measurement of ISF Aβ and quantification of local neuronal 
activity.  First, we chose two lesser injury severities (1.5 and 1.0 mm) and measured ISF 
Aβ dynamics for each, beginning approximately 12 hours after initial implantation, and 
measuring the baseline period for 12 hours before injury through 24 hours following 
injury (Fig. 53).   
The 1.0 mm impact did not produce a replicable injury in this model.  Grossly, the 
dura was broken in some cases, but sometimes remained intact.  This variable tissue 
response likely resulted in variable ISF Aβ levels.  Because of the inhomogeneity of the 
1.0 mm injury, it was excluded from further analysis of ISF Aβ dynamics.   
Post-TBI dynamics of sham, 1.5 mm and 2.0 mm groups were significantly 
different (p = 0.0142, repeated measures ANOVA, group × time interaction).  The means 
for post-TBI timepoints of injuries vs sham were significantly different (p < 0.05 for both 
sham vs. 1.5 mm and sham vs. 2.0 mm; Kruskal-Wallis test followed by Dunn’s multiple 
comparisons test).  Howevere, the dynamics of the 1.5 mm injury were not significantly 
different from the 2.0 mm injury (p = 0.893, repeated measures ANOVA) (Fig. 53).   
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Figure 53.  Effect of different injury severities on ISF Aβ dynamics after TBI.  
Microdialysis measurements of ISF Aβ beginning approximately 12 hours after 
implantation, from 12 hours prior to injury through 24 hours post-TBI.  Data shown for 4 
groups: sham (n=6), 1.0 mm (n=5), 1.5 mm (n=6), and 2.0 mm (n=6).  
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We also measured local EEG and quantified the average RMS amplitudes for each 90-
minute period corresponding to a single microdialysis sample.  Below are the group-
averaged results for sham, 1.0, 1.5 and 2.0 mm injury severities (Fig. 54).  Post-TBI 
dynamics of all four injury severities were significantly different (p = 0.0272, repeated 
measures ANOVA, group × time interaction). 
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Figure 54.  Effect of different injury severities on neuronal activity after TBI.  Local 
EEG activity as quantified by RMS amplitude, beginning approximately 12 hours after 
implantation, from 12 hours prior to injury through 24 hours post-TBI.  Data shown for 4 
groups: sham (n=5), 1.0 mm (n=5), 1.5 mm (n=5), and 2.0 mm (n=5).  
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Among mice in the 1.0 mm group, the local EEG signals were highly variable.  
Similar to the dynamics of ISF Aβ after TBI, this variability was likely due to the 
variable effect of the 1.0 mm impact on the dura.  Some mice demonstrated epileptiform 
activity in the first 6-12 hours after injury, contributing to the apparent increase in 
amplitude.  However, after 12 hours post-TBI the EEG amplitude in this group was no 
different than baseline.  By contrast, the 1.5 and 2.0 mm-injured groups showed 
significant decreases in neuronal activity by repeated measures-ANOVA that were not 
significantly different from one another (p = 0.826, group × time interaction).   
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To determine the relationship between these decreases in neuronal activity with 
ISF Aβ dynamics in the 1.5 and 2.0 mm injury groups, we plotted paired coordinates of 
the group means for each 90-minute sampling period.  If it is generally true that reduced 
Aβ is associated with reduced RMS amplitude following a 1.5 or 2.0 mm impact, then we 
can test the strength of the hypothesized relationship by a non-parametric test, the 
Spearman’s rank order correlation (Fig. 55).  Because previous work has shown that 
epileptiform activity induced by high-frequency stimulation can increase ISF Aβ in the 
hippocampus (Cirrito, et al., 2005), it was also possible that increased activity in the 1.0 
mm group in the first 12 hours post-TBI could be associated with the increased ISF Aβ 
levels observed in the 12-24 hour period.  Based on this hypothesis, a Spearman 
correlation was also tested for data pooled from all four severities: sham, 1.0, 1.5, and 2.0 
mm (Fig. 55A) and for non-sham injured groups only (Fig. 55B).  However, due to the 
variable tissue response to the 1.0 mm impact, a separate analysis was performed on data 
from just the 1.5 and 2.0 mm injuries (Fig. 55C).  Finally, because we used the 2.0 mm 
injury as the standard TBI in our manuscript, we computed a Spearman correlation for 
data from only this group as well (Fig. 55D).  The timepoints began at 6 hours prior to 
TBI (baseline) through 24 hours post-injury, for a total of 20 coordinate pairs per injury 
severity. 
There were significant correlations using all injury severities including sham (Fig. 
55A, Spearman r = 0.3190, 95% C.I., 0.1061-0.5073; p=0.0037) and the three non-sham 
injuries (Fig. 55B, Spearman r = 0.4117, 95% C.I., 0.1731-0.6046; p=0.009).  However, 
the strength of the correlation further increased when we included data from just the 1.5 
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and 2.0 mm injuries (Fig. 55C, Spearman r = 0.4388, 95% C.I., 0.1465-0.6606; p = 
0.0037) and was the strongest for the most severe injury alone: 2.0 mm (Fig. 55D, 
Spearman r = 0.6506, 95% C.I., 0.2919-0.8489; p = 0.0037).  Because the pooling of 
multiple, lesser severities yielded weaker correlations, it might be hypothesized that 
milder injuries including sham tend to produce more variable results, and that ISF Aβ is 
not well-correlated with neuronal activity in milder injury and sham.  However, the 
correlation within just the 2.0 mm group yielded a Spearman r = 0.6506.  Although this is 
not significantly stronger than correlations computed for pooled data due to overlap of 
the 95% confidence intervals, this anaylsis suggests that there may not be a linear 
response across injuries in terms of the relationship between ISF Aβ and local EEG 
activity.  Specifically, more severe injuries (1.5 and 2.0 mm impacts) tended to show a 
better correlation of these two measures, while less severe injuries (1.0 mm and sham) 
did not show significant correlations between these measures.  Perhaps this is because the 
more severe injuries have a larger range of coordinates, from baseline (100% on average) 
to post-TBI, which could be as low as ~40% for ISF Aβ and 60% for RMS amplitude.  
Figure 56 compares correlation strengths between different pools of data analyzed. 
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Figure 55.  Correlation between change in ISF Aβ with change in RMS amplitude 
after TBI for different injury severities.  Each point represents paired measurements of 
mean % baseline Aβ and mean % baseline RMS amplitude.  The baseline coordinates are 
included, beginning 6 hours prior to injury.  Data are plotted for all 90-minute periods, 
from -6 h to 24 h after injury for a total of 20 pairs per group.  A, Spearman correlation  
for sham, 1.0, 1.5, and 2.0 mm.  (r = 0.3190; two-tailed p = 0.0037).    B, Spearman 
correlation for 1.0, 1.5, and 2.0 mm.  (r = 0.4117; two-tailed p = 0.0009).  C, Spearman 
correlation for 1.5 and 2.0 mm.  (r = 0.4388; two-tailed p = 0.0037). D, Spearman 
correlation for 2.0 mm (r = 0.6506, two-tailed p = 0.0014). 
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Figure 56.  Correlation between change in ISF Aβ and change in RMS amplitude 
after TBI for different injury severities.  Plot of Spearman r (correlation strength) for 
each pool of data analyzed in Figure 55; 95% confidence intervals are shown. 
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Finally, given that the 1.5 and 2.0 mm injuries yielded similar results in terms of post-
TBI decreases in ISF Aβ and local EEG activity, we asked whether there were any tissue 
changes in the 1.5 mm group, and again whether 1.5 and 2.0 mm groups were similar.  
Below is a scatterplot of Aβ1-x levels for sham, 1.5, and 2.0 mm groups at 2h after injury 
in serial tissue extracts (PBS, carbonate, and guanidine) from ipsilateral hippocampus and 
cortex (Fig. 57).  Again, data from the 1.5 mm-injured group looked much like the 2.0 
mm-injured group in that there was a significant decrease in PBS-soluble hippocampus 
(Fig. 57A).  There were no significant changes in carbonate and guanidine-soluble 
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hippocampal extracts, and no changes in any extracts from cortical tissues (Fig. 57B-F).  
In addition, Aβx-40 and Aβ1-42 were also measured in all extracts (data not shown).  Except 
for a significant decrease in Aβx-40 in the PBS-soluble hippocampal extract for both 1.5 
mm and 2.0 mm groups, no changes were seen in individual 40 and 42 isoforms. 
 In summary, the 1.5 mm injury produced similar results to a 2.0 mm severity in 
terms of decreased ISF Aβ levels, decreased PBS-soluble hippocampal levels, and 
decreased neuronal activity.  By contrast, the 1.0 mm injury yielded highly variable and 
unpredictable dynamics based on the variable tissue response to impact.  There was not a 
clear “graded response,” then, among these three severities.  Future studies might use a 
different range, for example, a 1.25 mm and 2.5 or 2.75 mm injury, to determine whether 
a relationship exists between response to injury as measured by ISF Aβ dynamics, acute 
tissue levels, and neuronal activity. 
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Figure 57.  Effects of 1.5 and 2.0 mm injury severities on Aβ levels in ipsilateral 
hippocampal and cortical homogenates.  PDAPP+/- mice underwent sham, 1.5 mm, or 
2.0 mm injury and were sacrificed after 2 hours (n=5 per group).  Aβ1-x was measured in 
serial extracts, and values were normalized to total protein in each homogenate.  Data 
plotted for individual mice in PBS (A, D), carbonate (B, E), and guanidine-soluble 
extracts (C, F).  Significant differences were observed in the PBS-soluble hippocampal 
extract between sham and both TBI groups (p=0.0493, Kruskal-Wallis test).  
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Chapter 8. 
 
Proposed studies of mechanism: production vs. clearance 
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The question of mechanism is raised by our main finding, that hippocampal Aβ 
was immediately reduced by approximately 50% of baseline levels in the ISF as 
measured by microdialysis and in PBS-soluble tissue extracts at 2h post-injury.  What 
underlies the observed decreases?  Based on the concept that ISF Aβ levels result from 
the balance between production and clearance rates, we can divide subsequent tests of 
mechanism into production and clearance.  Two mechanisms resulting in changes of 
production of Aβ: changes in full-length APP protein levels and changes in local 
neuronal activity, as well as a clearance mechanism, acute Aβ deposition, have already 
been tested (Ch. 5). 
Firstly, on the production side, if amyloid precursor protein (APP) were 
downregulated, there would be less available substrate for the Aβ-cleaving enzymes, β- 
and γ-secretases, leading to reduced Aβ levels.  Our RIPA-extracted homogenates did not 
reveal any differences in APP content between sham and injured hippocampi at the 2 h 
timepoint.  This result is consistent with our finding that carbonate and guanidine-
extracted tissues contained equal amounts of Aβ in injured and sham tissues. 
Also on the production side, we drew an analogy between ours and previous 
experiments reported by Cirrito et al. in his 2005 paper that established a role for 
neuronal activity in the regulation of ISF Aβ (Cirrito, et al., 2005).  Briefly, if neuronal 
activity was increased, ISF Aβ was increased, and if neuronal activity was decreased, so 
was ISF Aβ.  Our local measurements of electrical activity in the vicinity of the 
microdialysis probe demonstrated an acute decrease in neuronal activity that lasted over 
24 hours following injury.  This result strongly suggests that decreased neuronal activity 
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may play a role in the decreased levels of ISF Aβ.  However, it remains unknown 
whether neuronal activity is causal, coincident, or parametrically related to ISF Aβ 
following injury. 
On the clearance side, we examined the possibility that Aβ was acutely deposited 
into extracellular plaques or intra-axonal aggregations, thereby leading to reduced ISF 
levels and a lesser amount in the PBS-soluble tissues.  When brains were examined at the 
24 h timepoint, no deposition or aggregation was seen using a middle-domain antibody 
that detects Aβ deposition in PDAPP mice at 10 and 20 months of age (Ch. 5, Fig. 37).  
In summary, APP levels were unchanged at the 2h timepoint and no Aβ 
deposition or aggregation was observed at the 24 h timepoint.  Therefore, these 
mechanisms likely play no direct role in ISF Aβ dynamics.  By contrast, neuronal activity 
was acutely decreased after injury.  As compared to baseline, changes in neuronal activity 
correlated with changes in ISF Aβ levels.  However, the correlation was not strong 
enough to suggest that neuronal activity is solely responsible for observed changes 
(Spearman r = 0.6506, 95% C.I. 0.2919-0.8489 for n=5, 2.0 mm-injured PDAPP mice; 
Ch. 6, Fig. 55D).  A general approach to mechanisms of production vs. clearance is 
addressed in this chapter.  Two experiments are proposed to test the hypotheses that 
either one of these could lead to the observed post-injury ISF Aβ dynamics.  
   
Tests of clearance 
Generally, differences in clearance can be quantified using a very simple method 
in which production of Aβ is shut off using a γ-secretase inhibitor, and Aβ is measured as 
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it clears from the ISF.  The kinetics of clearance can be modeled using an exponential 
decay function.  We chose the highly potent γ-secretase inhibitor LY411,575, whose 
effects on Aβ production in Tg2576 mice have been described (Lanz, et al., 2004).  This 
compound was also previously used to determine ISF Aβ half-life in PDAPP mice using 
in vivo microdialysis (Cirrito, et al., 2003). 
In some preliminary experiments using young Tg2576 / hApoE3 mice, we 
measured clearance rates in terms of half life in uninjured animals.  Briefly, mice were 
implanted with microdialysis probes in the standard location and allowed to equilibrate 
for at least 4-5 hours.  Baseline samples were collected for at least 4 hours prior to 
administration of LY411,575.  We increased the sampling rate from every 90 to every 20 
minutes, 80 minutes prior to drug administration.  Mice were then subcutaneously 
injected with 3 mg/kg of LY411,575 suspended in corn oil.  In these mice, the half-life of 
ISF Aβ was approximately 55 minutes.  The results of those experiments are shown in 
Figure 58 (plot of mean % baseline Aβ) and Figure 59 (semi-log plot of data in Fig. 58). 
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Figure 58.  Effect of γ-secretase inhibitor on ISF Aβ.  Mean % baseline Aβ as 
measured by microdialysis every 20-min in uninjured Tg2576 / hApoE3 (n=4) at baseline 
and after injection of 3 mg/kg LY411,575 at t=0.  Error bars, standard error of the mean.   
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Figure 59.  Determination of half-life of ISF Aβ using exponential decay model.  
Natural log of mean % baseline Aβ plotted against time.  Slope value gives decay 
constant then used to calculate half-life (~55 min). 
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As shown in our preliminary experiments and other published results (Cirrito, et 
al., 2003), clearance of ISF Aβ occurs according to first-order kinetics.  Figure 60 depicts 
idealized data for two outcomes of a clearance experiment in sham and TBI groups (Fig. 
60A, B).  In Figure 60A, SHAM and TBI curves display predicted dynamics of mean % 
baseline Aβ if clearance is unchanged within the first ~2-8 h after injury.  After 
administration of LY411,575 and inhibition of γ-secretase, the kinetics of Aβ clearance 
would be identical in the sham and injured groups.  Alternatively, Figure 60B displays 
predicted dynamics of SHAM and TBI groups if clearance is increased in the TBI group 
after injury. 
To compare the clearance rates of two groups, sham and TBI, the natural log 
values of the mean % baseline Aβ values would be plotted against time.  Figure 60C-F 
displays semi-log plots of the hypothetical data in Figure 60A and B.  If clearance is 
unchanged, then post-LY slopes should not be significantly different (Fig. 60C).  If 
clearance is increased after TBI, then the slope of the TBI group should be significantly 
more negative (Fig. 60D). 
Using a program such as GraphPad or Statistica, a linear regression analysis 
would be performed on this data to compare slope values and the 95% confidence 
intervals around each slope (Fig. 60E-F).  If the 95% confidence intervals of the TBI and 
SHAM slopes overlap, then the clearance rates would be considered not significantly 
different (Fig. 60E).  If they do not overlap, then TBI would have a significantly 
increased clearance rate (Fig. 60F). 
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Figure 60.  Alternative results of a hypothetical experiment to test for differences in 
clearance rate of ISF Aβ.  Two groups of mice would receive either a 2.0 mm or sham 
injury.  After 2h, when levels have reached a new equilibrium (100% for sham, or 
reduced to 50% for TBI), LY411,575 would be injected at 3 mg/kg.  A, expected results 
if clearance is unchanged after injury.  B, expected results if clearance is increased after 
injury.  To compare clearance rates, natural log values for mean % baseline Aβ would be 
calculated and plotted vs. time (C-F).  C, expected results for unchanged clearance after 
injury.  Model shown for baseline, post-TBI, and post-LY periods.  D, expected results 
for increased clearance after injury.  Model shown for baseline, post-TBI, and post-LY 
periods.  E, expected results for unchanged clearance after injury.  Model shown for post-
LY period only, 95% C.I. of regression line.  F, expected results for increased clearance 
after injury.  Model shown for post-LY period only, 95% C.I. of regression line.   
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If experimental data indicate an increase in clearance rate following TBI, further 
experiments would be needed to evaluate specific clearance mechanisms, such as the 
degradation of Aβ by insulin-degrading enzyme (IDE) and neprilysin.  Inhibition of these 
enzymes or use of an IDE or neprilysin knockout mouse would resolve their potential 
roles in post-TBI ISF Aβ dynamics.     
 
Statistical power calculations for tests of clearance 
How do we determine the number of mice needed in each group to reliably detect 
a difference in clearance rates?  The G*Power 3.1.0 program (written by Franz Faul, 
Universitat Kiel, Germany; available for free download) was used to estimate sample 
sizes for different levels of power.  The linear bivariate regression test was chosen.  
Assuming equal numbers of animals in each group, and statistical measures based on the 
preliminary experiment: standard deviation of the residuals = 0.18 (see Fig. 59), and a 
standard deviation of 1 for log-transformed y values, a plot of sample size as a function 
of power was generated (Fig. 61).  For power = 0.80, 4 mice per group are required to see 
an effect of 50% difference between slopes of the semi-log plot.  
 
  
173
Figure 61. Plot of power vs. sample size for an effect of 0.5 (50% difference in rates).  
Generated by the G*Power 3.1.0 program.   
 
 
 
If clearance were only one of several contributing factors to the observed decreases in Aβ 
levels such that clearance was increased less than 50%, then we would need larger 
sample sizes.  Table 1 gives the sample sizes necessary to detect different clearance rates 
at different levels of power. 
Power (1-β err prob)
t tests - Linear bivariate regression: Two groups, difference between slopes
Tail(s) = Two, Allocation ratio N2/N1 = 1, Std dev residual σ = 0.18,
Std dev σ_x1 = 1, Std dev σ_x2 = 1, α err prob = 0.05, |∆ slope| = 0.5
7
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Table 1: sample sizes to detect differences in clearance at different levels of power*  
Power level ∆ slope Sample size (per group) 
0.80 50% 4 
40% 5 
30% 7 
20% 13 
15% 24 
0.90 50% 5 
40% 6 
30% 9 
20% 18 
15% 32 
0.95 50% 5 
40% 7 
30% 11 
20% 22 
15% 36 
*model assumptions: standard deviation of the residuals = 0.18; 
  standard deviation = 1 for transformed y-values in each group 
 
In addition, controls are necessary for the injection of LY411,575.  A vehicle-injected 
group would be included.  To determine differences in clearance for the 2.0 mm-injured 
group, a total of four groups would be required.  Assuming a statistical power level of 
0.80 to detect either a 50%, 30%, or 20% difference in clearance rates (Table 1), the 
following numbers of mice would be needed (Table 2): 
 
Table 2: Number of mice needed for clearance experiment  
Group Purpose n (∆ = 50%) N (∆ = 30%) n (∆ = 20%) 
TBI + LY Experimental 4 7 13 
TBI + vehicle Control: injection 4 7 13 
SHAM + LY Control: injury 4 7 13 
SHAM + vehicle Control: both 4 7 13 
TOTAL  16 28 52 
Pilot experiments should be done with n = 4 mice per group to approximate the size of 
the effect and to determine whether the residuals are of the expected magnitude based on 
data collected in naïve animals.  
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Tests of production 
 Since EEG recordings suggest a positive correlation between decreases in 
neuronal activity and ISF Aβ following TBI, further experiments could be performed to 
determine whether this relationship is causal.  The contribution of neuronal activity to 
post-TBI levels of ISF Aβ will be assessed using textrodotoxin (TTX), a voltage-gated 
sodium channel blocker which strongly inhibits neuronal activity.  A continuous infusion 
of 5 uM TTX can be administered by reverse microdialysis beginning 6 h prior to TBI 
and ISF Aβ can be measured for further changes. This dose has been used in previous 
experiments not involving TBI (Fig. 62).  A dose-response approach could be used to 
achieve at least a 30% decrease in EEG activity, based on the observed (average) 
decreases during the post-TBI period in 2.0 mm-injured mice.   
 
Figure 62.  Inhibition of neuronal activity with TTX occludes the effect of restraint 
stress on ISF Aβ.  Reverse microdialysis delivery of 5 µM TTX immediately decreased 
Aβ levels; three hours of restraint stress at 8 h after TTX treatment did not result in 
significant change in Aβ levels compared with controls treated with TTX alone controls 
(n = 5). Modified from Kang et al., PNAS 2007. 
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To test the hypothesis that the changes in post-TBI ISF Aβ levels depend on 
neuronal activity, 5 µM TTX can be infused by reverse microdialysis during the baseline 
period, approximately 6 hours before TBI.  Two possible results of the alternative 
hypotheses are shown in Figure 64.  If the effects of TBI on ISF Aβ depend on TTX-
insensitive mechanisms, an additive effect of TTX would be expected; TBI would further 
decrease ISF Aβ in the presence of TTX (Fig. 63A).  However, if the effect of TBI on 
ISF Aβ is mediated by TTX-sensitive mechanisms, the rate of decease after TBI should 
be identical in injured mice pretreated with TTX compared to uninjured sham controls.  
In other words, TTX would occlude the effects of TBI if the effects of TBI are 
exclusively mediated decreased TTX-sensitive neuronal activity (Fig. 63B).  
  
Figure 63.  Hypothetical results for effect of TTX on ISF Aβ after TBI.  A, most of 
the pool of ISF Aβ is regulated in the post-TBI period by TTX-insensitive mechanisms, 
so TTX will not occlude decreases in ISF Aβ due to TBI. B, ISF Aβ is regulated in the 
post-TBI period by TTX-sensitive mechanisms, since TTX will occlude decreases in ISF 
Aβ due to TBI.   
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It has been suggested that even a reverse-microdialysis delivery approach might 
be lethal in CCI-injured animals.  Due to the breach of the blood-brain barrier, TTX 
could enter the bloodstream and reach the lungs and heart, where it could inhibit 
respiration and cardiac muscle signaling (J. Cirrito, unpublished observations).  If TTX is 
in fact lethal at the dosages required to achieve a significant decrease in the remaining 
neuronal activity following TBI, then another, non-lethal way to inhibit neuronal activity 
would be required.  Two strategies would be to increase inhibitory firing using a 
GABAergic agonist and to inhibit excitatory firing using either an antagonist of the 
metabotropic glutamate receptors 2/3 (mGluR2/3), or inhibitors of ionotropic glutamate 
channels, such as MK-801 for NMDA receptors.  Like TTX, the optimal dosing would be 
empirically determined based on the decrease in EEG RMS amplitude. 
 In summary, the proposed clearance and production experiments could be used to 
test hypothesized factors that contribute to the balance of ISF Aβ levels.  It is possible 
that mechanisms other than those specified here are involved.  On the production side, 
recent data suggest a role for endocytic-independent mechanisms in the regulation of 
~30% of total ISF Aβ levels (Cirrito, et al., 2008).  Tests involving the molecular 
mechanisms involved in this system would help elucidate the sources of hypothesized 
decreases in neuronal activity-dependent production following injury. 
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Chapter 9. 
 
Conclusions and future directions 
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Summary of main findings 
In conclusion, we present here the development of a mouse model of combined 
microdialysis-experimental traumatic brain injury.  Using this model, we measured the 
dynamics of ISF Aβ levels in PDAPP and wildtype mice, both before and after a 2.0 mm 
electromagnetic-controlled cortical impact injury (EM-CCI).  In PDAPP mice, we were 
able to achieve a time resolution of 90-minute samples for a baseline period of 
approximately 12 hours and a post-injury period of 24 hours in n=6 mice per group.  It 
was found that post-injury ISF levels were immediately decreased to approximately 50% 
of baseline levels, and remained low over the post-injury sampling period.  Probe 
function was controlled for in 3 different experiments: zero-flow extrapolation, 
measurement of endogenous urea, and retrodialysis of infused Aβ.  Probe function was 
unchanged before and after TBI as indicated by zero-flow and retrodialysis experiments.  
Based on the low frequency of abnormal probe function as indicated in routine urea 
measurements, we concluded that decreases in ISF Aβ reflected physiological 
phenomena rather than technical difficulty. 
One potential mechanism for the observed dynamics, the role of neuronal activity 
in the regulation of ISF Aβ, was suggested by the work of Cirrito, Kang and others.  We 
used intraparenchymal EEG recordings to measure local neuronal activity in the vicinity 
of the microdialysis probe.  We found the strongest positive correlation for group-
averaged coordinates from 2.0 mm-injured mice, from 6 hours before injury through 24 
hours post-injury (Spearman r = 0.6506, 95% C.I. 0.2919-0.8489; p = 0.0014).  This 
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correlation is consistent with a role for neuronal activity in the observed decreases in 
post-TBI ISF Aβ levels. 
To determine the relationship of Aβ levels in interstitial fluid to tissue levels, we 
also measured total Aβ1-x, Aβx-40, and Aβ1-42 in serial extracts of PBS, carbonate, and 
guanidine-soluble homogenates from ipsilateral hippocampal and cortical tissues in mice 
sacrificed 2h after sham or 2.0 mm injury.  PBS-soluble levels of Aβ1-x and Aβx-40 were 
significantly decreased to approximately 50% of sham levels in the hippocampus, 
consistent with the magnitude of decrease in ISF levels.  PBS and guanidine-soluble 
cortical extracts were also reduced in Aβ1-x, as were guanidine-soluble cortical extracts 
for Aβ1-42. 
We tested the hypothesis that Aβ might be retained within a pre-synaptic 
compartment, consistent with our measurements of reduced ISF and PBS-soluble tissue 
levels as well as reduced neuronal activity.  To do this, we prepared synaptosomes at the 
2h timepoint in sham and 2.0 mm injured mice and measured Aβx-40 and Aβ1-42 in 
individual hippocampi from ipsilateral and contralateral sides.  There were no significant 
differences between sham and TBI groups in either isoform, suggesting that retention 
within this compartment is not likely a mechanism of reduced ISF and extracellular Aβ 
levels.  
We used a range of severities to determine whether there was a graded response to 
injury in terms of ISF Aβ, neuronal activity, and tissue levels.  We compared sham, 1.0 
mm, 1.5 mm, and 2.0 mm groups.  The 1.0 mm group demonstrated variable responses to 
the impact, possibly contributing to the variable ISF Aβ dynamics and EEG patterns.  
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The 1.5 mm group showed similar ISF Aβ dynamics to the 2.0 mm group.  These 
dynamics were not significantly different between 1.5 and 2.0 mm-injured groups by 
repeated measures ANOVA.  The 1.5 mm-injured group also showed reduced neuronal 
activity that was not significantly different than the 2.0 mm group, on average, for the 
post-injury period.  Likewise, tissue levels of Aβ1-x in the 1.5 mm group were similar to 
the 2.0 mm group in all serial extracts of hippocampal and cortical homogenates. 
We proposed an approach to testing hypothesized mechanisms based on the 
concept of a balance between ISF Aβ production and clearance.  Two mechanisms of 
decreased Aβ production were tested: decreased full-length APP protein levels, and 
decreased neuronal activity.  One theoretical clearance mechanism, acute Aβ deposition, 
was also tested.  While there appeared to be no acute changes in APP levels and no 
observed Aβ deposition, neuronal activity was reduced.  We proposed two main 
experiments to further test clearance vs. production mechanisms.  First, we can measure 
the rate of clearance from the ISF by inhibition of the Aβ-cleaving enzyme, γ-secretase.  
An enhanced, or increased, clearance rate might contribute to the acute deceases seen in 
the ISF.  On the production side, we have already determined that neuronal activity is 
locally decreased after a 2.0 mm injury.  To test whether this decrease causes or actively 
contributes to the decreases in ISF Aβ, we can inhibit neuronal activity using TTX prior 
to injury.  Any further decreases in ISF Aβ as a result of TBI would be attributed to TTX-
insensitive mechanisms, suggesting a role for activity-independent production of Aβ. 
 Finally, we have used the results of these experiments to help interpret the post-
injury dynamics in human clinical microdialysis studies, in which baseline measurements 
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cannot be taken.  In turn, the clinical study demonstrated that changes in neurological 
status were correlated with ISF Aβ dynamics, suggesting that neuronal activity might be 
worth investigating as a mechanism in the animal model.  Thus, our studies exemplify the 
complementary relationship of clinical and animal microdialysis research.  Table 3 
compares study parameters between the human and mouse studies. 
Table 3. Comparison of clinical and research microdialysis studies of Aβ dynamics. 
 Human clinical study Mouse research study 
Injury variable consistent (CCI) 
Time of initial 
measurement 
12-24 h after injury 18-24 h before injury 
Duration of 
measurements 
72 h post-implantation 24 h pre, 24 h post-injury 
Catheter or probe 
location 
most in right, prefrontal 
subcortical white matter 
ipsilateral hippocampus 
Catheter or probe type CMA 71, 100 kD MWCO BAS BR-2, 38 kD MWCO 
Aβ assay m266/3D6 sandwich ELISA m266/3D6 sandwich ELISA 
Time resolution 2 h 90 min 
   
Future translational studies should be designed to measure pre and post-TBI 
dynamics of different small molecules and peptides, and to explore the potential 
mechanisms underlying these dynamics.  Others in the lab have applied and adapted this 
combined microdialysis-TBI mouse model to measure the neuropeptide orexin in the 
hypothalamus and other brain regions (J. Willie, unpublished results).  Plans are 
underway to measure this peptide in human CSF and microdialysates, and to test a 
hypothesized correlation with measures of activity and arousal in human clinical studies. 
 Given these findings, what can be said about the relationship of this project to 
outstanding questions in the fields of clinical microdialysis, Aβ deposition, TBI-related 
dementia, and future directions?       
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What does this project contribute to our understanding of clinical studies in human 
patients? 
A main goal of this project was to measure pre and post-injury ISF Aβ dynamics 
in the same animal, avoiding the potential errors of cross-sectional, timepoint studies of 
post-TBI tissue levels of Aβ.  We hypothesized these results would contextualize the 
findings of the clinical study, in which only post-injury levels and dynamics could be 
measured.  In human patients, it was unknown whether the levels at some time after 
injury were low, equal, or higher than before injury.  Furthermore, it was not clear 
whether levels remained below baseline, normalized within the typical 3-6 day 
measurement period, or were rising beyond baseline.  Using a 2.0 mm CCI injury, the 
mouse experiments suggested that ISF Aβ levels dropped below baseline within the first 
90-minute sample, decreased to ~50% and remained low throughout the 24 hour period 
of measurement.  Using a 1.5 mm injury, the ISF Aβ levels dropped to nearly the same 
levels as with a 2.0 mm injury (mean ± standard deviation: 51 ± 35% for 1.5 mm, 51± 
37% for 2.0 mm).  Local, intrahippocampal EEG activity as quantified by RMS 
amplitude was also decreased after an injury.  Although neuronal activity was not as 
depressed in the 1.5 mm group (87 ± 24%) as the 2.0 mm group (69 ± 26%), this 
difference was not statistically significant.  Using a mild injury at an impact depth of 1.0 
mm, the variable tissue responses precluded inclusion of these data in subsequent 
analyses. 
 The relatively stable dynamics of both post-TBI ISF Aβ and neuronal activity 
over 24 h in this experimental model were non-identical to most of the human patient 
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data, for which levels tended to fluctuate over at least 72 hours.  One important difference 
between the model and the clinical study was the homogeneity of subjects, especially 
with respect to injury type and severity.  All mice were similarly injured and were of 
similar age.  By contrast, the clinical data were collected from a variety of acute brain 
injuries, including both TBI and aneurysmal subarachnoid hemorrhage.  Additionally, 
patient ages ranged from early 20s to late 60s.  Finally, microdialysis catheter placement 
within the brain was not always standardized.  One way to better match the animal model 
to the clinical data would be to have a variety of injuries besides CCI, including a model 
of subarachnoid hemorrhage, performed across different ages.   
However, despite the potential discrepancies, the results of the experimental 
studies are fundamentally concordant with the findings of the clinical study, in which 
changes in the Glasgow Coma Score (GCS) correlated with changed in ISF Aβ levels.  
What does it mean that correlations were found in both the experimental and clinical 
studies?  One criticism is that comparing GCS with local EEG activity is an invalid 
analogy.  The GCS is an ordinal assessment of voluntary and involuntary behavioral 
responses to stimuli, in contrast to the relatively continuous EEG data representing 
intrinsic field-potentials.  Even if there is a direct relationship between neuronal activity 
and behavioral output, intrahippocampal EEG measurement is localized, whereas the 
GCS depends largely on the integration of central and peripheral nervous system 
functions.  Nonetheless, the correlation between ISF Aβ dynamics and changes in either 
local EEG activity in the mouse experiments, or GCS in the clinical patients, suggest that 
future experiments be done in both mouse and human patients to determine the 
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relationship between local neuronal activity and global measures such as the GCS.  To 
address this criticism, the mouse study could be better matched to the original clinical 
study by using a mouse behavioral scale, such as the NeuroScore.  Alternatively, future 
clinical studies might plan to measure electrical signals as captured by 5-lead EEG or the 
BIS monitoring system to see if the correlation holds for intrinsic neuronal activity. 
  
What does this project contribute to our understanding of acute deposition after 
TBI in mice and in human patients? 
 This study offers no additional insight into mechanisms responsible for the acute 
deposition of Aβ observed in 30% of severely injured or deceased human patients.  Our 
findings are consistent with the experimental literature, in which there are no reports of 
positive findings of acute deposition after CCI injury in PDAPP mice.  By contrast, there 
are reports of a reduced total burden of Aβ plaque 5-8 months after TBI (Nakagawa, et 
al., 1999) and a regression of established plaques in aged mice 16 weeks after injury 
(Nakagawa, et al., 2000).  In summary, the lack of positive findings in the literature is 
consistent with our observations, that there is no acute Aβ deposition in either PDAPP or 
Tg2576 mice acutely after CCI injury. 
 By contrast, some models of experimental TBI in swine recapitulate key elements 
of human neuropathology: accumulations of APP, neurofilament, and Aβ in axonal bulbs; 
axonal bulbs near regions of foamy macrophage infiltration; and plaque-like extracellular 
Aβ deposits (Chen, et al., 2004, Smith, et al., 1999).  These features were seen both at 7 
days and 6 months post-injury.  Swine models might better model acute Aβ deposition 
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and accumulation in the setting of axonal injury.  However, certain transgenic mouse 
strains also show post-TBI deposition (see “Future work to expand repertoire of injury 
types and animal models”). 
 
What does this project contribute to our understanding of chronic deposition after 
TBI in mice and in human patients? 
 As with acute deposition, this study does not explicitly test the hypothesis that 
TBI might lead to increased deposition during the chronic phase.  We examined PDAPP 
mice from 24-120 hours after injury.  Other studies have looked 4-8 months later, and 
have found persistent behavioral deficits as well as histological evidence of damaged 
tissue, such as atrophy, reductions of Aβ plaque burden, and even regression of 
established plaques (Nakagawa, et al., 1999, Nakagawa, et al., 2000).  Based on these 
findings, future experiments should be designed to compare ISF Aβ levels at baseline 
with chronic stages.  Given the atrophy and cell loss, it would be worthwhile to determine 
if or how levels change over time.  A multiple regression model would be most 
appropriate for this type of analysis given the effect of age on ISF Aβ levels in PDAPP 
mice (Cirrito, et al., 2003). 
 One recent study examined autopsy samples from TBI patients who died in 
chronic stages of injury for evidence of Aβ deposition (Chen, et al., 2009).  Interestingly, 
within a few years of injury, it appears the majority of immunohistochemical staining is 
intra-axonal with a paucity of extracellular plaques.  This finding is not inconsistent with 
other reports of extracellular plaques and tangles in brains with known TBI residuals in 
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patients who died at least 7 years after their injuries (Jellinger, et al., 2001).  One 
hypothesis is that, given the increased incidence of abnormal intra-axonal accumulations, 
there might be increased neuronal dysfunction, leading to or coincident with an earlier 
occurrence of plaque deposition.  These elements of accelerated neuropathology are 
consistent with the notion that TBI might hasten the onset of dementia.  Again, future 
studies should be designed to examine a large cross section of autopsied brains from TBI 
patients who died over a broad range of time from injury to determine the natural history 
of Aβ accumulation and deposition associated with brain injury. 
 
What does this project contribute to our understanding of the link between remote 
TBI and the development of dementia later in life? 
 This project does not suggest any definite role for acute ISF Aβ dynamics in the 
later development of dementia.  The Alzheimer’s literature contains many studies that 
test hypotheses concerning the pathological link between Aβ and dementia, and whether 
plaque load corresponds directly to the degree of clinical impairment (Nelson, et al., 
2009).  Similarly, both animal studies and recent clinical data in which anti-Aβ antibodies 
were shown to clear plaques suggest that even when plaques are reduced or eliminated, 
cognitive deficits may persist.  Hence, Aβ plaque load is certainly not solely responsible 
for cognitive dysfunction and deficits.  There are several alternative possibilities: plaques 
contribute to neuronal dysfunction; plaques are a sign of neuronal dysfunction, but 
neither exacerbate nor ameliorate it; or, plaques are actually neuroprotective.  Further 
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work is required to determine this peptide’s relative contribution to acute and chronic 
deficits. 
 
Future work to characterize other proteins implicated in TBI-related 
neurodegeneration 
 Besides Aβ deposition, many other proteins and peptides have been linked to both 
genetic (familial) and sporadic neurodegenerative dementias.  Chief among these is tau, a 
microtubule-stabilizing protein that exists in abundance in neurons.  In its 
hyperphosphorylated, paired-helical-filament (PHF) form, tau is widely known as the 
other pathological hallmark of Alzheimer’s disease.  This protein is important in axonal 
transport, and disruption of its function has profound implications for neuronal viability.  
Tau is also increased in the CSF of both clinical patients and in rodent studies of TBI in 
the setting of acute injury, and is detectable by high molecular weight catheters in 
humans and most recently, mice.  Due to its myriad known functions, and evidence for its 
aberrant dynamics in TBI, tau is of great interest for its potential role in the association 
between remote TBI and dementia.  Future experiments should be designed to 
characterize the pre and post-injury dynamics of tau and the immunohistochemical 
patterns of its various isoforms. 
 
Future work to expand repertoire of injury types and animal models 
 One limitation of these findings is the injury model in which they were made.  
The controlled cortical impact has been a reliable model for many investigations over the 
  
189
past two decades.  However, the majority of clinical patients have very different injuries 
than a focal contusion.  Other mixed models should be explored, particularly those 
incorporating diffuse axonal injury (DAI) and repeated concussive injuries. 
 Different transgenic mice demonstrate different responses to injury.  Other 
transgenic models might yield additional insights into the dynamics of both Aβ and other 
proteins, such as tau.  One example is the 3X Tg mouse, which expresses mutant human 
isoforms of PS1, APP, and tau shown to be associated with familial AD (Oddo, et al., 
2003).  However, while mice are a convenient species for genetic manipulation, the 
mouse brain has less-than-ideal biomechanics to model human brain injury. 
Swine models bear a closer resemblance to the human brain in terms of size, 
presence of gyri and sulci, and distribution of gray and white matter.  Moreover, previous 
studies have demonstrated the similarities between brain injuries in swine and humans in 
multiple aspects.  For example, experimental TBI in swine often necessitates multimodal 
monitoring, including intubation, sedation, controlled ventilation, and control of 
intracranial pressure and cerebral perfusion (Manley, et al., 2006).  The protocol is 
similar to that used for severely-injured human patients in an intensive-care setting, but 
very unlike in rodents who generally recover without external assistance.  Another 
experimental TBI model, inertial brain injury, uses a rapid rotational acceleration of the 
head (Smith, et al., 1997).  Axial rotation alone induces coma, whereas axial and coronal 
rotations yield a robust model of DAI (Chen, et al., 2004, Smith, et al., 1999, Smith, et 
al., 1997, Smith, et al., 2000).  The ability to model DAI is a unique advantage of the 
swine model, since the biomechanics of the rodent brain preclude such an injury (Smith, 
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et al., 1997).  Finally, it has been shown that microdialysis monitoring can be combined 
with experimental CCI in a swine model (Alessandri, et al., 2003).  This combined model 
further expands the possibilities for improved translational research into the physiology 
of interstitial species, potential biomarkers, and pharmocodynamics (Hillered, et al., 
2005).  Swine can also better model pediatric TBI (Duhaime, 2006).  Although TBI 
research in large-animal models is far more costly in terms of capital expenses and time 
spent per animal, well-designed studies may reveal more about human injury and in the 
end save resources otherwise spent on limited mouse models.  However, a major 
advantage of mouse models is that genetic manipulations of the mice can be readily 
performed.  
Because certain genetic risk factors are unique to humans, they can be modeled 
only by transgenic manipulation in mice.  For example, the ApoE4 allele is a strong risk 
factor for sporadic and late-onset Alzhemier’s disease (Strittmatter, et al., 1993).  One 
mechanism by which ApoE4 increases the risk for AD was described by Holtzman et. al 
(Holtzman, et al., 2000).  Using PDAPP mice that co-expressed human ApoE isoforms, 
this study found that Aβ tends to aggregate into fibrillar plaques more readily in ApoE4+ 
animals than other ApoE genotypes (Holtzman, et al., 2000).  Epidemiological studies 
have strongly suggested that ApoE4 acts synergistically with TBI to increase the risk of 
dementia (Mayeux, et al., 1995).  Taken together, these findings suggest that the effects 
of ApoE4 to increase the risk of TBI-related dementia may be mediated through Aβ 
pathology.  Evidence to support this hypothesis was shown in a study by Hartman et al. 
(Hartman, et al., 2002).  PDAPP mice co-expressing human isoforms of ApoE3 or 
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ApoE4, or that expressed no ApoE (mouse or human), were subjected to CCI injury at 9-
10 months of age and were examined 3 months later for neuropathology.  In the absence 
of TBI, these genotypes do not have Aβ deposits at the ages studied.  By contrast, in the 
CCI-injured mice, the PDAPP/ApoE4 animals were found to have thioflavin-S positive 
amyloid, and all genotypes showed positive staining for diffuse Aβ plaque deposition.  
Other measures of neurodegeneration did not differ among the genotypes.  The results of 
this study provide evidence that human isoforms of ApoE may be required for any sort of 
Aβ deposition after TBI, diffuse and fibrillar, and that ApoE4 in particular is required for 
fibrillar deposition.  This study could not have been done in a large-animal model, such 
as swine, due to the complicated nature of transgenic manipulations. 
In conclusion, both rodent studies and large-animal models are necessary and 
valuable in TBI research.  Mice are currently the best model for important transgenic 
investigations, while swine are better suited for recapitulating the biomechanics and 
diffuse axonal injury of human TBI.         
 
Future directions for translational models involving microdialysis and experimental 
TBI 
 In conclusion, this project presents a combined mouse model of microdialysis and 
experimental TBI.  Using pre and post-TBI measurements of ISF Aβ, we may be able to 
infer a relationship between baseline and post-injury levels in clinical data.  The 
correlations between changes in either GCS or local EEG activity with changes in ISF Aβ 
found in both the clinical data and the mouse model are consistent with the notion that a 
  
192
similar underlying mechanism gives rise to the observed phenomena.  Future mouse and 
swine models should be designed to further test hypothesized mechanisms.  Better 
matching of clinical and experimental designs will improve the accuracy and predictions 
gleaned from such translational research. 
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Combined microdialysis-controlled cortical impact protocol 
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TBI + Microdialysis protocol sheet From the RIGHT, impact on the LEFT 
Investigator _____ Date _____Experiment _______ 
Mouse strain ___ _ Genotype: _____ Sex ____ Weight (g)____  Toe clip # __________ 
Retrieve mouse from animal facility 6-24 hours before to acclimate to surgery room. 
 
SET-UP Day 1:  
Make 0.15% human albumin-CMA perfusion fluid (30 uL 25% hAlb in 5 mL CMA) 
Tubing connectors in 100% EtOH, 5-10 min 
Syringe pump settings: 51.7 mm length for 3 cc Luer-slip syringe. 
Wash 0.12 mm FEP tubing + BR-2 probe in CMA + 0.15% hAlb @ 3 µl/min x 10’ 
Put BR-2 on holder, flush with hAlb/CMA according to instructions.  
Put guide cannula on holder on 23 cm arm, tighten. 
Right arm: drill w/burr bit, 0° switch to 23 cm arm for guide canula insertion at 37.6° 
Cut ring off top of 1.5 mL test tube, cut out ~150-180° to slip around screws 
Assemble: 2 large weigh boats for DuraLay, bone screws, suture, extra plastic rings, etc. 
Bead-sterilize tools.  Turn on stereotactic, lights, temp. 
 
CRANIOTOMY and GUIDE CANULA PLACEMENT: Day 1 
Induce Anesthesia: isoflurane 5%: time ______ (valve open to induction ONLY) 
Shake to assess depth of anesthesia: if no response, turn to 2%, valve open to nosecone 
Clear tongue, position on tooth bar 
Insert temperature probe ____  record time _____ 
Shave head gently, protect airway, align earbars (head adjuster on left), tighten; clean 
Level skull: Bregma ___ Lambda ___bregma -2.54 mm: 2.2 mm L ____, 2.2 mm R_____ 
Mark 3.8 mm crani: (1.1 Ant of lamba, 3.6 L); (3 Ant of lamba, 1.7 L). 
Drill groove at Bregma -2.54 mm: 0.0 mm, 0.5 mm L, 0.3 above/below at 0.5 mm L of 
groove, 1.0 mm L (0.2 mm above/below 1.0 mm L also helps) 
*Shiny tissue MUST be visible for clean probe insertion. 
Drill 3 holes for bone screws: (-0.75 Ant, 1 R); (-0.75 Ant, 3 R); (-3.75 Ant, 3 R).   
Insert small bone anchor screws – flat (BAS) 
Using 3.8 mm trephine: crani drill at 15-20° or greater; drill skull.  
Check depth frequently.  Use curette and rongeur to remove flap. 
Remove arm with drill to improve visualization of landmarks & guide canula. 
Vet-Bond modified skull cap.  Leave groove fully open! 
Remove drill, replace with clamp on 23 cm arm. 
Insert guide canula at 37.6° (38°) into Left hippocampus at bregma -2.54 mm: 
Right edge at 0.5 mm left of midline, touch to brain tissue 
Zero D-V, lower to -1.3 mm slowly. 
*Watch for slipping/grinding of the canula on skull edges.  DRY SKULL well. 
Position plastic ring around screws; clear skin away, drape on ring edge.  
Mix DuraLay powder/solvent: very liquid at first so that it pours, “soupy” 
Hold ring flush against screws as needed; allow cement to harden, ~10-15 min. 
Out of earbars, loosen nosecone to allow free head rotation 
Unscrew canula holder, take off arm. 
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Suture posterior skin, take out of frame, suture anterior skin, antibiotic ointment. 
Secure canula w/ needle drivers, stabilize lateral wrist on small white box: 
Pull stylet out (NO twisting!); look for hole, carefully insert probe. 
Attach orange collar and black RatTurn “leash;” drape mouse gently in Rat Turn  
Pump at 1.5 µl/min, wait for dead volume to clear (12µl/m – measure tube length)  
Start baseline: ____ min fractions at _____ µl/min. Time started ____ 
Check 1st, 2nd fractions to ensure equal volumes; 2x/day, refresh H2O, sharp pellets 
 
SET-UP 2: allow t > 30 min 
Equip stereotactic arms: Left: EM CCI, 20° 
Assemble: suture, skull cap trimmed to indent for DuraLay. 
Check that all tools are clean and ready.  Turn on stereotactic, lights, temp. probe.  
Turn on computer, EM CCI power, then Cntl-Alt-Del: pass = Qwer1234;  
Matlab: “main,” “3,” Velocity: 7 V for 5 m/s, dwell 100 ms.  Test impact.   
Return to “main,” “3,” STOP at “position impact at reference depth.” 
Cut a plastic disk to make a modified skull cap (tongue-and-groove to fit with glue). 
 
TBI: Day 2  
Reanesthetize isoflurane 5%, lines still attached. Time _________ 
Record Baseline Temp _________ and record time   _________  
Eye protectant, cut sutures, in earbars. 
Position head: use eyes to align in ear bars.  Top of ear bar = lower canthus.  Raise 
incisor bar as needed. 
Position impactor tip in dead center of 3.8 mm crani. 
Dry impactor tip, dry brain, clip touch detector to impactor tip, pad under paw, turn on 
touch detector 
Lower Z-axis to touch brain (singing detector); remove alligator clip, paw pad. 
Press “enter” to pull the EM impactor up to ready position 
SET INJURY SEVERITY: lower Z axis to -____ mm or SHAM____ 
Stabilize wrist on small white box, grip guide w/ needle driver, pull probe STRAIGHT 
out 2 mm 
Hold probe poised in hand, drop needle driver, reach over, press “enter” to deliver 
impact: time ________ 
Note breathing – remove isoflurane, loosen from earbars if necessary. 
Stabilize wrist on small white box, grip guide w/ needle driver, look for hole, replace 
probe carefully. 
Raise Z-axis up to clear field.  Irrigate with PBS if bleeding; dry with swabs, hemostasis 
with swabs. 
Vet-Bond modified skull cap, suture, turn off isoflurane & thermo controller.  Antibiotic, 
eye protectant. 
Weigh mouse _______ g 
Return to Raturn.  Wait _8-10_min for dead volume to clear, advance fraction collector. 
Restart dialysis: ____ minute fractions. Fraction #s _____ Time started __________ 
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Manufacture of guide canula with EEG leads, EEG monitoring, and analysis  
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Instructions and troubleshooting guide: intraparenchymal EEG and microdialysis 
 
Manufacture equipment: 
a. MD-2250 guide canula (or other appropriate canula)  
b. Teflon-coated, platinum-iridium wire (A-M Systems, #777000) 
- Outer diameter 0.0055” (coated), inner diameter 0.003” (bare) 
 c. Exacto scalpel + #10 blade 
d. Elmer’s Super-Fast Epoxy & Resin, 200 uL tip, weigh boats to mix 
 e. 1 bone screw (Bioanalytical Systems MD-1310) 
f. 3-pin strip header (Newark-In-One, Mfr. #929647-01-36-I) 
 - 0.1” pit spacing 
 - Copper alloy contact material 
 - Gold plated 
 g. Solder 
- Radioshack #64-002E, Standard Rosin Core Solder, 0.062” diam. 
h. Soldering iron 
- Radioshack #64-2802B, 30 Watt*, 120 V, 60 Hz 
i. Stay Clean tinning flux 
 h. fine, flat-tipped FST forceps (2 pair), small Roboz RS7107 hemostat  
 
* 30W is key to getting a fast “melt” on your solder for good contact; irons 
with less power than 30W do not melt solder very well and harder to get 
good contact 
 
I. Manufacture 
a. Preparation of electrodes 
i. Cut off 3 strands of Teflon-coated platinum-iridium wire from roll 
with Exacto knife on black lab bench  
ii. 2 for recording (~4 cm long), 1 for ground (~6 cm long) 
iii. Recording leads: using Exacto knife, scrape off layer of Teflon 
such that > 0.5 mm of bare metal is exposed from ONE end  
iv. These ends will be soldered to the prongs on 3-prong plug 
v. You might see “sheaths” of plastic-appearing Teflon peel back 
from bare wire; cut these scraps off 
vi. Bare metal is shiny, and skinnier than dull-appearing coated wire 
vii. Other end: leave blunt for now; these are inserted and will be cut 
on diagonal just before implantation 
viii. Ground: scrape off Teflon from both ends; one end is soldered to 
ground screw, the other end to a prong on 3-prong plug 
b. Adhesion of recording leads to guide canula 
i. Using flat forceps, bend recording leads at a 90º angle so 
scraped/soldered end is ~1.5 cm, inserted/blunt end is ~2.5 cm 
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ii. Mix Elmer’s epoxy-cement in 1:1 ratio (enough just to cover guide 
canula shaft) just before ready to attach wires 
iii. Epoxy tends to begin drying immediately, use within 2-3 min. of 
mixing together 
iv. Grip guide canula with small hemostat; balance hemostat handle 
off end of tip box so canula shaft extends parallel to, over bench 
v. Attach the longer (2.5 cm), blunt-tip end to guide canula shaft; 
leave AT LEAST 2 mm end free to allow insertion through skull 
groove into parenchyma, and to prevent epoxy from clogging shaft 
vi. NOTE: epoxy tends to run or drip off canula if too wet or too 
much; be sparing in application. 
vii. VERY IMPORTANT: leads must be parallel to and at 180º 
around shaft circumference from one another, ~0.5 mm apart 
viii. Allow 1st epoxy application to dry ~15 min, and reinforce with 2nd 
application.  
c. Soldering ground electrode to bone screw and 3-prong plug 
i. While 2nd application of epoxy on guide canula-recording leads 
dries, prepare ground screw for soldering (MD-1310, BAS Inc.) 
ii. Grip flat screw head with spring-loaded clamp, place on tip box so 
threaded end extends over bench 
iii. IMPORTANT: apply tinning flux to threaded end to clean before 
attempting to solder; only enough tinning flux to coat, remove 
excess by pulling back on syringe 
iv. Curl one, bare-stripped end of ground electrode in half-
circumference to fit around top thread of bone screw 
v. Drape curled end on thread so electrode hangs off; apply small 
pearl of tin solder 
vi. Make sure to avoid getting tin a) in groove on head; b) along 
bottom threads. 
vii. VERY IMPORTANT: when screwing the ground screw into 
bone, the electrode sometimes breaks off at junction of tin solder; 
make sure this is well adhered and that most of the bared end is 
covered by solder.  If not, insulate and strengthen with epoxy.   
viii. Solder other bared end to 1 (outside) prong on 3-prong plug; grip 
black plastic of plug with spring-loaded clamp, lay flat on tip box, 
extend plug over benchtop  
ix. Mark long side of prong with Black Sharpie: designates GROUND 
x. Clean short prong with tinning flux, curl or bend other (bared) end 
of ground electrode around short prong; apply pearl of tin solder 
xi. Again – make sure most of bared end is covered by solder; if not, 
insulate with epoxy.  
d. Soldering recording leads to 3 prong plug 
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i. Once 2nd application of epoxy is dry, secure guide canula stylet 
head in hemostat, balance handles on tip box with canula 
extending out over bench 
ii. Rotate canula such that bared ends of leads face 3-prong plug (also 
extending out over bench, gripped with spring-loaded device 
iii. Clean short prongs with tinning flux just before application of tin 
solder 
iv. Curl bared ends or allow them to “grip” prongs before attempting 
to apply pearl of solder 
v. Ensure bare wire is covered in solder, or apply epoxy for insulation 
after solder hardens 
vi. IMPORTANT NOTES: solder can be applied once or twice, but 
multiple applications and removals compromise electrical contact 
between metal prong and bare wire.  Avoid this.  If wire appears 
compromised, dirty, oxidized, etc., cut off, scrape off more Teflon, 
and start over.  ALWAYS apply tinning flux just before every 
solder attempt. 
vii. Finally, cut off recording leads at the blunt or “insertion end” at 
45º angle to increase surface area.  They should extend 2 mm past 
end of guide canula shaft.  This will place recording electrodes at 
end of microdialysis probe.  Do not make too short (records from 
cortex rather than hippocampus) or too long (could puncture lateral 
ventricle).  Do not bend – must remain as straight as possible.  
Cirrito et al. attempted to use stainless steel wire, but was too 
flexible so switched to a stiffer platinum-iridium wire.  
 
II. Surgery 
a. Drilling groove for canula insertion; dural puncture 
i. SAME as normal 38º microdialysis-CCI procedure: after leveling 
skull, drill groove at 3 locations medial-lateral (0, 0.5, 1 mm left-
lateral at -2.54 Bregma along A-P axis); use 0.70 mm burr bit 
ii. Additionally, allow for increased width of canula + electrodes: drill 
anterior and posterior ~0.4 mm (for example, -2.14 mm Bregma 
and 2.98 mm Bregma) at 0.5 and 1.0 mm lateral to midline 
iii. Clear groove of bone chip debris, irrigate with sterile-filtered PBS, 
ensure dura is visualized 
b. Placement of ground (occipital/cerebellar bone screw anchor) 
i. Drill an additional hole on RIGHT lateral occipital bone above 
cerebellum.  This bone screw is larger than anchors, so increase 
circumference by slightly shifting burr bit (“mini-groove”).  This 
bone is deep at this angle. 
ii. VERY IMPORTANT: a secure ground screw is the KEY to a 
good signal.  Drill deep so the bone screw is well-anchored! 
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iii. Next, drill craniotomy, place skull cap, screw in 3 cortical bone 
anchors as usual for simple microdialysis-CCI procedure 
iv. Align canula+electrodes on stereotactic arm at 38º; lower enough 
so that ground screw is within reach of occipital groove. 
v. Screw in ground screw until secure (1-2 rotations).  Take care not 
to break off electrode wire.  It will twist around the ground screw, 
this is normal. 
vi. NOTE: I have done “spot repair” to solder a ground lead back in 
pace during surgery; this sometimes works but is not optimal. 
 
c. Insertion of canula-electrodes into groove 
i. Once ground screw is secure, carefully lower canual+electrodes 
through left-lateral groove.  Electrodes should enter dura & 
parenchyma easily, without resistance, and straight!  No 
bending allowed.  Some bleeding may occur more than with canula 
alone.  This is normal.  Dab and allow clotting to occur, it will 
subside once canula is inserted to full depth (1.3 mm). 
d. Dental cement as insulator 
i. Building a dental cement crown is more challenging in this 
procedure, as you must wrap the excess wire around the crown 
and “bury” it within the dental cement.  Take care to cover the 
ground-screw area very well, to both secure the screw and 
insulate any bare wire that might be exposed. 
ii. The long prongs on the 3-prong plug should sit at a 50-60º angle 
relative to the plane of the skull, the more vertical the better.  Wipe 
any excess cement off the prongs for good electrical contact. 
iii. Allow dental cement to dry ~15 min.  Make sure it has hardened 
before suturing.  
e. Skin closure 
i. Close skin well, the crown is larger and somewhat irregular 
compared to a crown without EEG leads. 
 
III. Monitoring during microdialysis 
a. Equipment: head stage amplifier, Grass amplifier, Mini-Digitizer, PC 
i. PLUG IN YOUR MOUSE: be very gentle when plugging in the 
3-prong strip into its small black receptacle.  This is easiest 
when mouse is still anesthetized.  If the mouse is fighting or 
tossing its head, especially when just awakening from anesthesia, 
you risk breaking off the crown.  Make sure mouse is still KO’d. 
ii. Electrical noise in the room can vary.  Sometimes the signal can 
pick up noise (ex., 60 Hz signal) from the surroundings and then 
appear more physiological; it is hard to predict when this is the 
case.  Sometimes there is an equilibration period, up to ~60 
minutes, for the signal to reach a steady state.  If the signal has not 
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“settled down” after 90 minutes, it is more likely that your 
grounding or insulation is faulty, and you will not be able to use 
EEG recordings from that experiment.  
b. Axoscope program (Axoscope 9.2) 
i. Turn on head stage amplifier, Grass amplifier, and PC.  Make sure 
the green LED on the Mini-Digi is lit when the circuit is on.  The 
usual settings on the Grass amplifier are:  
1. Low-pass filter, 0.1 Hz; high pass filter, 0.1 kHz 
2. Calibrator = 200 µV; x 1000 or 10? x 1000 
3. Input = Use 
4. Amplification = 10 
5. Line filter = In   
c. Attaching 3-prong plug to head stage amplifier 
i. NOTE: head stage amplifier can run off a 9V battery or via an 
AC adaptor.  The AC house supply can introduce noise.  You 
must change the 9V battery every 24 hours; although the 
amplifier has a battery power “check” (lights a green LED; bright 
= more power, dim / off = less or dead) the battery can be depleted 
to 7.5 or 8V and still appear to “check” as good.  Use a Voltmeter 
(bottom drawer, red tool cabinet) to verify battery voltage. 
ii. The receptacle for the 3 prong plug is a fixed input into the head 
stage amplifier (custom designed by WU Electronics Shop) 
iii. The receptacle has a large black mass on one side; this is the 
GROUND side.  Make sure your GROUND prong (marked with 
black Sharpie) is plugged in on this side. 
iv. From head stage amplifier, an OUTPUT coaxial cable splits into 3 
lines: ground (black); EEG reference (white); and EEG active 
(red).  These three lines are plugged into the gray 3 pin receptacle, 
marked with colored dots: YELLOW for ground, BLUE for EEG 
reference, and GREEN for EEG active.  This gray 3 pin receptacle 
re-winds into one cable, is INPUT into the Grass amplifier (front). 
v. The output for the Grass amplifier goes directly to the MiniDigi 
(note which Channel, 0 or 1, so you can enter this information in 
the Axoscope program.  Default is Channel 0). 
vi. MiniDigi output is a USB ending, plug into PC laptop.  Make sure 
laptop “recognizes” the New Device.  Has not been a problem yet. 
d. Securing lines to reduce electrical noise 
i. Tape all electrical cables securely to bench, wall, shelf, or 
whatever fixed surface is available.  Pay special attention to 
securing the 3 wires from head-stage amplifier output as they go 
into the gray 3 pin receptacle.  Tape each side of this connection 
firmly to the shelf, tape the junction as well.   
e. Display on Axoscope 
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i. Open the Axoscope 9.2 program (oscilloscope icon on Desktop).  
A blank grid should pop up immediately. 
ii. The recording program we use should be the default.  Look for 
“Gap-free” at the top.  If not, specify the recording parameters: 
1. Under “Configure” menu, choose “Acquire” 
2. Under “Acquire  Digitizer  MiniDigi  OK.” 
3. Next, go back to “Configure”  “Acquire.” 
4. Under “Acquire  Edit Protocol  Mode/Rate.” 
5. Choose “Gap-free” mode; “Trial Length = Disk Space” 
6. Choose “Sample rate = 1 kHz.” 
f. Now, “Gap-free” should be displayed at the top of the grid. 
g. Click the black arrow to “Play,” black dot to “Stop,” and red dot to 
“Record.” 
i. If no trace appears at all when you click on “Play,” try closing 
the program and/or restarting the computer. 
ii. You can modify the timescale on the X-axis (200-500 ms is 
generally useful) and the voltage scale on the Y-axis (5-10 V is 
what we use, but for smaller amplitudes < 2V may be necessary) 
h. When you are finished recording: 
i. Click the black dot to “Stop.” 
ii. Under “File,” click on “Last recording*” 
iii. The entire trace should appear on the grid.  It may take a minute or 
so to display.  Be patient. 
iv. Save your file on the PC before transferrng it to your USB. 
v. NOTE: if you record another file before saving the last, you have 
lost the previous record!  Make sure to save last recorded file 
before recording again.  Saving can also take a minute or two. 
vi. The PC in the Surgery Room is not hooked up to the network.  
You must transfer files by USB.  An >8 GB USB device is 
optimal.  Files tend to be quite large (100,000 KB for 24h) 
vii. Files are saved as “Axon Binary File” or .abf. 
 
IV. Analysis of RMS amplitude signal by Clampfit 9.2 
a. Opening files 
i. Open Clampfit 9.2 (white X-Y plot icon on Desktop) 
ii. A blank data spreadsheet should appear named “Results 1.”  
iii. Go to “File  Open data  (choose USB port)  your file” 
iv. Your trace should appear exactly as you saved it in Axoscope   
b. Selecting a window for analysis 
i. There are 4 cursors that should appear on your tracing: use cursors 
1 and 2 to select a window 
ii. Go to “View  Zoom  Between cursors” 
iii. The portion of the record between Cursors 1 and 2 should appear 
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iv. Absolute time (from beginning of record) is displayed on Cursor 1, 
and the difference between 1 and 2 is displayed on Cursor 2 
v. Zoom in until you have about ~40-60 min. displayed 
vi. Then use Cursors 1 and 2 to find your selected epochs 
c. Using Clampfit 9.2 to calculate  
i. Place Cursors 1-2 at 1-1.5 min. distance at your desired epoch 
ii. Choose “Analyze  Power Spectrum  Hamming window” 
iii. “Exclude 1st “1” spectral bins” 
iv. “Trace selection” should be “Active signal, one continuous trace”  
v. “Region to analyze: Cursors 1…2; ”click “OK” 
vi. A new window appears: a “Power Spectrum” graph, and in the 
“Results” spreadsheet you should see your data 
vii. Look at “RMS incl., RMS excl., and RMS all bins” in Results 
viii. If data is uniform over the 1-1.5 min epoch, then “RMS excl.” 
should be “0” or very small.  This is good quality data.  If not, then 
perhaps choose another epoch or look at the quality of your signal. 
ix. You can copy this spreadsheet into Excel for further analysis. 
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Synaptosomes: materials and protocol 
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Materials: 
47 mm diameter filtration apparatus 
Millipore AP15 “prefilter” (ordered; to be used with Hirsch-type filter, also ordered) 
 
12 mL polycarbonate centrifuges tubes, 16 x 100 mm 
50 mL polycarbonate centrifuge tubes (transparent) 
 - Wheaton cat. # 358009 
 
Beckmann JA-20/Sorvall SS-34: fixed angle rotor 
 
Percoll – received as slurry.  Filter through Millipore AP15 prefilters to remove 
aggregated incompletely coated particles. 
Store filtered solution at 4º C if required in next few days; otherwise, store at -20º C in 
200 mL lots; repeat filtration every 2 weeks. 
 
CRITICAL: use double distilled or double deionized water throughout. 
 
Solutions: 
1. 100 mM HCl 
a. 10 mL of 1M into glass beaker w/ 90 mL water; store at RT 
2. 0.2 M EDTA 
a. Add 7.445 g EDTA to 75 mL water; adjust to pH 7.4 with saturated 
solution of Tris base while stirring on magnetic stirrer  
b. Then, dilute to 100 mL and store in 100 mL bottle at 4º C  
3. 4X gradient buffer 
a. Dissolve 109.54 g sucrose and 606 mg Tris in ~ 200 mL water 
b. Add 5 mL 0.2M EDTA stock 
c. Dilute to 240 mL 
d. Check pH, adjust if necessary. 
e. Dilute to final volume of 250 mL; store as 50 mL aliquots in capped 50 
mL plastic tubes at -20º C  
4. Sucrose/EDTA buffer 
a. Dilute 50 mL 4X gradient buffer to 200 mL total with water; store on ice. 
5. 50 mM DTT 
a. Dissolve 154 mg DTT in 10 mL water 
b. Store as 1 mL aliquots in 1.5 mL-capped tubes at -20º C [in lab, -20 box] 
6. Percoll gradient solutions 
a. Thaw 1 tube 4X gradient buffer + 1 tube 50 mM DTT stock, on ice. 
b. Filter Percoll, insert stir bar, adjust to pH 7.4 with 100 mM HCl. 
c. To 50 mL capped tubes, add specified amount of Percoll, 4X gradient 
buffer, 50 mM DTT, and water according to TABLE 1 (see below) to 
make a total volume of 25 mL. 
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d. NOTE: Addition of salts to Percoll/gradient buffer leads to aggregation of 
membranes, disruption of normal subcellular fractions.  It is essential to 
minimize addition of extra salts in gradient solutions. 
 
Reagent Percoll 
(mL) 
4X Gradient 
buffer (mL) 
50 mM DTT 
(uL) 
Water 
(mL) 
Homogenizing 
buffer 
0 6.25 125 18.625 
3% Percoll (v/v) 0.75 6.25 125 17.875 
10% Percoll (v/v) 2.50 6.25 125 16.125 
15% Percoll (v/v) 3.75 6.25 125 14.875 
23% Percoll (v/v) 5.75 6.25 125 12.875 
 
 
What is Percoll? 
- Polyvinyl, pyrrolidone-coated silica particles 
- 17 nm diameter (uniform) 
- Developed for cell & subcellular fractionation 
- Advantages? 
o Low viscosity = more rapid sedimentation than Ficoll 
o Can be prepared in isotonic solution (isotonic sucrose) 
 
Two labs independently developed Percoll gradient procedures for synaptosome prep, 
beginning with P2 fraction  applying P2 to discontinuous Percoll gradient 
 
This procedure took less centrifugation time, but Dunkley et al. is in widespread use. 
 
Also, further reduced time by applying S1 directly to gradient; avoided need to prepare 
P2 fraction and eliminated the mechanically-damaging step of P2 resuspension. 
 
Briefly: 
1. S1 fraction prepared by homogenization of fresh brain tissue in isotonic sucrose 
2. S1 then directly applied to discontinuous Percoll gradient: 3, 10, 15, 23% (v/v) 
3. Centrifuge gradient in medium-speed centrifuge x 5 min (exclude acc/decel time) 
4. Five (5) major fractions then collected from INTERFACES of Percoll layers 
a. Fraction 1: small, unidentified membranous material (0-3%) 
b. Fraction 2: myelin, membranes and membrane vesicles (3-10%) 
c. Fraction 3: synaptosomes and membrane vesicles (10-15%) 
d. *Fraction 4: synaptosomes (15-23%) 
e. Fraction 5: extrasynaptosomal mitochondria (below 23%, bottom) 
5. Fractions are diluted, centrifuged to remove Percoll, and resuspended in 
physiological buffer for analysis 
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6. *Authors recommend using Fraction 4 for most highly purified and maximally 
viable synaptosomes are required; however, yield is low. 
7. If maximal yield is required and membrane contamination is NOT a concern, 
some labs pool Fractions 3 + 4 either AFTER purification or by omitting 15% 
Percoll layer during purification; then, collect in single fraction atop 23% layer. 
8. Fraction 3 vs Fraction 4: Fraction 4 synaptosomes are larger and denser (for 
cortex, 0.64 um vs 0.55 um).  Fraction 4 contains more mitochrondria. 
 
Notes from 2.2.09 Tim Miller training session 
1. Go very slowly, circling the inner diameter of centrifuge tube with pipette tip 
2. Stay close to meniscus 
3. Mark after each layer so interfaces may be detected after spin to best approximate 
location of desired fraction (Fraction 4) 
 
Prepare Percoll gradient 
1. Filtered Percoll may be kept up several days at 4º C 
2. Percoll gradients may be used up to 24h after manufacture (kept on ice or 
refrigerated) 
 
Preparation of S1 fraction from brain tissue (~30 min)  
1. Extract required tissue from brain 
a. Rinse several times in excess volumes of ice-cold homogenizing buffer to 
reduce blood levels 
b. Remove as much liquid as possible using filter paper 
c. Add 9 mL of ice-cold homogenizing buffer to 1 g of fresh brain tissue in 
small glass beaker 
d. NOTE: although synaptosomes have been prepared from frozen tissue 
using Percoll, it is preferable that tissue never be frozen or fixed before 
use because no studies exist on homogeneity, yield or viability of these 
synaptosomes 
e. Complete sacrifice as quickly as possible; remove all bone, blood and 
meninges by washing in ice-cold homogenizing buffer; cool tissue to 4º C 
as quickly as possible 
f. AVOID saline (PBS-heparin) ,as salts will disrupt distribution of 
subcellular tissues in the gradient*** 
g. If anesthesia is used before killing animals, it will still be present in 
resulting synaptosomes; consider effect on synaptic transmission / 
functional experiments  
h. CRITICAL: all equipment should be kept at 4º C 
i. Ratio of homogenization buffer : tissue weight is critical is critical to 
subsequent fractionization of synaptosomes; must carefully control 
j. If 2X amount of tissue is used, Fraction 2 becomes overloaded during 
centrifugation and it is difficult to separate from Fraction 3 synaptosomes, 
and recovery of Fraction 4 synaptosomes is decreased 
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2. Homogenization (30 min) 
a. Rapidly cut brain tissue into small pieces, using scissors (step not required 
if smaller amounts of tissue or slices are to be used that can be readily 
homogenized  
b. Wheaton tissue grinder (358009 15 mL, 19 x 84, $158.92 from Wheaton) 
1501 North 10th Street, Millville, NJ 08332-2038, USA  
Tel: 800-225-1437 Fax: 856-825-1368 
c. Pour chopped tissue into 15 mL Teflon-glass tissue grinder; homogenize 
with 10 even strokes (1st stroke = 5 s, subsequent strokes = 3-4 s) using 
motor driven pestle @ 500-800 rpm (?) ask! 
d. Pre-chill in beaker of ice before homogenization 
e. ***Time between sacrifice and homogenization is critical; try for 1-2 min 
f. Clearance of Teflon-glass tissue grinder, speed of pestle rotation, and and 
rate of up and down strokes all contribute to eventual SIZE of 
synaptosomes and contaminating membrane vesicles formed during 
homogenization; strokes may vary 6-10, rpm may vary 500-800 rpm 
3. Centrifugation (30 min)  
a. STEP 1: centrifuge at 3600 rpm (1000g @ average radius of centrifuge 
tube) x 10 min @ 4º C in 12 mL polycarbonate tube using JA-20 rotor 
(equivalent, Sorvall SS34) in high-speed centrifuge 
b. Collect supernatant (“S1”), transfer to 50 mL plastic tube on ice, and CAP 
c. Discard pellet  
d. Original paper call for S1 to be centrifuged again @ 15,000g x 30 min  
P2; P2 was then resuspended and treated as per S1 in current protocol 
e. S1 procedure as good as P2; synaptosomes as pure, viable, homogenous 
4. Percoll gradient fractionation procedure (30 min)  
a. Dilute S1 supernatant (9 mL) to 10-14 mL with homogenizing buffer; 
keep on ice, measure protein content with BCA  essential that final 
protein content of S1 = 4-5 mg/mL; if protein content too high, add more 
buffer; if too low, then adjust ratio of tissue to homogenizing buffer in 
Step 2 (increase tissue/buffer) 
b. Slowly and carefully pipette 2 mL of diluted S1 fraction over top 3% layer 
in each tube containing Percoll gradient from step 1; pipette @ 1 mL/min,, 
should be slow and smooth 
c. Centrifuge tubes @ 20,000 rpm (31,000g) @  4º C x 5 min (AT SPEED) 
d. Brake should be set to full for most of deceleration, but very slow for last 
500 rpm 
e. ***Must be timed precisely so time @ max speed = 5 min exactly 
f. Remove centrifuge tubes from rotor, place on ice; careful not to disturb 
the gradient; collect all fractions individually OR specific fractions 
5. Collection of fractions  
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a. If only synaptosomes are required, attach a thin metal tube (extremely 
wide bore 18-20 gauge, 9-10 cm long needle) via 2 cm silicon tubing @ 
end of 10 mL pipette 
b. Using pipette-aid, carefully insert tube into gradient down to required 
fraction; withdraw and dispense in pre-chilled tube on ice 
6. Transfer from sucrose to isotonic solution (45 min)  
a.  Dilute Fraction 4 (or other fraction of interest) to 80 mL with ice-cold 
sucrose-EDTA buffer in beaker, or other suitable container 
b. Divide over 2 50-mL polycarbonate centrifuge tubes 
c. Centrifuge at 16,000 rpm (20,000g) in SS34 rotor @ 4º C x 30 min 
d. If Fractions 3 + 4 are combined, ensure that Percoll is diluted 3-4X before 
centrifugation 
e. If material is NOT properly pelleted, apply less brake to avoid disturbing 
the pellet when centrifuge reaches a sudden stop 
f. Combine pellets and carefully resuspend in the required amount of 
isotonic physiological buffer of choice (CHECK) 
g. Synaptosomes can be used at this point  saves time and potentially 
damaging, resuspension step 
h. If presence of sucrose or EDTA might interfere with subsequent assays, 
synaptosomes can be washed free of sucrose/EDTA by centrifuging 
resuspended synaptosomes x 10 min @ 15,000 rpm (18,000g), 4º C 
i. Resulting pellet should be gently resuspended in isotonic physiological 
buffer to required concentration for subsequent experiments 
j. Measure amount of protein to standardize [X]protein (expect 5 mg/mL when 
all of Fraction 4 is fully resuspended in 600 uL of isotonic buffer (without 
extra wash step), assuming 1 g cortex was used as starting material 
 
Sucrose/EDTA buffer 
- 0.32M sucrose, 1 mM EDTA, 5 mM Tris pH 7.4) 
- Dilute 50 mL of 4X gradient buffer to 200 mL with MQ water; add 5 mL 
0.2M EDTA stock and keep on ice. 
 
Isotonic buffer 
- Freshly prepare a batch of isotonic physiological buffer 
- Buffer depends on particular experiments planned for synaptosomes, etc. 
- Examples given in refs. 39, 40, 49, 60 
 
Notes: 
- Sacrifice: deep anesthesia with isoflurane, open chest, cut R.A., infuse 5 mL ice-
cold homogenizing buffer; put into cold preweighed histology vial and weighed 
- Homogenized 0.5 g whole brain in 5 mL buffer (add to vial, cut w/ Exacto 1st) 
- 10 strokes, slowly with half-twists, 5 s down and up 
- Spin down (S1 fraction; pour off supernatant, discard pellet) 
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- Ended up saving S1 fraction; frozen in centrifuge tubes at -80º C 
- Poured 2 mL each on two gradients (saved two gradients for Thurs if needed) 
- Spun down, collected both Fractions 3 and 4 and pooled immediately 
o Diluted fractions to 8 mL with ice-cold sucrose-EDTA buffer in 
beaker, or other suitable container 
- Did not resuspend, but protein content 3-4.5 mg/mL (expected) 
 
 
 
 
 
 
 
